HEXO (HEXO) 40-F 30 Oct 20 2020 FY Annual report (Canada) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jul. 31, 2020shares
Document And Entity Information [Abstract]
Entity Registrant Name	HEXO Corp.
Entity Central Index Key	0001690947
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding	482,465,748
Document Type	40-F
Document Period End Date	Jul. 31, 2020
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Trading Symbol	HEXO
Security Exchange Name	NYSE
Title of 12(g) Security	Common Shares, no par value

Consolidated Statements of Fina

Consolidated Statements of Financial Position $ in Thousands, $ in Thousands	Jul. 31, 2020CAD ($)	Jul. 31, 2019CAD ($)
Current assets
Cash and cash equivalents	$ 184,173	$ 113,568
Restricted funds	8,261	22,350
Short-term investments	0	25,937
Trade receivables	19,426	19,693
Commodity taxes recoverable and other receivables	16,733	15,247
Convertible debentures receivable	0	13,354
Prepaid expenses - current	4,606	10,762
Inventory	64,933	83,854
Biological assets	7,571	7,371
Total current assets	305,703	312,136
Non-current assets
Property, plant and equipment	285,366	258,793
Intangible assets	16,008	127,282
Investment in associate and joint ventures	76,306	52,849
Lease receivable	3,865
License and prepaid royalty - HIP	1,020	1,409
Prepaid expenses	1,392
Long-term investments	3,209	14,277
Goodwill	0	111,877
Total assets	692,869	878,623
Current liabilities
Accounts payable and accrued liabilities	32,451	45,581
Excise taxes payable	7,121	3,494
Warrant liabilities	3,450	493
Lease liability - current	4,772
Term loan	29,930	33,374
Onerous contract	4,763
Total current liabilities	82,487	82,942
Non-current liabilities
Deferred rent liability		946
Deferred tax liability		6,023
Lease liability	24,344	0
Convertible debentures	28,969
Other long-term liabilities	393
Total liabilities	136,193	89,911
Shareholders' equity
Share capital	1,023,788	799,706
Share-based payment reserve	65,746	40,315
Warrant reserve	95,617	60,433
Contributed surplus	27,377
Accumulated deficit	(659,231)	(112,742)
Non-controlling interest	3,379	1,000
Total Shareholders' equity	556,676	788,712
Total equity and liabilities	$ 692,869	$ 878,623

Consolidated Statements of Net

Consolidated Statements of Net Loss and Comprehensive Loss - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Profit (Loss)
Revenue from sale of goods	$ 110,149	$ 59,256
Excise taxes	(29,598)	(11,914)
Net revenue from sale of goods	80,551	47,342
Ancillary revenue	233	199
Net revenue	80,784	47,541
Cost of goods sold	127,205	45,532
Gross (loss)/profit before fair value adjustments	(46,421)	2,009
Realized fair value amounts on inventory sold	40,910	16,357
Unrealized gain on changes in fair value of biological assets	(29,356)	(38,856)
Gross (loss)/profit	(57,975)	24,508
Operating expenses
Selling, general and administrative	52,793	45,947
Marketing and promotion	12,474	31,191
Share-based compensation	25,790	28,008
Research and development	4,639	2,822
Depreciation of property, plant and equipment	6,072	1,747
Amortization of intangible assets	3,939	1,767
Restructuring costs	4,767
Impairment of property, plant and equipment	79,418
Impairment of intangible assets	108,189
Impairment of goodwill	111,877
Loss on onerous contract	4,763
Loss on disposal of property, plant and equipment	3,855
Total expenses, by nature	418,576	111,482
Loss from operations	(476,551)	(86,974)
Revaluation of financial instruments gain/(loss)	6,533	(3,730)
Share of loss from investment in associate and joint ventures	(6,331)	(2,964)
Loss on induced conversion of debentures	(54,283)
(Realized loss)/unrealized gain on convertible debenture receivable	(4,806)	1,737
Unrealized loss on investments	(12,880)	(315)
Realized gain on investments	24	(215)
Foreign exchange gain/(loss)	1,392	(78)
Interest and financing expenses	(10,043)	(469)
Interest income	1,902	5,187
Other income	2,531
Loss and comprehensive loss attributable to shareholders before tax	(552,512)	(87,821)
Income tax recovery	6,023	18,213
Net loss and comprehensive loss	(546,489)	(69,608)
Comprehensive loss attributable to:
Shareholders of HEXO Corp.	(546,489)	(69,608)
Non-controlling interest	0	0
Total comprehensive loss	$ (546,489)	$ (69,608)
Net loss per share, basic and diluted	$ (1.77)	$ (0.33)
Weighted average number of outstanding shares
Basic and diluted (in shares)	309,504,695	212,740,552

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Share capital	Share-based payment reserve	Warrants	Contributed surplus	Non-controlling Interest	Deficit	Total
Balance at Jul. 31, 2018	$ 347,233	$ 6,139	$ 12,635			$ (43,134)	$ 322,873
Balance (shares) at Jul. 31, 2018	193,629,116
Issuance of common shares	$ 57,558						57,558
Issuance of common shares (shares)	8,855,000
Share issuance upon acquisition	$ 322,439						322,439
Share issuance upon acquisition (shares)	35,394,041
Share issuance costs	$ (3,827)						(3,827)
Replacement stock options		7,134					7,134
Replacement warrants			12,229				12,229
Issuance of warrants			42,386				42,386
Exercise of stock options	$ 7,044	(2,751)					4,293
Exercise of stock options (shares)	3,567,867
Exercise of warrants	$ 61,350		(5,204)				56,146
Exercise of warrants (shares)	13,619,202
Exercise of Broker/Finder warrants	$ 7,909		(1,613)				6,296
Exercise of Broker/Finder warrants (shares)	1,916,527
Equity-settled share-based payments		29,793					29,793
Non-controlling interest					$ 1,000		1,000
Net loss and comprehensive loss						(69,608)	(69,608)
Balance at Jul. 31, 2019	$ 799,706	40,315	60,433		1,000	(112,742)	788,712
Balance (shares) at Jul. 31, 2019	256,981,753
June 2020 at the market offering	$ 33,263						33,263
June 2020 at the market offering (Shares)	32,942,479
May 2020 underwritten offering	$ 43,495		10,998				54,493
May 2020 underwritten offering (shares)	63,940,000
April 2020 underwritten offering	$ 22,928		20,182				43,110
April 2020 underwritten offering (shares)	59,800,000
Issuance of common shares - USD$20m registered offering	$ 21,073						21,073
Issuance of common shares - USD$20m registered offering (shares)	11,976,048
Issuance of common shares - USD$25m registered offering	$ 25,229						25,229
Issuance of common shares - USD$25m registered offering (shares)	14,970,062
$70m private placement unsecured convertible debentures				$ 23,902			23,902
Early conversion of debentures	$ 72,005		13,354	(10,362)			74,997
Early conversion of debentures (shares)	37,325,000
Share issuance costs				(27)			(27)
Exercise of stock options	$ 223	(89)					134
Exercise of stock options (shares)	116,532
Expiry of stock options		(5,983)		5,983
Exercise of warrants	$ 5,866		(1,469)				4,397
Exercise of warrants (shares)	4,413,874
Expiry of warrants			(7,881)	7,881
Equity-settled share-based payments		31,503					31,503
Non-controlling interest					2,379		2,379
Net loss and comprehensive loss						(546,489)	(546,489)
Balance at Jul. 31, 2020	$ 1,023,788	$ 65,746	$ 95,617	$ 27,377	$ 3,379	$ (659,231)	$ 556,676
Balance (shares) at Jul. 31, 2020	482,465,748

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Operating activities
Total net loss	$ (546,489)	$ (69,608)
Items not affecting cash	508,484	16,669
Changes in non-cash operating working capital items	(56,549)	(71,767)
Cash used in operating activities	(94,554)	(124,706)
Financing activities
Issuance of common shares	196,843	57,558
Issuance fees	(10,170)	(3,827)
Proceeds from the exercise of stock options	134	4,293
Proceeds from the exercise of warrants	4,291	56,075
Acquisition of term loan		32,778
Payments on term loan	(3,500)
Debt interest payments	(1,849)
Lease payments	(4,341)
Issuance of unsecured convertible debentures	70,000
Interest paid on unsecured convertible debentures	(3,205)
Cash from financing activities	248,203	146,877
Investing activities
Settlement of short-term investments	25,420	119,810
Proceeds from sale of investments	7,871
Restricted cash	13,089	(22,350)
Proceeds from sale of property, plant and equipment	10,966
Acquisition of property, plant and equipment	(109,040)	(138,034)
Purchase of intangible assets	(856)	(3,010)
Investment in associate and joint ventures	(30,494)	(13,427)
Net cash acquired on business acquisition		49,366
Cash used in investing activities	(83,044)	(7,645)
Increase in cash and cash equivalents	70,605	14,526
Cash and cash equivalents, beginning of year	113,568	99,042
Cash and cash equivalents, end of year	$ 184,173	$ 113,568

Description of Business

Description of Business	12 Months Ended
	Jul. 31, 2020
Disclosure Description Of Business [Abstract]
Description of Business	1. Description of Business HEXO Corp. (the "Company"), is a publicly traded corporation, incorporated in Ontario. HEXO is licensed to produce and sell cannabis and cannabis products under the Cannabis Act. Its head office is located at 3000 Solandt Road Ottawa, Canada. The Company's common shares are listed on the Toronto Stock Exchange ("TSX") and the New York Stock Exchange ("NYSE"), both under the trading symbol "HEXO". COVID-19 In December 2019, a novel strain of coronavirus ("COVID-19") emerged in Wuhan, China. Since then, it has spread to most other countries and infections have been reported around the world. Canada confirmed its first case of COVID-19 on January 25, 2020 and its first death related to COVID-19 on March 9, 2020. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. In response to the outbreak, governmental authorities in Canada and internationally have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and social distancing. These measures remain in effect as at July 31, 2020. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and economic disruptions. As of July 31, 2020, we have not observed material changes to our business as a direct result of the COVID-19 pandemic.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Jul. 31, 2020
Basis Of Presentation [Abstract]
Basis of Presentation	2. Basis of Preparation Statement of Compliance These consolidated financial statements have been prepared in compliance with the International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") including IFRS Interpretations Committee ("IFRIC"). These consolidated financial statements were approved and authorized for issue by the Board of Directors on October 29, 2020. Basis of Measurement The consolidated financial statements have been prepared on an historical cost basis except for certain financial instruments and biological assets, which are carried at remeasured amounts or fair value, as detailed in the Company's accounting policies. New and Amended Standards The Company has applied IFRS 16 - Leases Certain new accounting standards and interpretations have been published that are not mandatory for the year ended July 31, 2020 and have not been early adopted by the Company. These standards are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions. Functional and Presentation Currency The consolidated financial statements are presented in Canadian dollars. Each entity within the Company determines its own functional currency based on the primary economic environment in which it operates. Basis of Consolidation SUBSIDIARIES Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed, or have rights to, to the variable returns from its activities. The financial statements of subsidiaries are consolidated from the date that control commences until the date that control ceases. All intercompany transactions, balances, and unrealized gains and losses are eliminated upon consolidation. Non-controlling interest ("NCI") represents the portion of equity ownership in subsidiaries not attributable to the Company's shareholders. NCI is initially measured as the proportionate share of its interest in the acquiree's identifiable net assets as at the date of acquisition and subsequently adjusted for the proportionate share of net earnings and other comprehensive income (loss) attributable to the NCI, as well as any dividends or distributions paid to the NCI. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statements of loss and comprehensive loss, statements of changes in equity and balance sheets respectively. Principal Operating Subsidiaries Jurisdiction Interest Held Principal Activity HEXO Operations Inc. Ontario, Canada 100% To produce and sell cannabis and cannabis products under the Cannabis Act. HEXO USA Inc. Delaware, USA 100% To facilitate expansion into the US market. Keystone Isolation Technologies Inc. ("KIT'') Ontario, Canada 60% Intended to provide the Company with high quality extraction technology to facilitate an efficiently processed and consistent supply of CBD and THC to supply the Canadian and global market for cannabis derivatives Neal Up Brands Inc. Ontario, Canada 60% To produce and sell cannabis and cannabis products under the Cannabis Act. JOINT ARRANGEMENTS Investments in joint arrangements are classified as either joint operations or joint ventures. The classification depends on the contractual rights and obligations of each investor, rather than the legal structure of the joint arrangement. The Company currently holds interests in joint ventures but has no interest in joint operations. Joint ventures Interests in joint ventures are accounted for using the equity method (see "Equity Method" below), after initially being recognized at cost in the consolidated balance sheet. The following are the Company's joint ventures however, none are considered material to the Company: Significant Joint Ventures Jurisdiction Interest Held Principal Activity HEXO MED A.E. Athens, Greece 51% Intended to serve as the Company's entry point into the European medical cannabis markets. Belleville Complex Inc. Ontario, Canada 25% The venture was established to manage the property of Belleville facility. Associates Associates are all entities over which the Company has significant influence but not control or joint control. This is generally the case where the Company holds between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting (see "Equity Method" below), after initially being recognized at cost The following associates are significant to the Company; however, only Truss Limited Partnership is considered material to the Company: Significant Associates Jurisdiction Interest Held Principal Activity Truss Limited Partnership ("Truss LP") Ontario, Canada 42.5% To pursue opportunities to develop non-alcoholic, cannabis-infused beverages for the Canadian market following adult-use legalization. Truss CBD USA LLC ("Truss CBD US") Colorado, USA 42.5% To explore opportunities for non-alcohol hemp-derived CBD beverages in the State of Colorado. EQUITY METHOD Under the equity method of accounting, the investments are initially recognized at cost and adjusted thereafter to recognize the Company's share of the post-acquisition profits or losses of the investee in profit or loss, and the Company's share of movements in other comprehensive income of the investee in other comprehensive income. Dividends received or receivable from associates and joint ventures are recognized as a reduction in the carrying amount of the investment. Where the Company's share of losses in an equity-accounted investment equals or exceeds its interest in the entity, including any other unsecured long-term receivables, the Company does not recognize further losses, unless it has incurred obligations or made payments on behalf of the other entity. Unrealized gains on transactions between the Company and its associates and joint ventures are eliminated to the extent of the Company's interest in these entities. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity-accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Company. The carrying amount of equity-accounted investments is tested for impairment in accordance with the policy described herein. OPERATING SEGMENTS An operating segment is a component of the Company for which discrete financial information is available and whose operating results are regularly reviewed by the entity's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and that engages in business activities from which it may earn revenue and incur expenses. The Company only has one operating segment.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jul. 31, 2020
Significant Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies CASH AND CASH EQUIVALENTS Cash and cash equivalents are comprised of cash and highly liquid investments that are readily convertibles into known amounts of cash with original maturities of three months or less. RESTRICTED FUNDS Restricted funds represent cash that is pledged as collateral or guarantees for certain of the Company's projects, obligations, and agreements. SHORT TERM INVESTMENTS Short term investments are comprised of liquid investments with maturities between 3 and 12 months. Short term investments are measured at amortized cost using the effective interest method, less loss allowance. TRADE RECEIVABLES Trade receivables are recognized initially at the amount of consideration that is unconditional, unless they contain significant financing components when they are recognized at fair value. Trade receivables are subsequently measured at amortized cost using the effective interest method, less loss allowance. COMMODITY TAX RECOVERIES & OTHER RECEIVABLES The Company measures commodity tax recoveries and other receivables at fair value fair value and subsequently measured at amortized cost, less any provisions for impairment. BIOLOGICAL ASSETS The Company measures biological assets consisting of cannabis plants using the income approach at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of related inventories after harvest. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs (including share based compensation), grow consumables, materials, utilities, facilities costs, depreciation, overhead, quality and testing costs. The identified capitalized direct and indirect costs of biological assets are subsequently recorded within the line item 'costs of goods sold' on the statement of loss and comprehensive loss in the period that the related product is sold. Unrealized gains or losses arising from changes in fair value less cost to sell during the period are included in the results of operations and presented on a separate line of statement of comprehensive loss of the related period. INVENTORY Inventory is valued at the lower of cost and net realizable value. Cost is determined using the weighted average method. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost of the inventory. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Subsequent costs include materials, overhead, depreciation, amortization, and labor related costs (including share-based compensation) involved in packaging and quality assurance. The identified capitalized direct and indirect costs related to inventory are subsequently recorded within 'cost of goods sold' on the statement of loss and comprehensive loss at the time the product is sold, with the exclusion of realized fair value amounts included in inventory sold which are recorded as a separate line within gross profit. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Packaging and supplies are initially valued at cost and subsequently at the lower of cost and net realizable value. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Construction in progress is transferred to a depreciable asset class property, plant and equipment when the assets are available for use and depreciation of the assets commences at that point. Depreciation is provided using the following terms and methods: Land Not depreciated No term Buildings Straight line 5 to 20 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years Construction in progress Not depreciated No term An asset's residual value and useful life are reviewed at each reporting date and adjusted if appropriate. When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of equipment are determined by comparing the proceeds from disposal with the carrying amount of the equipment and are recognized in profit or loss. FINITE LIFE INTANGIBLE ASSETS Finite life intangible assets are measured at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3 to 5 years Patents Straight line 20 years The estimated useful life is reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Research expenditure and development expenditure that do not meet the recognition criteria for intangible assets are recognized as an expense as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period. INDEFINITE LIFE INTANGIBLE ASSETS Indefinite intangible assets are deemed to have no foreseeable limit over which the asset is expected to generate net cash inflows. Following initial recognition, intangible assets with indefinite useful lives are carried at cost less any accumulated impairment losses and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The Company intends to utilize the brand indefinitely. The capitalized brand consists of the Company's premium Up brand, which was recognized upon the acquisition of Newstrike (Note 14). Brand Not amortized Indefinite GOODWILL Goodwill is not amortized but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired and is carried at cost less accumulated impairment losses. Goodwill is allocated to cash-generating units for the purpose of impairment testing. The allocation is made to those cash-generating units or groups of cash-generating units that are expected to benefit from the business combination in which the goodwill arose. The units or groups of units are identified at the lowest level at which goodwill is monitored for internal management purposes, being the Company's single operating segment. IMPAIRMENT OF NON-FINANCIAL ASSETS Goodwill and intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. A CGU's recoverable amount is the higher of its fair value less costs of disposal ("FVLCD") and its value in use ("VIU"). In assessing the VIU, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money to the Company and the risks specific to the asset. BUSINESS ACQUISITION The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the: fair values of the assets transferred liabilities incurred to the former owners of the acquired business equity interests issued by the Company fair value of any asset or liability resulting from a contingent consideration arrangement, and fair value of any pre-existing equity interest in the subsidiary. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. The Company recognises any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest's proportionate share of the acquired entity's net identifiable assets. Acquisition-related costs are expensed as incurred. The excess of the: consideration transferred, amount of any non-controlling interest in the acquired entity, and acquisition-date fair value of any previous equity interest in the acquired entity over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognised directly in profit or loss as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value, with changes in fair value recognised in profit or loss. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognised in profit or loss. NON-CURRENT ASSETS (OR DISPOSAL GROUPS) HELD FOR SALE Non-current assets (or disposal groups) are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable. They are measured at the lower of their carrying amount and fair value less costs to sell, except for assets such as deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are specifically exempt from this requirement. An impairment loss is recognised for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognised for any subsequent increases in fair value less costs to sell of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognised. A gain or loss not previously recognised by the date of the sale of the non-current asset (or disposal group) is recognised at the date of derecognition. Non-current assets (including those part of a disposal group) are not depreciated or amortised while they are classified as held for sale. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognised. Non-current assets classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities represent liabilities for goods and services provided to the Company prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. Accounts payable and accrued liabilities are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method. REVENUE RECOGNITION Revenue from the direct sale of cannabis to customers for a fixed price is recognized when the Company transfers the control of the good(s) to the customer upon delivery and acceptance by the customer. The Company recognizes revenue in an amount that reflects the consideration which the Company expects to receive taking into account the impact which may arise from any rights of return on sales, price concessions or similar obligations. Net revenue is presented net of taxes, estimated returns, allowances and discounts. Canada Revenue Agency ("CRA") levies excise taxes on the sale of medical and adult-us cannabis products. The Company becomes liable for these excise duties when cannabis products are delivered to the customer. The excise taxes payable is the higher of (i) a flat-rate duty which is imposed when a cannabis product is packaged, and (ii) an advalorem duty that is imposed when a cannabis product is delivered to the customer. Effective May 1, 2019, excise tax calculated on edible cannabis products, cannabis extracts and cannabis topicals will prospectively be calculated as a flat rate based on the quantity of total tetrahydrocannabinol (THC) contained in the final product. There were no changes in the legislation in calculating excise taxes for fresh cannabis, dried cannabis, seeds and plants. Net revenue from sale of goods, as presented on the consolidated statements of comprehensive (loss) income, represents revenue from the sale of goods less applicable excise taxes. COST OF GOODS SOLD Cost of goods sold includes cost of inventory expensed, packaging costs, shipping costs and related labor. INCOME TAXES The income tax expense or recovery for the period is the tax payable on the current period's taxable income, based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax expense or recovery is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and considers whether it is probable that a taxation authority will accept an uncertain tax treatment. The Company measures its tax balances either based on the most likely amount or the expected value, depending on which method provides a better prediction of the resolution of the uncertainty. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Deferred tax assets and liabilities are offset where there is a legally enforceable right to offset current tax assets and liabilities and where the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. SHARE-BASED COMPENSATION The Company has an employee stock option plan. The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company's estimate of equity instruments that will eventually vest. Forfeitures are adjusted for on an actual basis. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For stock options granted to non-employees the compensation expense is measured at the fair value of goods and services received except where the fair value cannot be estimated, in which case it is measured at the fair value of the equity instruments granted. Consideration paid by employees or non-employees on the exercise of stock options is recorded as share capital and the related share-based compensation is transferred from share-based payment reserve to share capital. RESTRICTED SHARE UNITS ("RSU's") RSUs are cash or equity settled share-based payments granted to certain employees, directors and executives within the Company. RSUs are measured at their initial fair value on the date of the grant utilizing the Black-Scholes Merton model. The fair value of cash-settled RSUs is revalued at each period end and is recognized as share-based compensation expense over the vesting period with a corresponding adjustment to the liability. Upon the settlement of cash based RSUs, which are valued at the market value at the time of exercise, the related liability is transferred to share capital. The fair value of equity-settled RSUs are recognized in the share-based reserve at the grant date. Upon the settlement of equity-based payments, RSUs are settled in the form of common shares and the related share-based reserve is transferred to share capital. Amounts recorded for forfeited RSUs are transferred to the accumulated deficit in the year of forfeiture or expiry. LOSS PER SHARE Loss per common share represents loss for the period attributable to common shareholders divided by the weighted average number of common shares outstanding during the year. Diluted loss per common share is calculated by dividing the applicable loss for the year by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the year. The calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive. BORROWING COSTS Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in profit or loss in the period which they are incurred. FINANCIAL INSTRUMENTS Financial assets and liabilities are recognized when the Company becomes a party to the contractual provision of the respective instrument. The Company classifies its financial assets in the following measurement categories: • • The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows. The Company has made the following classifications: IFRS 9 Classification Financial assets Cash and cash equivalents Amortized cost Restricted funds Amortized cost Short-term investments Amortized cost Trade receivables Amortized cost Convertible debenture receivable FVTPL Long term investments FVTPL Financial liabilities Accounts payable and accrued liabilities Amortized cost Warrant liabilities FVTPL Deferred rent liability Amortized cost C Amortized cost Lease liabilities Amortized cost Term loan Amortized cost Fair Value Through Profit or Loss ("FVTPL") Financial Assets Financial assets classified and measured at FVTPL are those assets that do not meet the criteria to be classified at amortized cost or at FVTOCI. This category includes debt instruments whose cash flow characteristics are not solely payments of principal and interest ("SPPI") or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell the financial asset. Amortized Cost Financial Assets Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. An amortized cost financial asset is initially measured at fair value, including transaction costs and subsequently at amortized cost using the effective interest rate. Impairment of Financial Assets Financial assets, other than those classified at fair value through profit and loss, are assessed for indicators of impairment at the end of each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected. Financial Liabilities and Other Financial Liabilities Financial liabilities are classified as either financial liabilities at FVTPL or other financial liabilities. Financial liabilities at FVTPL are stated at fair value, with changes being recognized through the consolidated statements of income. Other financial liabilities are initially measured at fair value, net of transaction costs, and are subsequently measured at amortized cost using the effective interest method. Derivatives Derivatives are initially measured at fair value in conjunction with the host contract; no bifurcation is performed, and any directly attributable transaction costs are recognised in profit or loss as incurred. Subsequent to initial recognition, the entire instrument, including the embedded derivative is measured at fair value and changes therein are recognised in profit or loss. The Company has a convertible loan receivable whereby the balance can be converted into equity. See Note 15 for transaction and valuation details. Compound Instruments The component parts of compound instruments (convertible debentures) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company's own equity instruments is an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest rate method until extinguished upon conversion or at the instrument's maturity date. The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized and included in equity and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity. No gain or loss is recognized in profit or loss upon conversion or expiration of the conversion option. Transaction costs that relate to the issue of the convertible debentures are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognized directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the term of the convertible debentures using the effective interest method. For compound instruments with non-equity derivatives, the fair value of the embedded derivative is determined first based on the contractual terms, and the initial carrying amount of the host instrument is the residual amount after separating the embedded derivative. Transaction Costs Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss. FOREIGN CURRENCY TRANSLATION Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Critical Accounting Judgements CGU Impairment CGUs are defined as the lowest level of integrated assets for which there are separately identifiable cash flows that are largely independent of cash flows from other assets or groups of assets. The classification of assets and the allocation of assets into respective CGUs require significant judgment, assumption and interpretations. Areas of judgement in the classification process, include the manner in which management reviews and makes decisions about its operations. The recoverability of assets are assessed at the CGU level and therefore could have a significant impact on impairment losses. Revenue -Principal versus Agent The Company evaluates whether it is the principal (reports on gross basis) or agent (reports on a net basis) for revenues generated by the direct sale of cannabis infused beverages (“CIB’s). The Company control’s the CIB’s prior to the sale to its customers as regulated and mandated under the Cannabis Act and Health Canada legislation. The Company’s control is evidenced by our sole ability to possess the CIB’s once the cannabis distillate has been added and thus establishing the inventory as a cannabis product requiring to be held a licensed producer. It is further evidenced by the Company possessing the sole ability to monetize the sale of CIB’s through the held sales agreements and purchase orders with customers. The Company presents the revenues from the sale of CIBs on a gross basis. Critical Accounting Estimates Valuation of Biological Assets In calculating the fair value less costs to sell of the Company's biological assets, management is required to make a number of estimates, including estimating the stage of growth of the cannabis, harvesting costs, selling costs, sales price and expected yields for the cannabis plant. Observable market selling prices of cannabis derived products less costs to sell are used to estimate the sales prices which are an input in the fair value less costs to sell calculation. Valuation of Inventory In calculating the net realizable value (NRV) of inventory, management determines the selling prices based on prevalent sales prices, selling costs, and includes an estimate of spoiled or expired inventory based on the most reliable evidence available at the time, to record inventory at the lower of cost or net realizable value. Impairment of Property, Plant and Equipment and Intangible Assets, including Goodwill The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets. The impairment is the amount by which the carrying amount of the asset or CGU exceeds its recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal and its value in use. Management exercises judgement in the determination of the Company's CGUs. Provisions Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. Allocation of Purchase Price In determining the allocation of the purchase price, estimates are used based on market research and appraisal values. Business Acquisitions In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates relate to private investments and intangible assets acquired. Management exercises judgment in estimating the probability and timing of when cash flows are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are fair valued using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. Acquisitions that do not meet the definition of a business combination are accounted for as asset acquisitions. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values. Asset acquisitions do not give rise to goodwill. Convertible Debentures Convertible debentures are financial instruments which are accounted for separately dependent on the

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-Term Investments	12 Months Ended
	Jul. 31, 2020
Categories of current financial assets [abstract]
Cash, Cash Equivalents and Short-Term Investments	4. Cash, Cash Equivalents and Short-Term Investments Interest rate July 31, 2020 July 31, 2019 Operating cash — $ 70,318 $ 5,993 High interest savings accounts 0.70% 113,855 107,575 Cash and cash equivalents $ 184,173 $ 113,568 Term deposits & GIC 2.85%-4.25% maturity of 3 to 12 months $ — $ 25,937 Short-term investments $ — $ 25,937

Restricted Funds

Restricted Funds	12 Months Ended
	Jul. 31, 2020
Disclosure Of Restricted Cash [Abstract]
Restricted Funds	5. Restricted Funds July 31, 2020 July 31, 2019 Capital contribution held in trust $ — $ 4,076 Debt service reserve account - term loan (Note 19) 8,191 9,200 Neal Up Brands Inc. (Note 30) — 2,500 Letters of credit, collateral and guarantees for purchases 70 6,574 Total $ 8,261 $ 22,350

Commodity Taxes Recoverable and

Commodity Taxes Recoverable and Other Receivables	12 Months Ended
	Jul. 31, 2020
Commodity Taxes Recoverable And Other Receivables [Abstract]
Commodity Taxes Recoverable and Other Receivables	6. Commodity Taxes Recoverable and Other Receivables July 31, 2020 July 31, 2019 Commodity taxes recoverable $ 12,821 $ 14,415 Accrued interest income — 570 Lease receivable - current ( 1) 630 — Other receivables 3,282 262 Total $ 16,733 $ 15,247 (1)

Convertible Debentures Receivab

Convertible Debentures Receivable	12 Months Ended
	Jul. 31, 2020
Disclosure Of Convertible Note Receivable [Abstract]
Convertible Debentures Receivable	7. Convertible Debentures Receivable July 31, 2020 July 31, 2019 12% Convertible debentures $ — $ 12,024 Zero interest convertible debentures — 1,330 Total $ — $ 13,354 12% CONVERTIBLE DEBENTURES On July 26, 2018, the Company purchased $10,000 in the form of unsecured and subordinated convertible debentures to an unrelated entity, Fire and Flower ("FAF"). The convertible debentures bore interest at 8%, which was paid semi-annually and matured July 31, 2020. The convertible debentures included a conversion feature which allowed for the conversion of the debenture into common shares of FAF at the lower of $1.15 and the share price as defined within the agreement. The Company obtained the debenture as a part of a strategic investment into the private retail cannabis market. The convertible debentures are measured using a level 2 valuation methodology under the fair value hierarchy. The debentures had the option of being converted into common shares or a loan on July 31, 2020, which bore interest at 12%, at the holder's option. On January 23, 2020, $3,000 of debentures were converted using a conversion rate of $1.15 into 2,608,695 common shares of FAF. The Company then fully disposed of these shares on January 27, 2020 at an average market price of $1.0541 for total proceeds of $2,724, net of commission expenses amounting to $26. On February 11, 2020, the remaining $7,000 of debentures were converted using a conversion rate of $1.15 into 6,086,956, common shares of FAF. The Company fully disposed of these shares on February 18, 2020 at an average market price of $0.75 for total proceeds of $4,504 net of commission expenses amounting to $61. The accrued and unpaid interest on February 11, 2020, was $367 which was settled through the issuance of 319,377 common shares of FAF to the Company (Note 11). The realized loss for the year ended July 31, 2020 was $4,396. ZERO INTEREST CONVERTIBLE DEBENTURES On May 24, 2019, the Company obtained $800 of unsecured and subordinated convertible debentures from FAF as a result of the acquisition of Newstrike (Note 14). On May 24, 2019, the debentures carried an initial fair value of $1,220. The convertible debenture bore zero interest and matured on November 30, 2019. On maturity, the debentures converted into 1,000,000 common shares of FAF, at a conversion rate of $0.80, as set out in the agreement (Note 11). The realized loss for the year ended July 31, 2020 was $410.

Inventory

Inventory	12 Months Ended
	Jul. 31, 2020
Classes of current inventories [abstract]
Inventory	8. Inventory As at July 31, 2020 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 29,702 $ 16,981 $ 46,683 Purchased dried cannabis 1,956 — 1,956 Oils 10,805 385 11,190 Hemp derived distillate 566 — 566 Packaging and supplies 4,538 — 4,538 $ 47,567 $ 17,366 $ 64,933 As at July 31, 2019 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 28,996 $ 19,349 $ 48,345 Purchased dried cannabis 8,087 — 8,087 Oils 17,377 5,366 22,743 Hemp derived distillate 1,523 — 1,523 Packaging and supplies 3,156 — 3,156 $ 59,139 $ 24,715 $ 83,854 The Company recognizes the costs of inventory expensed in two separate lines on the consolidated statement of loss. Capitalized costs relating to inventory expensed during the year was included in Cost of goods sold and amounted to $127,424 for the year ended July 31, 2020 (July 31, 2019 – $45,532). The unrealized fair value gain on biological fair value adjustments on the consolidated statement of loss during the year ended July 31, 2020 were $29,356 (July 31, 2019 – $38,856). The realized fair value amounts on inventory sold on the consolidated statement of loss was $40,910 for the year ended July 31, 2020 (July 31, 2019 – $16,357) and included a write down of inventory to its net realizable value of $12,962 (July 31, 2019 - $2,417). Total share-based compensation capitalized to inventory in the year ended July 31, 2020 was $6,105 (2019 - $1,724). Total depreciation capitalized to inventory in the year ended July 31, 2020 was $11,988 (2019 - $4,825). In the year ended July 31, 2020, the Company disposed of inventory of $4,392 (July 31, 2019 - $ nil

Biological Assets

Biological Assets	12 Months Ended
	Jul. 31, 2020
Disclosure of detailed information about biological assets [abstract]
Biological Assets	9. Biological Assets The Company’s biological assets consist of cannabis plants from seeds all the way through to mature plants. The changes in the carrying value of biological assets are as follows: For the years ended July 31, 2020 July 31, 2019 Balance, beginning of year $ 7,371 $ 2,332 Acquired through acquisition 1 — 3,291 Production costs capitalized 38,638 19,215 Net increase in fair value due to biological transformation 29,356 38,856 Transferred to inventory upon harvest (67,131 ) (56,323 ) Disposal of biological assets (663 ) — Balance, end of year $ 7,571 $ 7,371 1 Acquired through the Newstrike acquisition on May 24, 2019 During the year ended July 31, 2020, the Company recorded a loss of $663 relating to plants disposed of prior to harvest (2019 - $ Nil The valuation of biological assets is based on an income approach (Level 3) in which the fair value at the point of harvesting is estimated based on selling prices less the costs to sell. For in process biological assets, the fair value at the point of harvest is adjusted based on the stage of growth at period-end. The significant estimates used in determining the fair value of cannabis plants are as follows: • yield per plant; • stage of growth percentage estimated as costs incurred as a percentage of total cost as applied to the estimated total fair value per gram (less fulfilment costs) to arrive at an in-process fair value for estimated biological assets, which have not yet been harvested; • percentage of costs incurred for each stage of plant growth. • fair value selling price per gram less cost to complete and cost to sell. • destruction/wastage of plants during the harvesting and processing process. Management’s identified significant unobservable inputs, their range of values and sensitivity analysis are presented in the tables below. Unobservable inputs Input values An increase or decrease of 5% applied to the July 31, 2020 July 31, 2019 July 31, 2020 July 31, 2019 Weighted average selling price Derived from actual retail prices on a per product basis using the expected Flower and Trim yields per plant. $3.23 per dried gram $4.23 per dried gram $550 $480 Yield per plant Derived from historical harvest cycle results on a per strain basis. 46 - 135 grams per plant - grams per plant $376 $344 Stage of growth Derived from the estimates of stage of completion within the harvest cycle. Average of 43% completion Average of 29% completion $376 $1,148 Waste Derived from the estimates of planned removal and naturally occurring waste within the cultivation and production cycle. 0%-21% dependent upon the stage within the harvest cycle 0%-30% dependent upon the stage within the harvest cycle No material variance $302

Investments In Associates & Joi

Investments In Associates & Joint Ventures	12 Months Ended
	Jul. 31, 2020
Disclosure Of Associate And Joint Ventures [Abstract]
Investments in Associates & Joint Ventures	10. Investments in Associates & Joint Ventures For the year ended July 31, 2020 July 31, 2019 Truss LP Other Total Truss LP Other Total $ $ $ $ $ $ Opening Balance 51,786 1,063 52,849 — — — Cash contributed to investment 29,155 1,231 30,386 11,476 1,106 12,582 Fair value of warrant consideration — — — 42,386 — 42,386 Capitalized transaction costs — 109 109 720 125 845 Share of net loss for the year (5,975 ) (356 ) (6,331 ) (2,796) (168 ) (2,964 ) Impairment — (707 ) (707 ) — — — Ending Balance 74,966 1,340 76,306 51,786 1,063 52,849 The table below summarises financial information for the Company's associate that are material to the group, which is the investment in Truss LP. The information disclosed reflects the amounts presented in the financial statements of the associate and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, including fair value adjustments and modifications for differences in accounting policy. Truss LP As at July 31, 2020 July 31, 2019 Statement of Financial Position $ $ Cash and cash equivalents 19,561 14,318 Current assets (excluded cash and cash equivalents) 7,867 5,701 Non- current assets 66,863 7,880 Current liabilities 11,112 7,477 Non-current liabilities 8,903 — Period year ended July 31, 2020 11 months ended July 31, 2019 Statement of Comprehensive Loss Revenue 705 (1) — Operating expenses excluding depreciation and amortization (12,243 ) (6,579 ) Depreciation and amortization (617 ) — Other expenses (7 ) — Loss from operations (13,423 ) (6,579 ) Interest income 1 — Interest expenses (233 ) — Income tax expenses — — Total comprehensive loss (13,655 ) (6,579 ) 1 The following table is a reconciliation of summarized financial information of the Company's' significant investment in Truss LP to the carrying amount of the investment for the year ended July 31, 2020 and 2019. For the year ended July 31, 2020 July 31, 2019 $ $ Opening net assets 20,423 — Acquisition of associate/capital calls 68,600 27,002 Total comprehensive loss (14,059 ) (6,579 ) Closing net assets 74,964 20,423 Interest in associate 42.5% 42.5% Interest in associate value 31,860 8,680 Fair value of warrant consideration 42,386 42,386 Capitalized transaction costs 720 720 Total interest in associate value 74,966 51,786 Truss On October 4, 2018, the formation of the entity Truss Limited Partnership between the Company and Molson Coors Canada (the "Partner") was finalized. Truss is a standalone entity with its own board of directors and an independent management team and is incorporated in Canada. Truss is a private limited partnership and its principal operating activities consist of pursuing opportunities to develop non-alcoholic, cannabis-infused beverages. The Partner holds 57,500 common shares representing 57.5% controlling interest in Truss with the Company holding 42,500 common shares and representing the remaining 42.5%. In connection with the formation of Truss, the Company granted the Partner 11,500,000 common share warrants in the Company at an exercise price of $6.00 for a period of three years (Note 16).

Long-term Investments

Long-term Investments	12 Months Ended
	Jul. 31, 2020
Disclosure Of Long Term Investment Abstract
Long-term Investments	11. Long-term Investments Fair value July 31, 2019 Investment/ Divestiture Change in fair value Fair value July 31, 2020 $ $ $ $ $ Level 1 Investments Fire and Flower common shares — 1,232 — 60 1,292 Inner Spirit common shares 3,000 — (643 ) (1,097 ) 1,260 Other long-term investments — 517 — — 517 Level 2 Investments Inner Spirit common share purchase warrants 403 — — (403 ) — Level 3 Investments Greentank Technologies 6,574 — — (6,574 ) — Neal Brothers Inc. 4,000 — — (4,000 ) — Segra International Corp. 300 — — (160 ) 140 Total 14,277 1,749 (643 ) (12,174 ) 3,209 Fair value July 31, 2018 Investment Divesture Change in fair value Fair value July 31, 2019 $ $ $ $ $ Level 1 Investments Fire & Flower Inc. common shares — 2,970 (2,493 ) (477 ) — Fire & Flower Inc. common share purchase warrants 1 — 505 (262 ) (243 ) — Inner Spirit common shares 1 — 2,850 — 150 3,000 Level 2 Investments Inner Spirit common share purchase warrants 1 — 414 — (11 ) 403 Level 3 Investments Greentank Technologies 1 — 6,723 — (149 ) 6,574 Neal Brothers Inc. 1 — 4,000 — — 4,000 Segra International Corp. 100 — — 200 300 Total 100 17,462 (2,755 ) (530 ) 14,277 1 Fire & Flower Common Shares On November 30, 2019, the Company obtained 1,000,000 common shares in FAF through the conversion of its $800 zero interest bearing convertible debentures (Note 16). The debentures were convertible at $0.80 per common share. The fair value of the shares upon conversion was $920. The shares were revalued to $980 using a market rate of $0.98 as at July 31, 2020. The Company incurred a gain of $60 upon revaluation. On February 11, 2020, the Company received 319,377 common shares of FAF as settlement for the accrued and unpaid interest on the FAF convertible debentures on that date (Note 7). The shares were valued to $313 using a market rate of $0.98 as at July 31, 2020. On November 1, 2018, the Company obtained 1,980,000 subscription receipts in FAF for proceeds of $2,970. The subscription receipts converted into common shares of FAF at a 1:1 ratio on February 19, 2019 upon the commencement of trading on the TSX Venture and recognised at an initial fair value of $2,970. On July 25, 2019, the Company liquidated the investment in full resulting in cash proceeds of $2,493. The Level 1 long-term investment fair value and associated realized loss as at July 31, 2019 were $ nil Common Share Purchase Warrants On May 24, 2019, through the acquisition of Newstrike, the Company obtained 1,000,000 common share purchase warrants in the entity FAF. Each warrant entitles the Company to a common share at a ratio of 1:1. The warrants held an initial fair value of $505. The investment was fair valued through the Black-Scholes-Merton option pricing model at $243 and disposed of on July 30, 2019. The Company realized a loss of ($243) as at July 30, 2019 based upon the following assumptions and inputs: market price of $1.33; expected life of 8.4 $ nil 100% volatility based upon comparative market indicators and historical data; and Risk- free interest rate of 1.46%. Inner Spirit Holdings Inc. Common Shares On May 24, 2019, on acquisition of Newstrike, the Company acquired 15,000,000 common shares in Inner Spirit Holdings Inc., which were valued at $2,850 on initial recognition. During the year ended July 31, 2020, the Company disposed of 6,005,500 common shares, at prices ranging from $0.09-$0.15 per share, resulting in a gain of $24 (July 31, 2019 - $ nil Common Share Purchase Warrants On May 24, 2019, through the acquisition of Newstrike, the Company obtained 7,500,000 common share purchase warrants in Inner Spirit Holdings Inc. Each warrant entitles the Company to a common share at a ratio of 1:1. The warrants held an initial fair value of $414. The investment is fair valued through the Black-Scholes-Merton option pricing model. The Company agreed to the early termination of the warrants with the issuer on February 17, 2020 and realized a loss of $403 (July 31, 2019 - unrealized loss of $11). Greentank Technologies On May 24, 2019, on acquisition of Newstrike, the Company acquired 1,953,125 preferred shares of Greentank Technologies, which were valued at $6,723 on acquisition date. During the year ended July 31, 2020, through the assessment of relevant financial information the Company determined the fair value of the investment was $ nil Neal Brothers Brands Inc. The Company also acquired 19.9% of the shares of Neal Brothers Brands Inc. through the acquisition of Newstrike on May 24, 2019. The Company does not hold, nor is it entitled to a board seat. The fair value of the investment was $4,000 on acquisition date. During the year ended July 31, 2020, the private investment was written down to $nil based on the Company's assessment of relevant financial information (July 31, 2019 - $nil) therefore, during the year ended July 31, 2020, the impairment loss totaled $4,000 (July 31, 2019 - $ nil

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jul. 31, 2020
Property, plant and equipment [abstract]
Property, Plant and Equipment	12. Property, Plant and Equipment Cost Land Buildings Leasehold Cultivation Furniture, Construction Right-of-Use Total $ $ $ $ $ $ $ $ At July 31, 2018 1,038 32,536 206 4,031 2,471 15,433 — 55,715 Business acquisitions 4,301 18,855 — 9,913 648 12,286 — 46,003 Additions — 11,365 421 28,085 7,249 117,909 — 165,029 Transfers — 88,078 — — — (88,078 ) — — At July 31, 2019 5,339 150,834 627 42,029 10,368 57,550 — 266,747 Additions — 24,432 1,395 14,969 9,404 66,246 24,405 140,851 Disposals (3,683 ) (18,260 ) — (13,402 ) (909 ) (5,428 ) — (41,682 ) Transfers — 7,943 22,417 (10,135 ) 8 (20,233 ) — — At July 31, 2020 1,656 164,949 24,439 33,461 18,871 98,135 24,405 365,916 Accumulated depreciation and impairments At July 31, 2018 — 533 9 69 771 — — 1,382 Depreciation — 3,859 121 1,497 1,095 — — 6,572 Transfers — — — 650 (650 ) — — — At July 31, 2019 — 4,392 130 2,216 1,216 — — 7,954 Depreciation — 7,395 879 3,702 3,562 — 2,522 18,060 Transfers — — — 271 (271 ) — — — Disposals — (17,081 ) — (7,435 ) (366 ) — — (24,882 ) Impairments 307 19,006 — 9,937 — 48,990 1,178 79,418 At July 31, 2020 307 13,712 1,009 8,691 4,141 48,890 3,700 80,550 Net book value At July 31, 2018 1,038 32,003 197 3,962 1,700 15,433 — 54,333 At July 31, 2019 5,339 146,442 497 39,813 9,152 57,550 — 258,793 At July 31, 2020 1,349 151,237 23,430 24,770 14,730 49,145 20,705 285,366 During the year ended July 31, 2020, the Company capitalized $11,988 (July 31, 2019 – $4,825) of depreciation to inventory. During the year ended July 31, 2020, depreciation expensed to the consolidated statement of loss and comprehensive loss was $6,072 (July 31, 2019 - $1,747). Capitalized borrowing costs to buildings were realized in the year ended July 31, 2020 in the amount of $2,385 (July 31, 2019 – $511) at an average interest rate of 7.22% (July 31, 2019 – 3.2%). Transfers are inclusive of $21,100 ($12,941 of cultivation and production equipment and $8,189 of buildings) added to construction in progress for of non-depreciated assets which the Company has not and cannot utilize. Transfers to construction in progress during the year reflect the activation of an asset's useful life, transitioning from construction in progress to the appropriate property, plant and equipment classification. Right-of-use assets in the year were impaired by an amount of $1,178 due to the abandonment of a commercial administration building which the Company intends to sublease and included in the additions is the deferred rent liability of $1,116, previously accounted for under IAS 17 - Leases IMPAIRMENT AND SALE OF NIAGARA FACILITY On March 2, 2020, the Company completed a strategic review of its cultivation capacity and made the decision to market the Niagara facility for sale. As a result, the carrying amount of the Niagara facility was expected to be recovered principally through its sale. The sale was completed June 17, 2020. The Niagara facility was subject to impairment testing during the fiscal year. The Niagara facility was acquired from Newstrike in May 2019 and consists primarily of equipment, cultivation and processing facilities and land assets that are included within property, plant and equipment, as well as related cultivation and processing licenses that are recorded as intangible assets (Note 13). These assets were previously included in the HEXO CGU. The recoverable amount was determined by reference to fair value less costs of disposal using a market approach. The market approach was based on comparable transactions for similar assets, which is categorized within Level 2 of the fair value hierarchy. As a result, an impairment loss of $31,606 was recorded in property, plant and equipment. Additional impairment losses were recorded for cultivation and processing licenses (Note 13). The adjustments reflect the activation of an asset's useful life, transitioning from construction in progress to the appropriate property, plant and equipment classification. On June 17, 2020, the Company closed the sale of the Niagara Facility for proceeds of $12,250. The sale resulted in a loss of disposal of $2,219. IMPAIRMENT OF CERTAIN OPTIMIZATION PROJECTS As at July 31, 2020, the Company identified an impairment indicator for certain capital assets and expenditures made as a result of suspending certain optimization projects that were under construction. As a result, the Company recorded an impairment loss of $43,585 relating to redundant and idle capital assets, as well as excess leasehold improvement expenditure that is not expected to contribute to future cash flows of the Company. The recoverable amount of the assets was determined to be zero, as the assets have no continuing use to the Company and negligible value would be derived from sale as the assets were highly customised for a specific purpose and location. IMPARIMENT OF HEXO CGU On January 31, 2020, an indicator of impairment was identified for the HEXO CGU as the carrying amount of the Company’s total net assets significantly exceeded the Company’s market capitalization. The HEXO CGU consists of the Company’s Canadian cultivation and production facilities. The recoverable amount of the CGU was determined based on fair value less cost of disposal using a market-based approach (Level 3) based on an income based discounted cash flow analysis (DCF). The Company uses its market capitalization and comparative market multiples to aid in validating the discounted cash flow results. The significant assumptions in the DCF analysis were as follows: i. ii. iii. iv. v. As a result of the impairment, no further impairment losses were required to be recorded.

Intangible Assets

Intangible Assets	12 Months Ended
	Jul. 31, 2020
Changes in intangible assets other than goodwill [abstract]
Intangible Assets	13. Intangible Assets Cost Cultivating and Brand Software Domain Patents Other Total $ $ $ $ $ $ $ At July 31, 2018 2,545 — 1,800 585 — 312 5,242 Business acquisitions 113,888 8,440 12 — — — 122,340 Additions — — 1,746 — 1,231 — 2,977 Transfers — — — — (312 ) (312 ) At July 31, 2019 116,433 8,440 3,558 585 1,231 — 130,247 Additions — — 702 — 875 — 1,577 Disposals — — (550 ) — (173 ) — (723 ) At July 31, 2020 116,433 8,440 3,710 585 1,933 — 131,101 Accumulated amortization At July 31, 2018 403 — 786 9 — — 1,198 Amortization 1,198 — 483 57 29 — 1,767 At July 31, 2019 1,601 — 1,269 66 29 — 2,965 Amortization 3,167 — 697 59 16 — 3,939 Impairment 106,189 2,000 — — — — 108,189 At July 31, 2020 110,957 2,000 1,966 125 45 — 115,093 Net book value At July 31, 2018 2,142 — 1,014 576 — 312 4,044 At July 31, 2019 114,832 8,440 2,289 519 1,202 — 127,282 At July 31, 2020 5,476 6,440 1,744 460 1,888 — 16,008 Research and development expenses in the period amounted to $4,639 (July 31, 2019 - $2,822). The transfer represents $212 of capitalized transaction costs being allocated to the Truss investment in associate (Note 10) and $100 other longer-term investment has been reclassified to long-term investments. IMPAIRMENT In connection with the impairment loss recorded in the second quarter of fiscal 2020, for the Niagara facility, the Company recorded an impairment loss of $106,189 relating to cultivation and processing licenses associated with the Niagara facility. The acquired brand (Note 14) was also impaired by $2,000 as a result of an impairment test as at July 31, 2020.

Business Acquisition

Business Acquisition	12 Months Ended
	Jul. 31, 2020
Disclosure of detailed information about business combination [abstract]
Business Acquisition	14. Business Acquisition Acquisition of Newstrike Brands Limited. On May 24, 2019, the Company acquired 100% of the issued and outstanding common shares of Newstrike Brands Limited (“Newstrike”) pursuant to an arrangement agreement entered into on March 13, 2019. Newstrike is a licensed producer of cannabis operating in Ontario, Canada and was acquired for additional production capacity, established sales relationships and its brand. Under the arrangement, each former Newstrike common share was exchanged for 0.06332 of a HEXO common share (the “Exchange Ratio”), subject to certain exceptions. In addition, all issued and outstanding stock options of Newstrike were replaced with stock options of HEXO having the same terms but adjusted for the Exchange Ratio, and all issued and outstanding common share purchase warrants of Newstrike became exercisable for HEXO common shares adjusted for the Exchange Ratio. The following table summarizes the preliminary values of the net assets acquired from Newstrike on the acquisition date. Note Number of Shares, Warrants and Options Share Price Amount Consideration Shares issued (i) 35,394,041 9.11 322,439 Warrants outstanding (ii) 7,196,164 12,229 Replacement options issued (iii) 2,002,365 7,134 Total fair value of consideration 341,802 Net assets acquired Current assets Cash and cash equivalents 49,366 Accounts receivable 1,204 Other receivables 4,585 Inventory 22,359 Biological assets 3,291 Long-term assets Property, Plant and Equipment 46,003 Investments (iv) 14,492 Convertible debenture receivable 1,220 Prepaid expenses 1,631 Prepaid expense and license 1,526 Software 10 Cultivation and processing license 113,888 Brand 8,440 Goodwill 111,877 Total assets 379,892 Current liabilities Accounts payable and accrued liabilities 12,849 Payment received in advance 5 Long-term liabilities Deferred tax liabilities 24,236 Total liabilities 37,090 Non-controlling 1,000 Total net assets acquired 341,802 Net accounts receivables acquired Total accounts receivable 5,789 Expected uncollectible receivables — Net accounts receivables acquired 5,789 (i) Share price based upon the TSX market price of common shares as at May 24, 2019. (ii) Warrants were valued using the Black-Scholes option pricing model as at the acquisition date May 24, 2019, using the following assumptions and inputs; • Risk free rate of 1.48% – 1.57% • Expected life of 0.73 – 4.07 years • Volatility rate of 75%; determined using historical volatility data • Exercise prices of $11.84 – $27.64 • Stock price of $9.11 (iii) All replacement options were valued using the Black-Scholes option pricing model as at the acquisition date of May 24, 2019, using the following assumptions and inputs; • Risk free rate of 1.48% – 1.57% • Expected life of 1.2 – 4.7 years • Volatility rate of 75%; determined using historical volatility data • Exercise prices of $6.00 – $17.37 • Stock price of $9.11 The fair value of the vested options as at the acquisition date was deemed consideration paid in the transaction. The fair value of those options not yet vested at the acquisition date was added to the Company's share-based payment reserve to be expensed over the remaining vesting period of the options as permitted under IFRS 3 - Business Combinations (iv) Included in total investments were two level 3 private company investments (see ' Greentank Technologies Neal Brothers Inc Newstrike was amalgamated into HEXO Operations Inc on August 1, 2019. During the year ended July 31, 2019, Newstrike contributed net revenue of $2,770 and a net loss of $13,699 to the Company's consolidated results since the date of acquisition. If each acquisition had occurred on August 1, 2018, management estimates that the Company's consolidated net revenue would have increased by $9,287 and the net loss would have increased by $19,096 for the year ended July 31, 2019. Goodwill arising from the acquisition represents the expected synergies, future income and growth, and other intangibles that do not qualify for separate recognition. None of the goodwill arising on these acquisitions are expected to be deductible for tax purposes. During the year ended July 31, 2020, the associated Goodwill was assessed for impairment and written down to $Nil (Note 15). The Non-Controlling Interest ("NCI") acquired at the acquisition date arises from Newstrike holding a 60% interest in Neal Brothers Inc. The net assets of Neal Brothers Inc. consist of cash only and the NCI was measured at its fair value. The NCI acquired at the acquisition date arises from Newstrike holding a 60% interest in Neal Brothers Inc. as the NCI relates to the joint venture Neal Up Brands Inc. During the year ended July 31, 2020, the NCI was eliminated through the effective dissolution of the entity, there existed no operations and all cash was returned to the owners. Total non-capitalized transaction expenses in the year ended July 31, 2020 amounted to $ nil

Goodwill

Goodwill	12 Months Ended
	Jul. 31, 2020
Goodwill [Abstract]
Goodwill	15. Goodwill Balance as at July 31, 2018 $ — Additions 111,877 Balance as at July 31, 2019 $ 111,877 Impairment (111,877 ) Balance as at July 31, 2020 $ — Goodwill initially recognized on acquisition of Newstrike Brands Limited ("Newstrike") on May 24, 2019 and is monitored at the operating segment level, which is a company-wide level ("HEXO Corporate CGU"). On January 31, 2020, the carrying amount of the Company's total net assets significantly exceeded the Company's market capitalization. In addition, slower than expected retail store roll outs in Canada and delays in government approval for cannabis derivative products resulted in a constrained distribution channels, which have adversely affected overall market sales and profitability. As a result of these factors, management performed an indicator-based impairment test of goodwill as at January 31, 2020. The recoverable amount was determined based on fair value less cost of disposal using a market-based approach (Level 2) which considered both the adjusted current market capitalization of the Company and an income based discounted cash flow analysis (DCF). The calculation of the adjusted market capitalization was based on the share price of the Company on January 31, 2020, adjusted for a control premium of 10%, which was estimated by reference to premiums in recent acquisitions involving control, and from data on empirical control premium studies that considered industry, pricing, background, deal size, and timing of the observed premiums. If all other assumptions were held constant, and the share price declined by 5%, the impairment loss would increase by $26,647. If all other assumption were held constant and the control premium was decreased by 5%, the impairment loss would increase by $24,283.The income based Discounted cash flow ("DCF") analysis (Level 3) was also used to corroborate the results of the adjusted market capitalisation based valuation. The significant assumptions in the DCF analysis were as follows: i. ii. iii. iv. As a result, management concluded that the carrying value of the HEXO Corporate CGU was higher than the recoverable amount and recorded a goodwill impairment loss of $111,877 during the second quarter of fiscal year 2020. The Company's goodwill impairment loss for the year ended July 31, 2020 was $111,877 (July 31, 2019 - $ nil

Warrant Liabilities

Warrant Liabilities	12 Months Ended
	Jul. 31, 2020
Warrant Liabilities [Abstract]
Warrant Liabilities	16. Warrant Liabilities 2017 Unsecured Convertible Debentures Warrants USD$25,000 USD$20,000 Total Opening balance as at August 1, 2018 $ 3,130 $ — $ — $ 3,130 Exercised (6,367 ) — — (6,367 ) Loss in revaluation of financial instruments 3,730 — — 3,730 Balance as at July 31, 2019 $ 493 $ — $ — $ 493 Issued — 5,629 3,967 9,596 Exercised (106 ) — — (106 ) (Gain) in revaluation of financial instruments (387 ) (3,712 ) (2,434 ) (6,533 ) Balance as at July 31, 2020 $ — $ 1,917 $ 1,533 $ 3,450 USD$20,000 Registered Direct Offering - Warrants On January 21, 2020, the Company closed a registered direct offering with institutional investors for gross proceeds of USD$20,000 (Note 12). Under this offering, the Company issued 5,988,024 common share purchase warrants with an exercise price of USD$2.45 per share with a five year-term. The warrants are classified as a liability because the exercise price is denominated in US dollars, which is different to the functional currency of the Company. The warrant liability was initially recognized at $3,967 using the Black-Scholes-Merton option pricing model (Level 2), using the following assumptions: stock price of USD$1.45 expected life of 2.5 years; $ nil 80% volatility based upon historical data; risk free interest rate of 1.57%; and USD/CAD exchange rate of 1.3116. Financing costs of $223 were expensed at recognition. The warrant liability was revalued on July 31, 2020 using the Black-Scholes-Merton option pricing model (Level 2). The warrant liability was revalued to $1,533 (USD$1,144) using the following assumptions: stock price of USD$0.68; expected life of 2.5 years; $ nil 97% volatility based upon historical data; risk-free interest rate of 0.22%; and USD/CAD exchange rate of 1.3404. The gain on the revaluation of the warrant liability during the year ended July 31, 2020 was $2,434 which is recorded in Other income and losses on the consolidated statements of loss and comprehensive loss. USD$25,000 Registered Direct Offering - Warrants On December 31, 2019, the Company closed a registered direct offering with institutional investors for gross proceeds of USD$25,000 (Note 12). Under this offering, the Company issued 7,485,032 common share purchase warrants with an exercise price of USD$2.45 per share with a five year-term. The warrants are classified as a liability because the exercise price is denominated in US dollars, which is different to the functional currency of the Company. The warrant liability was initially recognized at $5,629 using the Black-Scholes-Merton option pricing model (Level 2), using the following assumptions: stock price of USD$1.59; expected life of 2.5 years; $ nil 79% volatility based upon historical data; risk-free interest rate of 1.71%; and USD/CAD exchange rate of 1.2988. Financing costs of $350 were expensed at recognition. The warrant liability was revalued on July 31, 2020 using the Black-Scholes-Merton option pricing model (Level 2). The warrant liability was revalued to $1,917 (USD$1,430) using the following assumptions: stock price of USD$0.68; expected life of 2.5 years; $ nil 97% volatility based upon historical data; risk-free interest rate of 0.22%; and USD/CAD exchange rate of 1.3404. The gain on the revaluation of the warrant liability during the year ended July 31, 2020 was $3,712 which is recorded in Other income and losses on the consolidated statements of loss and comprehensive loss. 2017 Unsecured Convertible Debenture - Warrants During the year ended July 31, 2020, 71,424 warrants were exercised prior to the expiry date of November 14, 2019, for cash proceeds of $72 (USD$54), based on an exercise price of USD$0.76. The gain on the revaluation of the warrant liability during the year ended July 31, 2020 was $387 which was recorded in Revaluation of financial instruments gain/(loss) on the consolidated statements of loss and comprehensive loss. During the year ended July 31, 2019, 863,693 warrants were exercised for cash proceeds of $863 (USD$656), based on an exercise price of USD$0.76. On the various dates of exercise, the warrant liability was revalued using the Black-Scholes-Merton option pricing model. Overall, the fair value of the warrants on exercise date was $6,367 (USD$4,819) using the following inputs: stock prices ranging from $5.90 to $10.36; expected life of 12 months; $ nil 75% volatility based upon comparative market indicators and historical data; Risk- free interest rates of 1.55% to 2.35%; and USD/CAD exchange rate of various. The warrant liability was revalued on July 31, 2019 using the Black-Scholes-Merton option pricing model (Level 2). The warrant liability was revalued to $493 (US$375); with a stock price of US$4.24; expected life of 12 months; $ nil

Convertible Debentures

Convertible Debentures	12 Months Ended
	Jul. 31, 2020
Debt instruments held [abstract]
Convertible Debentures	17. Convertible Debentures Balance as at July 31, 2019 $ — Issued at amortized, net issuance costs 45,922 Conversion (20,603 ) Interest expense 6,854 Interest paid (3,205 ) Balance as at July 31, 2020 $ 28,969 $70,000 Private Placement Unsecured Convertible Debentures On December 5, 2019, the Company closed a $70,000 private placement of convertible debentures. The Company issued a total of $70,000 principal amount of 8.0% unsecured convertible debentures maturing on December 5, 2022 (the "Debentures"). The Debentures are convertible at the option of the holder at any time after December 7, 2020 and prior to maturity at a conversion price of $3.16 per share (the "Conversion Price"), subject to adjustment in certain events. The Company may force the conversion of all of the then outstanding Debentures at the Conversion Price at any time after December 7, 2020 and prior to maturity on 30 days' notice if the daily volume weighted average trading price of the common shares of the Company is greater than $7.50 for any 15 consecutive trading days. At any time on or before December 4, 2020, the ‎Company may repay all, but not less than all, of the principal amount of the ‎Debentures, ‎plus accrued and unpaid interest. Upon maturity, the holders of the Debentures ‎have the right to require the Company to repay any principal amount of their ‎Debentures through the issuance of common shares of the Company in satisfaction of such ‎amounts at a price equal to the volume weighted average trading price of the ‎common shares on the TSX for the five trading days immediately preceding the ‎payment date. Upon recognition, the Company allocated the gross proceeds first to the discounted gross proceeds of the debentures, which amounted to $46,098. The remaining balance of $23,902, was allocated to the conversion feature, which represents its inherent fair value. In connection to closing the private placement, the Company incurred costs and fees of $204, which were allocated on a pro rata basis to the convertible debentures and conversion feature in the amounts of $176 and $28, respectively. Early Conversion Inducement In May 2020, the Company provided notice to all holders of the Debentures of an option to voluntarily convert their Debentures into units of the Company (the "Conversion Units") at a discounted early conversion price of $0.80 (the "Early Conversion Price") calculated based on the 5-day volume weighted average HEXO Corp. market prices (the "VWAP") preceding the announcement. The VWAP unitized data from both the TSX and NYSE. Each Conversion Unit will provide the holder one common share and one half common share purchase warrant (with an exercise price of $1.00 and term of three years). The early conversion occurred in two phases, the first being on June 10, 2020 followed by the second and final phase June 30, 2020. During phases one and two, $23,595 principal amount, or approximately 34%, and $6,265 principal amount, or approximately 9% of the Debentures were converted under the Early Conversion Price into 29,493,750 and 7,831,250 common shares and 14,746,875 and 3,915,625 common share purchase warrants of HEXO Corp, respectively. In accordance with IAS 32 - Financial Instruments: Presentation The loss is calculated as the difference between the fair value of the consideration the holders received on conversion under the revised terms and the fair value of the consideration the holders would have received under the original terms of the agreement. On July 31, 2020, there remains $40,140 in principal debentures, the net present value of the debt was $26,600 and the remaining balance of $13,540, was allocated to the conversion feature. Interest expense for the year ended July 31, 2020 was $6,854. The Company made interest payments of $3,205 in the year ended July 31, 2020. The accrued and unpaid interest as at July 31, 2020 was $202.

Lease Liabilities

Lease Liabilities	12 Months Ended
	Jul. 31, 2020
Disclosure of quantitative information about leases for lessee [abstract]
Lease Liabilities	18. Lease Liabilities The following is a continuity schedule of lease liabilities for the year ended July 31, 2020: $ Balance as at July 31, 2019 — Adjustment on adoption of IFRS 16 (Note 3) 21,360 Balance as at August 1, 2019 21,360 Lease additions 9,030 Lease payments (4,341 ) Interest expense on lease liabilities 3,067 Balance as at July 31, 2020 29,116 Current portion 4,772 Long-term portion 24,344 The Company's leases consist of administrative real estate leases and a production real estate property. The Company expensed variable lease payments of $3,769 for the year ended July 31, 2020. The following table is the Company's lease obligations over the next five fiscal years and thereafter as at July 31, 2020: Fiscal year 2021 2022 - 2023 2024 - 2025 Thereafter Total $ $ $ $ $ Lease obligations 4,737 9,787 8,764 31,082 54,370

Term Loan (Revised)

Term Loan (Revised)	12 Months Ended
	Jul. 31, 2020
Borrowings [abstract]
Term Loan (Revised)	19. Term Loan (Revised) Term Loan On February 14, 2019, the Company entered into a syndicated credit facility with Canadian Imperial Bank of Commerce ("CIBC") as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent (together "the Lenders"). The Lenders provided the Company with up to $65,000 in secured debt financing at a rate of interest that is expected to average in the mid-to-high 5% per annum range. The credit facility consisted of an up to $50,000 term loan ("Term Loan") and up to a $15,000 in a revolving credit facility ("Revolving Loan"). The credit facility matures in February 14, 2022. The Company may repay the loan without penalty, at any time and the loan is secured against the Company's property, plant and equipment. The Company shall repay at minimum 2.5% of the initial amount drawn each quarter per the terms of the credit facility agreement. On February 14, 2019, the Company received $35,000 on the Term Loan and incurred financing costs of $1,347. The Company had the ability to draw the remaining $15,000 on the Term Loan on or before December 31, 2019, which it did not exercise, as a result, that portion of the facility expired on December 31, 2019. On January 31, 2020, the Company amended its credit facility which resulted in: (i) i. ii. iii. (ii) re-instatement of the $15,000 Term Loan capacity that previously expired un-used on December 31, 2019. In order for the Company to draw on this additional capacity, the Company must be (i) in compliance with its debt covenants; and (ii) achieve net revenue of $28,400 for the quarter ended July 31, 2020. These conditions were not satisfied as at July 31, 2020 and therefore the Term Loan capacity was not drawn upon and is no longer available to the Company. The Company was in compliance with the revised financial covenants noted above as at July 31, 2020. On July 31, 2020 the Company was not in compliance with an administrative banking covenant which mandated that the Company not have a Canadian dollar operating banking account with any institution other than the Lenders. The Company was subject to the covenant 90 days after entering the syndicated credit facility on February 14, 2019. The Company received an amendment on October 29, 2020 allowing it to rectify this administrative breach by April 27, 2021. However, since the amendment was received after July 31, 2020, the Company has classified its Term Loan as a current liability and has revised the applicable comparative information (Note 37) to reflect the same. During the year ended July 31, 2020, total interest expense and total interest capitalized were $723 (July 31, 2019 - $252) and $896 (July 31, 2019 - $511). Non-cash interest expense relating to the amortization of deferred financing costs was $501 for the year ended July 31, 2020 (July 31, 2019 - $387). The following table illustrates the continuity schedule of the term loan as at July 31, 2020 and July 31, 2019: July 31, 2020 July 31, 2019 (Revised – Note 37) Term loan $ $ Opening balance 34,125 — Additions — 35,000 Repayments (3,500 ) (875 ) Ending balance 30,625 34,125 Deferred financing costs $ $ Opening balance (751 ) — Additions (445 ) (1,643 ) Adjustments — 296 Amortization of deferred finance costs 501 596 Ending balance (695 ) (751 ) Total term loan 29,930 33,374 Current portion 3,069 3,117 Long-term portion 26,861 30,257

Share Capital

Share Capital	12 Months Ended
	Jul. 31, 2020
Share Capital [Abstract]
Share Capital	20. Share Capital (a) Authorized An unlimited number of common shares and an unlimited number of special shares, issuable in series. (b) Issued and Outstanding As at July 31, 2020, a total of 482,465,748 (July 31, 2019 - 256,981,753) common shares were issued and outstanding. No special shares have been issued or are outstanding. Number of shares Share Capital Balance at July 31, 2019 256,981,753 $ 799,706 June 2020 at the market offering (i) 32,942,479 33,263 May 2020 underwritten public offering (ii) 63,940,000 43,495 April 2020 underwritten public offering (iii) 59,800,000 22,928 January 2020 registered offering (iv) 11,976,048 21,073 December 2019 registered offering (v) 14,970,062 25,229 December 2019 private placement Note 17 37,325,000 72,005 Options exercised Note 22 116,532 223 Warrants exercised Note 21 4,413,874 5,866 Balance at July 31, 2020 482,465,748 $ 1,023,788 (i) June 2020 At-the-market ("ATM") Offering On June 16, 2020, the Company established an ATM equity program allowing the Company to issue up to $34,500 (or its U.S. dollar equivalent) of common shares to the public. The common shares sold through the ATM program were sold through the TSX, the NYSE and other marketplaces on which the common shares were listed, quoted or otherwise traded, at the prevailing market price at the time of sale. The program closed on July 31, 2020 and a total of approximately $34,551 (after foreign exchange gains) was generated through the issuance of 32,942,479 common shares in the year ended July 31, 2020. On July 31, 2020 a receivable of $883 remained for irrevocable sales which occurred prior to year end and subsequently settled on August 5, 2020, at which time the remaining 979,500 shares were issued. Total issuance costs and broker fees amounted to $1,288. (ii) May 2020 Underwritten Public Offering On May 21, 2020 the Company closed an underwritten public offering for total gross proceeds or $57,545 through the issuance of 63,940,000 units at a price of $0.90 per unit. Each unit contained one common share and one half common share purchase warrant (Note 21) at an exercise price of $1.05. The net contribution to share capital, after warrant reserve adjustment, was $46,547 and total issuance costs amounted to $3,052. (iii) April 2020 Underwritten Public Offering On April 13, 2020, the Company closed an underwritten public offering in which 59,800,000 units were issued at $0.77 a unit for total gross proceeds of $46,046. Each unit consisted of one common share and one common share purchase warrant (Note 21) at an exercise price of $0.96. The net contribution to share capital after warrant reserve was $25,863 and total issuance costs amounted to $2,936. (iv) January 2020 Registered Direct Offering On January 22, 2020, the Company closed a registered direct offering in which 11,976,048 common shares were issued at $USD1.67 each for total gross proceeds of $26,290 (USD$20,000). Investors also received one half common share purchase warrant for each common share purchased (Note 21) at an exercise price of $USD2.45. The net contribution to share capital, after warrant reserve adjustment, was $22,323 and total issuance costs amounted to $1,250. (v) December 2019 Registered Direct Offering On December 31, 2020, the Company closed a registered direct offering in which 14,970,062 common shares were issued at $USD1.67 each for total gross proceeds of $32,411 (USD$25,000). Investors also received one half common share purchase warrant for each common share purchased (Note 21) at an exercise price of $USD2.45.

Common Share Purchase Warrants

Common Share Purchase Warrants	12 Months Ended
	Jul. 31, 2020
Disclosure Of Common Share Purchase Warrants [Abstract]
Common Share Purchase Warrants	21. Common Share Purchase Warrants The following table summarizes warrant activity during the year ended July 31, 2020 and year ended July 31, 2019. July 31, 2020 July 31, 2019 Number of Weighted average Number of Weighted average warrants exercise price 2 warrants exercise price Outstanding, beginning of year 29,585,408 $ 9.95 26,425,504 $ 4.35 Expired (15,559,483 ) 12.25 (531 ) — Assumed and reissued through acquisition 1 — — 7,196,164 23.10 Issued 123,905,556 1.24 11,500,000 6.00 Exercised (4,413,874 ) 0.97 (15,535,729 ) 3.61 Outstanding, end of year 133,517,607 $ 1.90 29,585,408 $ 9.95 1 2 No broker compensation warrants were exercised during the year ended July 31, 2020 (July 31, 2019 - 1,916,527). The following table summarizes the warrants issued during the years ended July 31, 2020 and July 31, 2019. Issuance date Exercise price Warrants Expiry period October 4, 2018 $6.00 11,500,000 3 years May 24, 2019 (1) $11.84-$27.64 7,196,164 0.73—4.07 years Total assumed and issued during the year ended July 31, 2019 18,696,164 December 31, 2019 USD$2.45 7,485,032 5 years January 22, 2020 USD$2.45 5,988,024 5 years April 13, 2020 $0.96 59,800,000 5 years May 21, 2020 $1.05 31,970,000 5 years June 10, 2020 $1.00 14,746,875 3 years June 30, 2020 $1.00 3,915,625 3 years Total issued during the year ended July 31, 2020 123,905,556 1 The following is a consolidated summary of warrants outstanding as at July 31, 2020 and July 31, 2019. July 31, 2020 July 31, 2019 Number Book value Number Book value Classified as Equity $ $ 2018 Equity financing Exercise price of $5.60 expired January 30, 2020 — — 10,512,208 5,674 February 2018 financing warrants Exercise price of $27.64 expired February 16, 2020 — — 4,413,498 1,331 June 2019 financing warrants Exercise price of $15.79 expiring June 19, 2023 2,184,540 10,022 2,184,540 9,998 April 2020 underwritten public offering warrants Exercise price of $0.96 expiring April 13, 2025 56,017,500 18,906 — — May 2020 underwritten public offering warrants Exercise price of $1.05 expiring May 21, 2025 31,410,050 10,805 — — Conversion Unit warrants Exercise price of $1.00 expiring June 10, 2023 14,746,875 11,426 — — Exercise price of $1.00 expiring June 30, 2023 3,915,625 1,928 — — Broker / Consultant warrants Exercise price of $20.85 expired February 16, 2020 — — 264,809 160 Exercise price of $11.84 expired June 19, 2020 — — 262,021 610 Exercise price of $0.75 expiring November 3, 2021 175,618 78 175,618 78 Exercise price of $0.75 expiring March 14, 2022 94,282 66 94,282 66 Exercise price of $15.79 expiring June 19, 2023 61 — 61 — Inner Spirit warrants Exercise price of $15.63 expired July 21, 2020 — — 71,235 129 Molson warrants Exercise price of $6.00 expiring October 4, 2021 11,500,000 42,386 11,500,000 42,386 120,044,551 95,617 29,478,272 60,432 Classified as Liability 2017 secured convertible debenture warrants Exercise price of USD$0.76 expired November 14, 2019 — — 107,136 493 USD$25m Registered Direct Offering Warrants Exercise price of USD$2.45 expiring December 31, 2024 7,485,032 1,917 — — USD$20m Registered Direct Offering Warrants Exercise price of USD$2.45 expiring January 22, 2025 5,988,024 1,533 — — 13,473,056 3,450 107,136 493 133,517,607 99,067 29,585,408 60,925

Share-based Compensation

Share-based Compensation	12 Months Ended
	Jul. 31, 2020
Stock Options And Restricted Share Units [Abstract]
Share-based Compensation	22. Share-based Compensation Omnibus Plan The Company has a share option plan (the "Former Plan"), adopted in July 2017, that was administered by the Board of Directors who established exercise prices and expiry dates. Expiry dates are up to 10 years from issuance, as determined by the Board of Directors at the time of issuance. On June 28, 2018, the Board of Directors put forth a new share option plan (the "Omnibus Plan") which was approved by shareholders on August 28, 2019. Unless otherwise determined by the Board of Directors, options issued under both the Former Plan and Omnibus Plan vest over a three-year period. The maximum number of common shares reserved for issuance for options that may be granted under the Omnibus Plan is 10% of the issued and outstanding common shares or 48,246,574 common shares as at July 31, 2020 (July 31, 2019 - 25,698,175). The Omnibus plan is subject to cash and equity settlement, the Former Plan and Newstrike plan are subject to equity settlements. Options issued prior to July 2018 under the outgoing plan and the options assumed through the acquisition of Newstrike do not contribute to the available option pool reserved for issuance. As of July 31, 2020, the Company had 25,288,328 issued and outstanding under the Omnibus Plan, 4,305,048 issued and outstanding under the Former Plan and 421,327 issued and outstanding under the assumed Newstrike plan. Stock Options The following table summarizes stock option activity during the year ended July 31, 2020 and the year ended July 31, 2019. July 31, 2020 July 31, 2019 Number of Weighted average Number of Weighted average options exercise price options exercise price Opening balance 24,288,919 $ 5.87 14,388,066 $ 3.02 Granted 11,946,027 1.62 12,693,118 7.27 Acquired and reissued through acquisition 1 — — 2,002,365 9.49 Forfeited (4,582,440 ) 5.55 (1,226,763 ) 6.33 Expired (1,521,271 ) 9.16 — — Exercised (116,532 ) 1.15 (3,567,867 ) 1.20 Closing balance 30,014,703 $ 4.07 24,288,919 $ 5.87 1 The following table summarizes the stock option grants during the years ended July 31, 2020 and July 31, 2019. Options granted Grant date Exercise price Executive and Non-executive Total Vesting terms Expiry period September 17, 2018 7.93 650,000 523,500 1,173,500 Terms A 10 years November 22, 2018 5.92 — 440,000 440,000 Terms A 10 years December 17, 2018 5.09 74,000 227,500 301,500 Terms A, C 10 years February 19, 2019 7.13 615,000 626,000 1,241,000 Terms A 10 years February 21, 2019 7.46 3,333,333 — 3,333,333 Terms D 10 years March 20, 2019 8.50 325,000 1,077,500 1,402,500 Terms A 10 years April 17, 2019 8.24 — 1,132,500 1,132,500 Terms A 10 years July 18, 2019 6.54 650,000 2,768,785 3,418,785 Terms A 10 years July 26, 2019 5.88 250,000 — 250,000 Terms A 10 years Total 5,897,333 6,795,785 12,693,118 October 29, 2019 3.30 829,034 2,732,277 3,561,311 Terms B 10 years January 29, 2020 1.80 — 293,021 293,021 Terms B 10 years April 28, 2020 0.69 900,000 2,565,322 3,465,322 Terms B 10 years June 26, 2020 1.02 3,055,025 732,410 3,787,435 Terms B 10 years July 28, 2020 0.96 — 838,938 838,938 Terms B 10 years Total 4,784,059 7,161,968 11,946,027 Vesting terms A - One-third of the options will vest on the one-year anniversary of the date of grant and the balance will vest quarterly over two years thereafter. Vesting terms B - One-third of the options will vest on each of the one-year anniversaries of the date of grant over a three-year period. Vesting terms C - 54,000 of the options granted to a director will fully vest 6-months from the grant date. Vesting terms D - Based upon organizational milestones. The following table summarizes information concerning stock options outstanding as at July 31, 2020. Exercise price Number outstanding Weighted average Number exercisable Weighted average $0.58-$2.69 11,371,022 8.87 2,769,874 6.08 $3.30-$6.54 12,100,157 6.21 6,002,653 7.85 $7.13-$8.50 6,302,656 8.53 1,547,062 8.44 $8.84-$17.37 240,868 1.67 220,285 1.74 30,014,703 10,539,874 Restricted Share Units ("RSUs") Under the Omnibus Plan, the Board of Directors is authorized to issue RSUs up to 10% of the issued and outstanding common shares, inclusive of the outstanding stock options. At the time of issuance, the Board of Directors establishes conversion values and expiry dates, which are up to 10 years from the date of issuance. The restriction criteria of the units are at the discretion of the Board of Directors and from time to time may be inclusive of Company based performance restrictions, employee-based performance restrictions or no restrictions to the units. The following table summarizes RSU activity during the year ended July 31, 2020 and the year ended July 31, 2019. July 31, 2020 July 31, 2019 Units Value of units Units Value of units Opening balance — $ — — $ — Granted 2,438,548 2.13 — — Forfeited (90,114 ) 2.94 — — Closing balance 2,348,434 $ 2.10 — $ — The following table summarizes the RSUs granted during the year ended July 31, 2020. No RSUs were issued in the year ended July 31, 2019. RSUs granted Grant date Unit value Executive and Non-executive Vesting terms Expiry period October 29, 2019 $0.53 - $1.16 1,428,449 — Terms A, B 10 years June 26, 2020 $0.71 1,010,101 — Terms A 10 years Vesting terms A - One-third of the units vest on each of the one-year anniversaries for the first three years after the grant date. Vesting terms B - The units vest in full on the third-year anniversary after the grant date. Share-based Compensation For the year ended July 31, 2020, the Company realized $31,896 (July 31, 2019 - $29,732), in total share-based compensation (expensed and capitalized), $406 (July 31, 2019 - $ nil July 31, 2020 July 31, 2019 Exercise price (weighted average) $ 6.51 $ 5.99 Stock price (weighted average) $ 6.61 $ 6.11 Risk-free interest rate (weighted average) 1.79% 2.11% Expected life (years) of options (weighted average) 5 5 Expected annualized volatility (weighted average) 75% 69% Volatility was estimated using the average historical volatility of the Company and comparable companies in the industry that have trading history and volatility history. For the year ended July 31, 2020, the Company allocated to inventory $6,105 (July 31, 2019 - $1,724) of share-based compensation applicable to direct and indirect labour in the cultivation and production process. The cash-settled share-based compensation liability is presented in Other liabilities. The following table summarizes the Company's equity-settled and cash-settled share-based payments for the year ended July 31, 2020 and 2019. For the year ended July 31, 2020 July 31, 2019 Stock option share-based compensation $ 31,503 $ 29,793 RSU share-based compensation — — Total equity-settled share-based compensation 31,503 29,793 RSU share-based compensation 393 — Total cash-settled share-based compensation $ 393 $ —

Net Loss per Share

Net Loss per Share	12 Months Ended
	Jul. 31, 2020
Earnings per share [abstract]
Net Loss per Share	23. Net Loss per Share The following securities could potentially dilute basic net loss per share in the future but have not been included in diluted loss per share because their effect was anti-dilutive: Instrument July 31, 2020 July 31, 2019 Stock Options 29,996,748 24,288,919 RSUs 2,348,434 — 2017 Secured convertible debenture warrants — 107,136 2018 Equity warrants — 10,512,208 2018 February 2018 financing warrants — 4,413,498 2019 June financing warrants 2,184,540 2,184,540 USD$25m registered direct offering warrants 7,485,032 — USD$20m registered direct offering warrants 5,988,024 — 2020 April underwritten public offering warrants 56,017,500 — 2020 May underwritten public offering warrants 31,410,050 — Warrants issued under conversion of debentures 18,662,500 — Joint venture and Inner Spirit issued warrants 11,500,000 11,571,235 Convertible debenture broker/finder warrants 269,961 796,791 165,862,789 53,874,327

Financial Instruments

Financial Instruments	12 Months Ended
	Jul. 31, 2020
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	24. Financial Instruments Market Risk Interest Risk The Company has minimal exposure to interest rate risk related to any investments of cash and cash equivalents and its term loan. The Company may invest cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. As at July 31, 2020, the Company had short-term investments of $ nil Price Risk Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company's level 1 and 2 investments are susceptible to price risk arising from uncertainties about their future outlook, future values and the impact of market conditions. The fair value of marketable securities and derivatives held in publicly traded entities is based on quoted market prices, which the shares of the investments can be exchanged for. The Company has early converted $29,860 of the aggregate principal amount of its 8% unsecured convertible debentures (Note 17) which partially mitigates the Company's Price Risk. There would be no material impact (July 31, 2019 - $340) if the fair value of these financial assets were to increase or decrease by 10% as of July 31, 2020. The price risk exposure as at July 31, 2020 is presented in the table below. July 31, 2020 July 31, 2019 $ $ Financial assets 2,692 16,756 Financial liabilities (3,450 ) (493 ) Total exposure (758 ) 16,263 Credit Risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's trade receivables and convertible debentures receivable. As at July 31, 2020, the Company was exposed to credit related losses in the event of non-performance by the counterparties. The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Since the majority of the medical sales are transacted with clients that are covered under various insurance programs, and adult use sales are transacted with crown corporations, the Company has limited credit risk. Cash and cash equivalents and short-term investments are held with four Canadian commercial banks that hold Dun and Bradstreet credit ratings of AA (July 31, 2019 - AA) and $176 is held with a credit union that does not have a publicly available credit rating. The majority of the trade receivables balance is held with crown corporations of Quebec, Ontario and Alberta. Creditworthiness of a counterparty is evaluated prior to the granting of credit. The Company has estimated the expected credit loss using a lifetime credit loss approach. The current expected credit loss for the year ended July 31, 2020 is $35 (July 31, 2019 - $37). In measuring the expected credit losses, the adult-use cannabis trade receivables have been assessed on a per customer basis as they consist of a low number of material contracts. Medical trade receivables have been assessed collectively as they have similar credit risk characteristics. They have been grouped based on the days past due. Credit risk from the convertible debenture receivable arises from the possibility that principal and/or interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationship. The carrying amount of cash and cash equivalents, restricted cash, short-term investments, trade receivables and convertible debentures receivable represents the maximum exposure to credit risk and as at July 31, 2020; this amounted to $211,860 (July 31, 2019 - $194,902). The following table summarizes the Company's aging of trade receivables as at July 31, 2020 and July 31, 2019: July 31, July 31, 2020 2019 $ $ 0-30 days 15,253 14,102 31-60 days 2,972 1,826 61-90 days 412 166 Over 90 days 789 3,599 Total 19,426 19,693 Economic Dependence Risk Economic dependence risk is the risk of reliance upon a select number of customers, which significantly impacts the financial performance of the Company. For the year ended July 31, 2020, the Company's recorded sales to the crown corporation; Société québécoise du cannabis represents 70%, of total applicable periods gross cannabis sales (July 31, 2019 - three crown corporations representing 81%). The Company holds trade receivables from the crown corporations Société québécoise du cannabis and the Ontario Cannabis Store representing 47% and 25%, respectively of total trade receivables as of July 31, 2020 (July 31, 2019 - 56% and 23%, respectively). Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements. As at July 31, 2020, the Company had $184,173 (July 31, 2019 - $139,505) of cash and cash equivalents and short-term investments and $19,426 (July 31, 2019 - $19,693) in trade receivables. The Company has current liabilities of $82,487 and contractual commitments of $14,741 due before July 31, 2021. The Company's existing cash and cash equivalents, short term investments and trade receivables are expected to provide sufficient liquidity to meet cash outflow requirements over the next twelve months. The Company's success in executing on its longer-term strategy is dependent upon its ability to fund the repayment of existing borrowings and to generate positive cash flows from operations. If additional liquidity is required, management plans to secure the necessary financing through the issuance of new public or private equity or debt instruments. There is no assurance that additional future funding will be available to the Company, or that it will be available on terms which are acceptable to management. The carrying values of cash and cash equivalents, trade receivables and accounts payable and accrued liabilities approximate their fair values due to their short-term to maturity. Foreign Currency Risk On July 31, 2020, the Company holds certain financial assets and liabilities denominated in United States Dollars ("USD") which consist of cash and cash equivalents, and warrant liabilities. The Company does not currently use foreign exchange contracts to hedge its exposure of its foreign currency cash flows as management has determined that this risk is not significant. The Company closely monitors relevant economic information to minimize its net exposure to foreign currency risk. The Company is exposed to unrealized foreign exchange risk through its cash and cash equivalents. As at July 31, 2020, approximately $42,981 USD ($57,652) of the Company's cash and cash equivalents was in USD. The Company engaged in several financing events during the year ended July 31, 2020 which resulted in the accumulation of USD cash and cash equivalents (Note 20). A 1% change in the foreign exchange rate would not result in a material change to the unrealized gain or loss on foreign exchange or on the gain or loss on financial instrument revaluation of USD denominated warrants.

Operating Expenses by Nature

Operating Expenses by Nature	12 Months Ended
	Jul. 31, 2020
Expenses by nature [abstract]
Operating Expenses by Nature	25. Operating Expenses by Nature For the year ended July 31, 2020 July 31, 2019 Salaries and benefits $ 12,202 $ 25,349 Consulting 7,425 11,176 Professional fees 9,811 8,258 Facilities 6,895 5,697 Selling, general and administrative 14,409 4,462 Travel 2,051 2,710 Share-based compensation 25,790 28,008 Marketing and promotion 12,474 22,308 Amortization of intangible assets 3,939 1,767 Depreciation of property, plant and equipment 6,072 1,747 Total $ 101,068 $ 111,482 The following table summarizes the nature of share-based compensation in the period: For the year ended July 31, 2020 July 31, 2019 General and administrative related share-based compensation $ 24,650 $ 26,322 Marketing and promotion related share-based compensation 1,140 1,686 Total operating expense related share-based compensation 25,790 28,008 Share based compensation capitalized to inventory 6,105 1,724 Total share-based compensation $ 31,895 $ 29,732 The following table summarizes the total payroll related wages and benefits by nature in the period: For the year ended July 31, 2020 July 31, 2019 General and administrative related wages and benefits $ 12,202 $ 17,975 Marketing and promotion related wages and benefits 5,625 6,162 Research and development related wages and benefits 2,717 1,212 Total operating expense related wages and benefits 20,544 25,349 Wages and benefits capitalized to inventory 21,128 10,905 Total wages and benefits $ 41,672 $ 36,254

Related Party Disclosure

Related Party Disclosure	12 Months Ended
	Jul. 31, 2020
Disclosure of transactions between related parties [abstract]
Related Party Disclosure	26. Related Party Disclosure Key Management Personnel Compensation Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the Company’s operations, directly or indirectly. Compensation provided to key management during the year was as follows: For the year ended July 31, 2020 July 31, 2019 Salary and/or consulting fees $ 3,069 $ 3,550 Termination benefits 1,043 470 Bonus compensation 42 481 Stock-based compensation 15,702 16,235 Total $ 19,856 $ 20,736 These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed by the related parties. Unless otherwise stated, the below granted stock options will vest on the one-year anniversary of the date of grant and the balance will vest quarterly over two years thereafter. On June 26, 2020, the Company granted certain of its directors and executives a total 1,800,000 and 1,255,025, respectively stock options with an exercise price of $1.02. One-third of the stock options will vest on each of the one-year anniversaries of the date of grant over a three-year period. A total of 1,010,101 RSU's were issued on the same date with a unit value of $0.99. The RSUs vest in full on the third-year anniversary after the grant date. On April 28, 2020, the Company granted certain of its executives a total 900,000 stock options with an exercise price of $0.69. One-third of the stock options will vest on each of the one-year anniversaries of the date of grant over a three-year period. On October 29, 2019, the Company granted certain of its executives a total of 829,034 stock options and 1,428,449 On July 26, 2019, the Company granted certain of its executives a total 250,000 stock options with an exercise price of $5.88 On July 18, 2019, the Company granted certain of its executives a total 650,000 stock options with an exercise price of $6.54. On March 20, 2019, the Company granted certain of its executives a total 325,000 stock options with an exercise price of $8.50. On February 21, 2019, the Company granted the CEO 3,333,333 stock options with an exercise price of $7.46. Additional to the standard vesting terms as defined in Note 11, is an achievement condition in which vesting may only occur once a volume weighted average trading price of $10 or greater is achieved for a 20-day On February 19, 2019, the Company granted certain of its executives a total 615,000 stock options with an exercise price of $7.13. On December 17, 2018, the Company granted certain of its executives a total 74,000 stock options with an exercise price of $5.09. Of which, 54,000 stock options will fully vest at the 6-month On September 17, 2018, the Company granted certain executives of the Company a total of 650,000 stock options with an exercise price of $7.93. Belleville Complex Inc. On October 31, 2018, the Company acquired a 25% interest in Belleville Complex Inc. ("BCI") with the related party Olegna Holdings Inc., a company owned and controlled by a director of the Company, holding the remaining 75% in BCI. BCI purchased a configured 2,004,000 sq. ft. facility through a $20,279 loan issued by the Company on September 7, 2018, bearing an annual 4% interest rate and interest payable monthly. The loan and all remaining accrued interest were repaid in full during the year ended July 31, 2019. As part of the initial agreement, the Company will be the anchor tenant for a period of 20 years, with an option to renew for 10 years. On October 22, 2019, the lease agreement was amended to a 15-year anchor tenant period, with an option to renew for 15 years and additional space to rent. The Company has also subleased a portion of the space to Truss Limited Partnership (Note 10). As a result, the lease was reassessed resulting in an addition to the right-of-use asset and lease liability as well as a lease receivable on the sublease component (Note 6). Consideration for the 25% interest on the joint venture is deemed $ nil nil nil The Company leases a space in Belleville from a related party BCI, that supports its manufacturing activities and is based in Belleville, Ontario. Under this lease arrangement, the Company incurred $7,511 in lease and operating expenses during the year ended July 31, 2020 (July 31, 2019 - $3,937). This lease liability is recognized on the Company's balance sheet under IFRS 16 (Note 18). Truss LP The Company owns a 42.5% interest in Truss LP and accounts for the interest as an investment in associate (Note 10). The Company subleases section of its Belleville lease to Truss LP this sublease is recognized as a finance lease receivable on the Company's balance sheet (Note 6). The Company recognizes a recovery on its partnership with Truss Limited Partnership in Other receivables and Other income. Under a Temporary Supply and Services Agreement (“TSSA”) with Truss LP, the Company produces and packages cannabis infused beverages in the CIB Facility (located at the Belleville Facility) and in the Gatineau Facility, an markets and sells beverages for the legal adult-use markets in Canada, in each case subject to the terms of its regulatory approvals and applicable laws, all for its own account and as a stand-lone division of HEXO. As of July 31, 2020, Truss LP intends to apply to be a licensed product of Cannabis, but until the time where Truss LP obtains all regulatory approval required under the Cannabis Act (Canada), the TSSA will remain in place. Under the TSSA, Truss LP will be an exclusive supplier to the Company of all property and all services required to carry on the business, other than specific services which are required to be provided by HEXO. As a result of this arrangement, there is a receivable from Truss of $3,405 at July 31, 2020. During the year, the Company purchased of $2,159 raw materials from Truss LP under the arrangement and received $2,531 of income.

Capital Management

Capital Management	12 Months Ended
	Jul. 31, 2020
Disclosure Of Capital Management [Abstract]
Capital Management	27. Capital Management The Company's objectives when managing capital are to (1) safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and (2) maintain an optimal capital structure to reduce the cost of capital. Management defines capital as the Company's shareholders' equity and interest-bearing debt. The Board of Directors does not establish quantitative return on capital criteria for management. The Company has not paid any dividends to its shareholders. The Company is not subject to any externally imposed capital requirements, with the exception of covenants related to the Company's Term Loan as set out in Note 19. As at July 31, 2020, total managed capital was $556,676 (July 31, 2019 - $788,712).

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2020
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and Contingencies	28. Commitments and Contingencies COMMITMENTS The Company has certain contractual financial obligations related to service agreements, purchase agreements, rental agreements and construction contracts. Some of these contracts have optional renewal terms that the Company may exercise at its option. The annual minimum payments payable under these obligations over the next five fiscal years and thereafter are as follows: July 31, 2021 $ 14,741 July 31, 2022 3,666 July 31, 2023 3,444 July 31, 2024 3,444 July 31, 2025 2,450 Thereafter 19,274 $ 47,019 See Note 18 for recognized contractual commitments regarding the Company's lease obligations under IFRS 16. Letters of Credit On August 1, 2019, the Company reissued a preexisting letter of credit with a Canadian financial institution under an agreement with a public utility provider entitling the utility provider to a maximum of $2,581, subject to certain operational requirements. On August 21, 2019, the Company entered into a five-year letter of credit with a Canadian financial institution to provide a maximum of $250 that amortizes $50 annually until its expiry on July 14, 2024. The letter of credit has not been drawn upon as at July 31, 2020. As at July 31, 2020, the letter of credit is secured by a combination of the Company's credit facility (Note 19). On November 26, 2019, the Company entered into a six-month standby letter of credit with a Canadian financial institution to provide up to a maximum limit of $6,391, reduced by $1,000 on a monthly basis and fully amortized on May 30, 2020. The letter of credit was not been drawn upon and was secured by a combination of the Company's Term Loan (Note 15) and cash held in collateral. Surety Bond The Company’s commercial surety bond, which was obtained July 3, 2019, with a North American insurance provider entitling the Company up to a maximum of $4,500 expired July 3, 2020. The bond bore a premium at 0.3% annually. The Company had obtained the surety bond as required under the Canada Revenue Agency's ("CRA") excise tax laws for the transporting of commercial goods throughout Canada. On April 4, 2020 the surety bond expired. The Company renegotiated the surety amount with the CRA on July 14, 2020 and as at July 31, 2020 the Company had until August 31, 2020 to provide a deposit in the amount of $1,657. Payment was made subsequent to the period on August 19, 2020. CONTINGENCIES The Company may be, from time to time, subject to various administrative and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated. As of July 31, 2020, the Company is named as a defendant in securities class actions that have been filed in superior courts of the provinces of Quebec and Ontario and in the Supreme Court of the State of New York and the U.S. District Court for the Southern District of New York. One or more of the Company's current and/or former officers and directors, and/or certain underwriters of past public offerings by the Company, are also named as defendants in certain of the actions. The lawsuits assert causes of action under Canadian and U.S. securities legislation and at common law, in connection with statements made by the defendants that are alleged to have been materially false and/or misleading statements and their alleged failure to disclose material adverse facts. The alleged misrepresentations relate to, among other things, the Company's forward-looking information, including but not limited to the Company's forecast revenues for Q4 2019 and fiscal 2020, its inventory, "channel stuffing" and the Company's supply agreement with the Province of Quebec. As at the date hereof, the amounts claimed for damages in each of these actions have not been quantified. These actions are in a preliminary stage and have not yet been certified as class actions. While the Company cannot predict the outcome of the actions discussed above, it intends to assert all available defences and vigorously defend these proceedings. Defending litigation, whether or not meritorious, is time-consuming for our management and detracts from our ability to fully focus our internal resources on our business activities. In addition, legal fees and costs incurred in connection with such activities may be significant and we could, in the future, be subject to judgments or enter into settlements of claims for significant monetary damages. Further, the Company's underwriting agreement with the underwriters contains contractual indemnification provisions that may require the Company to indemnify the underwriters with respect to the claims against them and their legal costs of defending the actions. A decision adverse to our interests could result in the payment of substantial damages and could have a material adverse effect on our cash flow, results of operations and financial position, and the limits of available insurance may be insufficient to cover our eventual liability. On January 24, 2020, the Company was served with a statement of claim commenced by a vendor in respect of a supply agreement that was purportedly entered into between UP Cannabis and the vendor prior to the Company's acquisition of Newstrike on May 24, 2019. The statement of claim filed against the Company is seeking payment of invoices alleged to be owing. In response, the Company filed a statement of defence and counterclaim on February 26, 2020. The supply agreement purports to contemplate that the Company would purchase certain cannabis products until February 2020. The Company intends to vigorously defend itself against such claim and intends to actively advance its counterclaim which alleges, among other things, that the supply agreement is void as it was entered into in bad faith. On June 18, 2020, the Company was named as a defendant in a proposed consumer protection class action filed in the Court of Queens' Bench in Alberta on behalf of residents of Canada who purchased cannabis products over specified periods of time. Several other licensed producers are also named as co-defendants in the action. The lawsuit asserts causes of action, including for breach of contract and breach of consumer protection legislation, arising out of allegations that the Tetrahydrocannabinol (THC) or Cannabidiol (CBD) content of medicinal and recreational cannabis products sold by the Company and the other defendants to consumers was different from what was advertised on the products' labels. Many of the cannabis products sold by the Company and other defendants were allegedly sold to consumers in containers using plastic bottles or caps that may have rapidly absorbed or degraded the THC or CBD content within them. By allegedly over-representing the true amount of THC or CBD in the products, the plaintiff claims that consumers would be required to consume substantially more product than they otherwise would have in order to obtain the desired effects or, in the alternative, would have consumed the product without obtaining the desired effects. The action has not yet been certified as a class action. ONEROUS CONTRACT During the year ended July 31, 2020, the Company recognized a $4,763 onerous contract provision related to a fixed price supply agreement for the supply of certain cannabis products. The supply agreement is currently the subject of legal proceedings as disclosed above. The costs and purchase obligations under the contract exceed the economic benefits expected to be received. The related loss has been included in Other gains and losses.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Jul. 31, 2020
Disclosure Of Fair Value Of Financial Instruments Explanatory [Abstract]
Fair Value of Financial Instruments	29. Fair Value of Financial Instruments The carrying values of the financial instruments as at July 31, 2020 are summarized in the following table: Financial liabilities Amortized designated as cost FVTPL as FVTPL Total Assets $ $ $ $ Cash and cash equivalents 184,173 — — 184,173 Restricted funds 8,261 — — 8,261 Trade receivables 19,426 — — 19,426 Commodity taxes recoverable and other receivables 16,773 — — 16,773 Lease receivable - long term 3,865 — — 3,865 Long - term investments — 3,209 — 3,209 Liabilities $ $ $ $ Accounts payable and accrued liabilities 32,451 — — 32,451 Warrant liability — 3,450 — 3,450 Lease liability - current 4,772 — — 4,772 Lease liability - long term 24,344 — — 24,344 Convertible debentures 28,969 — — 28,969 Term loan 29,930 — — 29,930 Other long-term liabilities — — 393 393 The carrying values of the financial instruments as at July 31, 2019 are summarized in the following table: Financial liabilities Amortized designated cost FVTPL as FVTPL Total Assets $ $ $ $ Cash and cash equivalents 113,568 — — 113,568 Restricted funds 22,350 — — 22,350 Short-term investments 25,937 — — 25,937 Trade receivables 19,693 — — 19,693 Commodity taxes recoverable and other receivables 15,247 — — 15,247 Convertible debenture receivable — 13,354 — 13,354 Long term investments — 14,277 — 14,277 Liabilities $ $ $ $ Accounts payable and accrued liabilities 45,581 — — 45,581 Warrant liability — 493 — 493 Deferred rent liability 946 — — 946 Term loan 33,374 — — 33,374 The carrying values of cash and cash equivalents, restricted funds, short term investments, trade and other receivables, lease receivables, accounts payable and accrued liabilities, lease liabilities and term loan approximate their fair values due to their relatively short periods to maturity.

Non-Controlling Interest

Non-Controlling Interest	12 Months Ended
	Jul. 31, 2020
Non Controlling Interest [Abstract]
Non-Controlling Interest	30. Non-Controlling The following table summarizes the information relating to the Company's interests in Neal Up Brands Inc. and KIT, before intercompany eliminations. July 31, 2020 July 31, 2019 KIT Neal Up Brands Inc. Current assets $ — $ 2,500 Non-current assets 7,455 — Current liabilities — — Non-current liabilities — — Non-controlling interest (%) 40% 40% Non-controlling interest $ 3,379 $ 1,000 The Company holds a 60% interest in KIT which is intended to principally operate out of Belleville Facility, and the remaining 40% $4,075 (USD3,100), subject to foreign exchange rates. Neal Up Brands Inc. has limited operations and during the year ended July 31, 2019, the current assets represent cash held in escrow by a third party. During the year ended July 31, 2020 the cash held in escrow was released back to the partners and the entity is in the process of being dissolved. Neal Up Brands Inc. had no revenues or expenses during the year ended July 31, 2020.

Revenue from Sale of Goods

Revenue from Sale of Goods	12 Months Ended
	Jul. 31, 2020
Revenue [abstract]
Revenue from Sale of Goods	31. Revenue from Sale of Goods The Company disaggregated it's revenues from the sale of goods between sales of cannabis beverages ("Cannabis beverage sales") and dried flower, vapes, and other cannabis products ("Cannabis sales excluding beverages"). The Company's cannabis beverage sales are derived from the Cannabis Infused Beverage ("CIB") line, which was established in order to manufacture, produce and sell cannabis beverage products. CIB operates under the Company's cannabis licensing and in compliance with Health Canada and the Cannabis Act's regulations. The Company has assessed the beverage revenue stream to be realized by the Company and presented on a gross basis as defined under IFRS 15 (see Note 3). The Company will continue to operate CIB until Truss has obtained its independent licensing to manufacture and sell cannabis products, at which point these operations will shift to Truss. For the year ended July 31, 2020 July 31, 2019 Revenue stream Cannabis sales Cannabis Total Cannabis sales Cannabis Total $ $ $ $ $ $ Retail 101,712 2,851 104,563 53,968 — 53,968 Medical 3,299 — 3,299 5,288 — 5,288 Wholesale 996 — 996 — — — International 1,291 — 1,291 — — — Total revenue from sale of goods 107,298 2,851 110,149 59,256 — 59,256 Total revenue from the sale of goods is presented net of provisions for sales returns and price concessions. During the year ended July 31, 2020, the Company incurred $6,942 (July 31, 2019 - $3,811) of sales provisions and price concessions.

Segmented Information

Segmented Information	12 Months Ended
	Jul. 31, 2020
Disclosure of operating segments [abstract]
Segmented Information	32. Segmented Information The Company operates in one operating segment. All property, plant and equipment and intangible assets are located in Canada.

Restructuring Provision

Restructuring Provision	12 Months Ended
	Jul. 31, 2020
Restructuring Provision Abstract
Restructuring Provision	33. Restructuring Provision $ Balance payable as at July 31, 2019 — Total restructuring costs 4,767 Less: payments made (4,737 ) Balance payable as at July 31, 2020 30 During the year ended July 31, 2020, restructuring efforts were undertaken to right size the Company. These expenses amounted to $4,767 and consisted of consulting services, severance and other payroll related termination costs.

Operating Cash Flow

Operating Cash Flow	12 Months Ended
	Jul. 31, 2020
Operating Cash Flow [Abstract]
Operating Cash Flow	34. Operating Cash Flow The following items comprise the Company's operating cash flow activity for the periods herein. For the year ended Note July 31, 2020 July 31, 2019 $ $ Items not affecting cash Income tax recovery (6,023 ) (18,213 ) Depreciation of property, plant and equipment 6,072 1,747 Depreciation of property, plant and equipment in cost of sales 3,567 — Amortization of intangible assets 3,939 1,767 Loss/(gain) on convertible debentures 4,806 (1,737 ) Unrealized gain on changes in fair value of biological assets (29,356 ) (38,856 ) Unrealized fair value adjustment on investments 12,880 315 Amortization of deferred financing costs 56 596 Accrued interest income 9,921 (397 ) Gain on investment (24 ) — Loss on induced conversion of debenture 54,283 — License depreciation and prepaid royalty expenses 389 117 Write-off of inventory and biological assets 5,055 — Write down of inventory to net realizable value 68,319 19,335 Realized fair value amounts on inventory sold 40,910 16,357 Loss from investment in associate and joint ventures 6,331 2,964 Share-based compensation 25 25,790 28,944 Revaluation of financial instruments (gain)/loss (6,533 ) 3,730 Impairment losses 299,484 — Loss on onerous contract 4,763 — Loss on disposal of property, plant and equipment 3,855 — Total items not affecting cash 508,484 16,669 Changes in non-cash operating working capital items Trade receivables 267 (17,845 ) Commodity taxes recoverable and other receivables (784 ) (6,425 ) Prepaid expenses 5,717 (4,927 ) Inventory (100,492 ) (90,748 ) Biological assets 28,493 37,108 Accounts payable and accrued liabilities 6,623 6,630 Excise taxes payable 3,627 3,494 Deferred rent liability — 946 Total non-cash operating working capital (56,549 ) (71,767 ) Additional supplementary cash flow information is as follows: For the year ended July 31, 2020 July 31, 2019 $ $ Property, plant and equipment in accounts payable 19,751 21,265 Right-of-use asset additions 24,405 — Capitalized borrowing costs 2,385 511 Interest paid 2,527 252

Comparative Information

Comparative Information	12 Months Ended
	Jul. 31, 2020
Disclosure Of Comparative Information [Abstract]
Comparative Information	35. Comparative Information The Company has reclassified Impairment loss on inventory within Cost of goods sold, to conform with the current presentation. The amount is disclosed in Note 8.

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2020
Income taxes paid (refund) [abstract]
Income Taxes	36. Income Taxes Income tax expense recognized in comprehensive loss consists of the following components: July 31, 2020 July 31, 2019 Current tax for the year $ — $ — Adjustments of previous years — — Total $ — $ — Components of deferred income tax expense (recovery): July 31, 2020 July 31, 2019 Origination and reversal of temporary differences $ (98,141 ) $ (13,007 ) Difference between statutory tax rate and deferred tax rate 2,555 172 Change in temporary difference for which no deferred tax assets are recorded 89,563 (5,378 ) Deferred income tax recovery $ (6,023 ) $ (18,213 ) The Company's expected tax rate is different from the combined federal and provincial income tax rate in Canada. These differences result from the following elements: July 31, 2020 July 31, 2019 Expected tax rate 26.54% 26.64% Earnings before income taxes $ (552,512 ) $ (87,281 ) Expected tax benefit resulting from loss (146,637 ) (23,252 ) Adjustments for the following items: Tax rate differences 2,555 172 Permanent differences 48,965 9,973 Change in temporary differences for which no tax assets are recorded 89,563 (5,770 ) True up and other (469 ) 664 $ (6,023 ) $ (18,213 ) The following is a reconciliation of the deferred tax assets and liabilities recognized by the Company: Opening Recognized in Recognized in Ending August 1, 2019 income equity July 31, 2020 $ $ $ $ Taxable temporary differences 6,858 3,557 — 10,415 Biological assets (1,514 ) 184 — (1,330 ) Inventory (2,920 ) (2,168 ) — (5,088 ) Loss carryforward 23,369 (23,369 ) — — Share issue costs 721 (721 ) — — Intangible assets (32,537 ) 28,540 — (3,997 ) Net deferred tax asset (liability) (6,023 ) 6,023 — — Opening Recognized in Recognized in Ending August 1, 2018 income goodwill July 31, 2019 $ $ $ $ Taxable temporary differences (117 ) 7,195 (200 ) 6,858 Biological assets (458 ) (764 ) (292 ) (1,514 ) Inventory (1,432 ) (930 ) (559 ) (2,920 ) Loss carryforward 2,007 14,058 7,304 23,369 Share issue costs — (1,003 ) 1,724 721 Intangible assets — (344 ) ( 32,193 ) (32,537 ) Net deferred tax asset (liability) — 18,212 (24,236 ) ( 6,023 ) Deferred income taxes reflect the impact of loss carryforwards and of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws. At July 31, 2020 deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized are attributable to the following: July 31, 2020 July 31, 2019 $ $ Losses carried forward 255,635 5,898 Research and development expenditures 669 266 Fixed Assets, intangibles and other assets 84,482 — Share issue costs 22,599 8,612 363,385 14,776 The Company has approximated non-capital losses available to reduce future years' federal and provincial taxable income which expires as follows: $ 2025 187 2026 199 2027 279 2028 236 2029 257 2030 205 2031 291 2032 781 2033 473 2034 1,547 2035 3,601 2036 6,389 2037 14,100 2038 37,111 2039 51,142 2040 132,646 249,444

Revision of Comparative Informa

Revision of Comparative Information	12 Months Ended
	Jul. 31, 2020
Revision Of Comparative Information [Abstract]
Revision of Comparative Information	37. Revision of Comparative Information During the reporting period, the Company determined that an administrative banking covenant related to the Term loan (Note 19) was not satisfied. This covenant mandated that the Company not have a Canadian dollar operating bank account with any institution other than the Lenders. The Company was subject to the covenant 90 days after entering the syndicated credit facility on February 14, 2019. On October 29, 2020, the Company obtained an amendment from the Lenders to discharge the Company of related historical recourse and rectify the breach by April 27, 2021. As the amendment was obtained after July 31, 2020, the term loan has been presented current for the year ended July 31, 2020 (Note 19). As the Company was in breach of this administrative covenant in the prior year as well, comparative financial information has been revised to reflect the term loan as a current liability (previously reported as a non-current liability).

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2020
Significant Accounting Policies [Abstract]
CASH AND CASH EQUIVALENTS	CASH AND CASH EQUIVALENTS Cash and cash equivalents are comprised of cash and highly liquid investments that are readily convertibles into known amounts of cash with original maturities of three months or less.
RESTRICTED FUNDS	RESTRICTED FUNDS Restricted funds represent cash that is pledged as collateral or guarantees for certain of the Company's projects, obligations, and agreements.
SHORT TERM INVESTMENTS	SHORT TERM INVESTMENTS Short term investments are comprised of liquid investments with maturities between 3 and 12 months. Short term investments are measured at amortized cost using the effective interest method, less loss allowance.
TRADE RECEIVABLES	TRADE RECEIVABLES Trade receivables are recognized initially at the amount of consideration that is unconditional, unless they contain significant financing components when they are recognized at fair value. Trade receivables are subsequently measured at amortized cost using the effective interest method, less loss allowance.
COMMODITY TAX RECOVERIES & OTHER RECEIVABLES	COMMODITY TAX RECOVERIES & OTHER RECEIVABLES The Company measures commodity tax recoveries and other receivables at fair value fair value and subsequently measured at amortized cost, less any provisions for impairment.
BIOLOGICAL ASSETS	BIOLOGICAL ASSETS The Company measures biological assets consisting of cannabis plants using the income approach at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of related inventories after harvest. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs (including share based compensation), grow consumables, materials, utilities, facilities costs, depreciation, overhead, quality and testing costs. The identified capitalized direct and indirect costs of biological assets are subsequently recorded within the line item 'costs of goods sold' on the statement of loss and comprehensive loss in the period that the related product is sold. Unrealized gains or losses arising from changes in fair value less cost to sell during the period are included in the results of operations and presented on a separate line of statement of comprehensive loss of the related period.
INVENTORY	INVENTORY Inventory is valued at the lower of cost and net realizable value. Cost is determined using the weighted average method. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost of the inventory. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Subsequent costs include materials, overhead, depreciation, amortization, and labor related costs (including share-based compensation) involved in packaging and quality assurance. The identified capitalized direct and indirect costs related to inventory are subsequently recorded within 'cost of goods sold' on the statement of loss and comprehensive loss at the time the product is sold, with the exclusion of realized fair value amounts included in inventory sold which are recorded as a separate line within gross profit. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Packaging and supplies are initially valued at cost and subsequently at the lower of cost and net realizable value.
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Construction in progress is transferred to a depreciable asset class property, plant and equipment when the assets are available for use and depreciation of the assets commences at that point. Depreciation is provided using the following terms and methods: Land Not depreciated No term Buildings Straight line 5 to 20 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years Construction in progress Not depreciated No term An asset's residual value and useful life are reviewed at each reporting date and adjusted if appropriate. When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of equipment are determined by comparing the proceeds from disposal with the carrying amount of the equipment and are recognized in profit or loss.
FINITE LIFE INTANGIBLE ASSETS	FINITE LIFE INTANGIBLE ASSETS Finite life intangible assets are measured at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3 to 5 years Patents Straight line 20 years The estimated useful life is reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Research expenditure and development expenditure that do not meet the recognition criteria for intangible assets are recognized as an expense as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period.
INDEFINITE LIFE INTANGIBLE ASSETS	INDEFINITE LIFE INTANGIBLE ASSETS Indefinite intangible assets are deemed to have no foreseeable limit over which the asset is expected to generate net cash inflows. Following initial recognition, intangible assets with indefinite useful lives are carried at cost less any accumulated impairment losses and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The Company intends to utilize the brand indefinitely. The capitalized brand consists of the Company's premium Up brand, which was recognized upon the acquisition of Newstrike (Note 14). Brand Not amortized Indefinite
GOODWILL	GOODWILL Goodwill is not amortized but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired and is carried at cost less accumulated impairment losses. Goodwill is allocated to cash-generating units for the purpose of impairment testing. The allocation is made to those cash-generating units or groups of cash-generating units that are expected to benefit from the business combination in which the goodwill arose. The units or groups of units are identified at the lowest level at which goodwill is monitored for internal management purposes, being the Company's single operating segment.
IMPAIRMENT OF NON-FINANCIAL ASSETS	IMPAIRMENT OF NON-FINANCIAL ASSETS Goodwill and intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. A CGU's recoverable amount is the higher of its fair value less costs of disposal ("FVLCD") and its value in use ("VIU"). In assessing the VIU, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money to the Company and the risks specific to the asset.
BUSINESS ACQUISITION	BUSINESS ACQUISITION The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the: fair values of the assets transferred liabilities incurred to the former owners of the acquired business equity interests issued by the Company fair value of any asset or liability resulting from a contingent consideration arrangement, and fair value of any pre-existing equity interest in the subsidiary. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. The Company recognises any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest's proportionate share of the acquired entity's net identifiable assets. Acquisition-related costs are expensed as incurred. The excess of the: consideration transferred, amount of any non-controlling interest in the acquired entity, and acquisition-date fair value of any previous equity interest in the acquired entity over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognised directly in profit or loss as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value, with changes in fair value recognised in profit or loss. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognised in profit or loss.
NON-CURRENT ASSETS (OR DISPOSAL GROUPS) HELD FOR SALE	NON-CURRENT ASSETS (OR DISPOSAL GROUPS) HELD FOR SALE Non-current assets (or disposal groups) are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable. They are measured at the lower of their carrying amount and fair value less costs to sell, except for assets such as deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are specifically exempt from this requirement. An impairment loss is recognised for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognised for any subsequent increases in fair value less costs to sell of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognised. A gain or loss not previously recognised by the date of the sale of the non-current asset (or disposal group) is recognised at the date of derecognition. Non-current assets (including those part of a disposal group) are not depreciated or amortised while they are classified as held for sale. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognised. Non-current assets classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet.
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities represent liabilities for goods and services provided to the Company prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. Accounts payable and accrued liabilities are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.
REVENUE RECOGNITION	REVENUE RECOGNITION Revenue from the direct sale of cannabis to customers for a fixed price is recognized when the Company transfers the control of the good(s) to the customer upon delivery and acceptance by the customer. The Company recognizes revenue in an amount that reflects the consideration which the Company expects to receive taking into account the impact which may arise from any rights of return on sales, price concessions or similar obligations. Net revenue is presented net of taxes, estimated returns, allowances and discounts. Canada Revenue Agency ("CRA") levies excise taxes on the sale of medical and adult-us cannabis products. The Company becomes liable for these excise duties when cannabis products are delivered to the customer. The excise taxes payable is the higher of (i) a flat-rate duty which is imposed when a cannabis product is packaged, and (ii) an advalorem duty that is imposed when a cannabis product is delivered to the customer. Effective May 1, 2019, excise tax calculated on edible cannabis products, cannabis extracts and cannabis topicals will prospectively be calculated as a flat rate based on the quantity of total tetrahydrocannabinol (THC) contained in the final product. There were no changes in the legislation in calculating excise taxes for fresh cannabis, dried cannabis, seeds and plants. Net revenue from sale of goods, as presented on the consolidated statements of comprehensive (loss) income, represents revenue from the sale of goods less applicable excise taxes.
COST OF GOODS SOLD	COST OF GOODS SOLD Cost of goods sold includes cost of inventory expensed, packaging costs, shipping costs and related labor.
INCOME TAXES	INCOME TAXES The income tax expense or recovery for the period is the tax payable on the current period's taxable income, based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax expense or recovery is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and considers whether it is probable that a taxation authority will accept an uncertain tax treatment. The Company measures its tax balances either based on the most likely amount or the expected value, depending on which method provides a better prediction of the resolution of the uncertainty. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that, at the time of the transaction, affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Deferred tax assets and liabilities are offset where there is a legally enforceable right to offset current tax assets and liabilities and where the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION The Company has an employee stock option plan. The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company's estimate of equity instruments that will eventually vest. Forfeitures are adjusted for on an actual basis. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For stock options granted to non-employees the compensation expense is measured at the fair value of goods and services received except where the fair value cannot be estimated, in which case it is measured at the fair value of the equity instruments granted. Consideration paid by employees or non-employees on the exercise of stock options is recorded as share capital and the related share-based compensation is transferred from share-based payment reserve to share capital.
RESTRICTED SHARE UNITS ("RSU's")	RESTRICTED SHARE UNITS ("RSU's") RSUs are cash or equity settled share-based payments granted to certain employees, directors and executives within the Company. RSUs are measured at their initial fair value on the date of the grant utilizing the Black-Scholes Merton model. The fair value of cash-settled RSUs is revalued at each period end and is recognized as share-based compensation expense over the vesting period with a corresponding adjustment to the liability. Upon the settlement of cash based RSUs, which are valued at the market value at the time of exercise, the related liability is transferred to share capital. The fair value of equity-settled RSUs are recognized in the share-based reserve at the grant date. Upon the settlement of equity-based payments, RSUs are settled in the form of common shares and the related share-based reserve is transferred to share capital. Amounts recorded for forfeited RSUs are transferred to the accumulated deficit in the year of forfeiture or expiry.
LOSS PER SHARE	LOSS PER SHARE Loss per common share represents loss for the period attributable to common shareholders divided by the weighted average number of common shares outstanding during the year. Diluted loss per common share is calculated by dividing the applicable loss for the year by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the year. The calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.
BORROWING COSTS	BORROWING COSTS Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in profit or loss in the period which they are incurred.
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS Financial assets and liabilities are recognized when the Company becomes a party to the contractual provision of the respective instrument. The Company classifies its financial assets in the following measurement categories: • • The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows. The Company has made the following classifications: IFRS 9 Classification Financial assets Cash and cash equivalents Amortized cost Restricted funds Amortized cost Short-term investments Amortized cost Trade receivables Amortized cost Convertible debenture receivable FVTPL Long term investments FVTPL Financial liabilities Accounts payable and accrued liabilities Amortized cost Warrant liabilities FVTPL Deferred rent liability Amortized cost C Amortized cost Lease liabilities Amortized cost Term loan Amortized cost Fair Value Through Profit or Loss ("FVTPL") Financial Assets Financial assets classified and measured at FVTPL are those assets that do not meet the criteria to be classified at amortized cost or at FVTOCI. This category includes debt instruments whose cash flow characteristics are not solely payments of principal and interest ("SPPI") or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell the financial asset. Amortized Cost Financial Assets Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. An amortized cost financial asset is initially measured at fair value, including transaction costs and subsequently at amortized cost using the effective interest rate. Impairment of Financial Assets Financial assets, other than those classified at fair value through profit and loss, are assessed for indicators of impairment at the end of each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected. Financial Liabilities and Other Financial Liabilities Financial liabilities are classified as either financial liabilities at FVTPL or other financial liabilities. Financial liabilities at FVTPL are stated at fair value, with changes being recognized through the consolidated statements of income. Other financial liabilities are initially measured at fair value, net of transaction costs, and are subsequently measured at amortized cost using the effective interest method. Derivatives Derivatives are initially measured at fair value in conjunction with the host contract; no bifurcation is performed, and any directly attributable transaction costs are recognised in profit or loss as incurred. Subsequent to initial recognition, the entire instrument, including the embedded derivative is measured at fair value and changes therein are recognised in profit or loss. The Company has a convertible loan receivable whereby the balance can be converted into equity. See Note 15 for transaction and valuation details. Compound Instruments The component parts of compound instruments (convertible debentures) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company's own equity instruments is an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest rate method until extinguished upon conversion or at the instrument's maturity date. The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized and included in equity and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity. No gain or loss is recognized in profit or loss upon conversion or expiration of the conversion option. Transaction costs that relate to the issue of the convertible debentures are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognized directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the term of the convertible debentures using the effective interest method. For compound instruments with non-equity derivatives, the fair value of the embedded derivative is determined first based on the contractual terms, and the initial carrying amount of the host instrument is the residual amount after separating the embedded derivative. Transaction Costs Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss.
FOREIGN CURRENCY TRANSLATION	FOREIGN CURRENCY TRANSLATION Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Critical Accounting Judgements CGU Impairment CGUs are defined as the lowest level of integrated assets for which there are separately identifiable cash flows that are largely independent of cash flows from other assets or groups of assets. The classification of assets and the allocation of assets into respective CGUs require significant judgment, assumption and interpretations. Areas of judgement in the classification process, include the manner in which management reviews and makes decisions about its operations. The recoverability of assets are assessed at the CGU level and therefore could have a significant impact on impairment losses. Revenue -Principal versus Agent The Company evaluates whether it is the principal (reports on gross basis) or agent (reports on a net basis) for revenues generated by the direct sale of cannabis infused beverages (“CIB’s). The Company control’s the CIB’s prior to the sale to its customers as regulated and mandated under the Cannabis Act and Health Canada legislation. The Company’s control is evidenced by our sole ability to possess the CIB’s once the cannabis distillate has been added and thus establishing the inventory as a cannabis product requiring to be held a licensed producer. It is further evidenced by the Company possessing the sole ability to monetize the sale of CIB’s through the held sales agreements and purchase orders with customers. The Company presents the revenues from the sale of CIBs on a gross basis. Critical Accounting Estimates Valuation of Biological Assets In calculating the fair value less costs to sell of the Company's biological assets, management is required to make a number of estimates, including estimating the stage of growth of the cannabis, harvesting costs, selling costs, sales price and expected yields for the cannabis plant. Observable market selling prices of cannabis derived products less costs to sell are used to estimate the sales prices which are an input in the fair value less costs to sell calculation. Valuation of Inventory In calculating the net realizable value (NRV) of inventory, management determines the selling prices based on prevalent sales prices, selling costs, and includes an estimate of spoiled or expired inventory based on the most reliable evidence available at the time, to record inventory at the lower of cost or net realizable value. Impairment of Property, Plant and Equipment and Intangible Assets, including Goodwill The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets. The impairment is the amount by which the carrying amount of the asset or CGU exceeds its recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal and its value in use. Management exercises judgement in the determination of the Company's CGUs. Provisions Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. Allocation of Purchase Price In determining the allocation of the purchase price, estimates are used based on market research and appraisal values. Business Acquisitions In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates relate to private investments and intangible assets acquired. Management exercises judgment in estimating the probability and timing of when cash flows are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are fair valued using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. Acquisitions that do not meet the definition of a business combination are accounted for as asset acquisitions. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values. Asset acquisitions do not give rise to goodwill. Convertible Debentures Convertible debentures are financial instruments which are accounted for separately dependent on the nature of their components: a financial liability and an equity instrument. The identification of such components embedded within a convertible debenture requires significant judgments including; discount rates and future cash flows. The conversion option has a fixed conversion rate thus the financial liability, which represents the obligation to pay coupon interest on the convertible debentures in the future, is initially measured at its fair value and subsequently measured at amortized cost. The residual balance, or conversion feature is accounted for as equity at issuance. Transaction costs are apportioned to the debt liability and equity component in proportion to the allocation of proceeds.
Newly Adopted Accounting Policies Effective August 1, 2019	Newly Adopted Accounting Policies Effective August 1, 2019 IFRS 16, LEASES The Company adopted IFRS 16 Leases At the inception of a contract, the Company assesses whether the contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. This policy is applied to contracts entered into, or modified, on or after August 1, 2019. Practical expedients Effective August 1, 2019, the IFRS 16 transition date, the Company elected to use the following practical expedients under the modified retrospective transition approach: Leases with lease terms of less than twelve months (short-term leases) and leases of low-value assets (less than $5,000 U.S. dollars) (low-value leases) that have been identified at transition were not recognized in the consolidated statement of financial position; Right-of-use assets on transition were measured at the amount equal to the lease liabilities at transition, adjusted by the amount of any prepaid or accrued lease payments; For certain leases having associated initial direct costs, the Company, at initial measurement on transition, excluded these directs costs from the measurement of the right-of-use assets; Application of a single discount rate to portfolios of leases with similar characteristics on transition; and Any provision for onerous lease contracts previously recognized at the date of adoption of IFRS 16 has been applied to the associated right-of-use asset recognized upon transition. The Company as a lessee Where the Company is a lessee, a right-of-use asset representing the right to use the underlying asset with a corresponding lease liability is recognized when the leased asset becomes available for use by the Company. The right-of-use asset is recognized at cost and is depreciated on a straight-line basis over the shorter of the estimated useful life of the asset and the lease term. The cost of the right-of-use asset is based on the following: the amount of initial recognition of related lease liability; adjusted by any lease payments made on or before inception of the lease; increased by any initial direct costs incurred; and decreased by lease incentives received and any costs to dismantle the leased asset. The lease term includes consideration of an option to extend or to terminate if the Company is reasonably certain to exercise that option. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability. Lease liabilities are initially recognized at the present value of the lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. Subsequent to recognition, lease liabilities are measured at amortized cost using the effective interest rate method. Lease liabilities are remeasured when there is a change in future lease payments arising mainly from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, renewal or termination option. The payments related to short-term leases and low-value leases are recognized as other expenses over the lease term in the statement of loss and comprehensive loss. Significant accounting estimates and assumptions In the situation where the implicit interest rate in the lease is not readily determined, the Company uses judgment to estimate the incremental borrowing rate for discounting the lease payments. The Company's incremental borrowing rate generally reflects the interest rate that the Company would have to pay to borrow a similar amount at a similar term and with a similar security. On adoption of IFRS 16, the Company has determined a single IBR as the discount rate across all administrative real estate leases due to the leases containing similar characteristics. A separate IBR was used for the discounting of the Company's production real estate property. The IBRs utilized for administrative real estate and production real estate were 8% and 12%, respectively. The Company estimates the lease term by considering the facts and circumstances that create an economic incentive to exercise an extension or termination option. Certain qualitative and quantitative assumptions are used when evaluating these incentives. The Company as a lessor The Company's consolidated financial statements were not impacted by the adoption of IFRS 16 Leases in relation to lessor accounting. Lessors will continue with the dual classification model for recognized leases with the resultant accounting remaining unchanged from IAS 17, Leases. Impact of Change in Accounting Policy On August 1, 2019, the Company recognized $21,360 of right-of-use assets and $21,360 of operating lease liabilities. The Company applied its weighted average incremental borrowing rate as at August 1, 2019 to determine the amount of lease liabilities. The effect of the adjustment to the amounts recognized in the Company's consolidated statement of financial position at August 1, 2019 is shown below. August 1, 2019, IFRS 16 remeasurement As reported under Assets Non-current Property, plant and equipment $ 258,793 $ 21,360 $ 280,153 Total Assets $ 258,793 $ 21,360 $ 280,153 Liabilities Current liabilities Lease liabilities — 3,556 3,556 Non-current liabilities Lease liabilities — 17,804 17,804 Total Liabilities $ — $ 21,360 $ 21,360 Total commitments as at July 31, 2019 were $ , which included certain contractual financial obligations related to service agreements, purchase agreements, operating lease agreements, and construction contracts. Of this total, $ is related to operating lease commitments. The following is a reconciliation of total operating lease commitments as at July 31, 2019 to the lease liabilities recognised as at August 1, 2019: Total operating leases commitments as at July 31, 2019 $ 101,741 Less: Variable components of operating leases (49,330 ) Less: Low value and/or short-term lease (88 ) Operating lease liability before discounting 52,323 Adjustment to reflect discounting of operating lease commitments at August 1, 2019, using the incremental borrowing rate (30,963 ) Total lease liabilities recognized under IFRS 16 as at August 1, 2019 (Note 18) $ 21,360

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
	Jul. 31, 2020
Basis Of Presentation [Abstract]
Schedule of major subsidiaries	Principal Operating Subsidiaries Jurisdiction Interest Held Principal Activity HEXO Operations Inc. Ontario, Canada 100% To produce and sell cannabis and cannabis products under the Cannabis Act. HEXO USA Inc. Delaware, USA 100% To facilitate expansion into the US market. Keystone Isolation Technologies Inc. ("KIT'') Ontario, Canada 60% Intended to provide the Company with high quality extraction technology to facilitate an efficiently processed and consistent supply of CBD and THC to supply the Canadian and global market for cannabis derivatives Neal Up Brands Inc. Ontario, Canada 60% To produce and sell cannabis and cannabis products under the Cannabis Act.
Schedule of major joint ventures	Significant Joint Ventures Jurisdiction Interest Held Principal Activity HEXO MED A.E. Athens, Greece 51% Intended to serve as the Company's entry point into the European medical cannabis markets. Belleville Complex Inc. Ontario, Canada 25% The venture was established to manage the property of Belleville facility.
Schedule of major associates	Significant Associates Jurisdiction Interest Held Principal Activity Truss Limited Partnership ("Truss LP") Ontario, Canada 42.5% To pursue opportunities to develop non-alcoholic, cannabis-infused beverages for the Canadian market following adult-use legalization. Truss CBD USA LLC ("Truss CBD US") Colorado, USA 42.5% To explore opportunities for non-alcohol hemp-derived CBD beverages in the State of Colorado.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Jul. 31, 2020
Significant Accounting Policies [Abstract]
Schedule of terms and method use to calculate amortization of tangible assets	Land Not depreciated No term Buildings Straight line 5 to 20 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years Construction in progress Not depreciated No term
Schedule of terms and method use to calculate amortization of intangible assets	Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3 to 5 years Patents Straight line 20 years
Schedule of effect of adjustment to amounts recognized in consolidated statement of financial position	August 1, 2019, IFRS 16 remeasurement As reported under Assets Non-current Property, plant and equipment $ 258,793 $ 21,360 $ 280,153 Total Assets $ 258,793 $ 21,360 $ 280,153 Liabilities Current liabilities Lease liabilities — 3,556 3,556 Non-current liabilities Lease liabilities — 17,804 17,804 Total Liabilities $ — $ 21,360 $ 21,360
Schedule of reconciliation of total operating lease commitments	Total operating leases commitments as at July 31, 2019 $ 101,741 Less: Variable components of operating leases (49,330 ) Less: Low value and/or short-term lease (88 ) Operating lease liability before discounting 52,323 Adjustment to reflect discounting of operating lease commitments at August 1, 2019, using the incremental borrowing rate (30,963 ) Total lease liabilities recognized under IFRS 16 as at August 1, 2019 (Note 18) $ 21,360

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-Term Investments (Tables)	12 Months Ended
	Jul. 31, 2020
Categories of current financial assets [abstract]
Schedule of cash, cash equivalents and short-term investments	Interest rate July 31, 2020 July 31, 2019 Operating cash — $ 70,318 $ 5,993 High interest savings accounts 0.70% 113,855 107,575 Cash and cash equivalents $ 184,173 $ 113,568 Term deposits & GIC 2.85%-4.25% maturity of 3 to 12 months $ — $ 25,937 Short-term investments $ — $ 25,937

Restricted Funds (Table)

Restricted Funds (Table)	12 Months Ended
	Jul. 31, 2020
Disclosure Of Restricted Cash [Abstract]
Schedule of restricted funds	July 31, 2020 July 31, 2019 Capital contribution held in trust $ — $ 4,076 Debt service reserve account - term loan (Note 19) 8,191 9,200 Neal Up Brands Inc. (Note 30) — 2,500 Letters of credit, collateral and guarantees for purchases 70 6,574 Total $ 8,261 $ 22,350

Commodity Taxes Recoverable a_2

Commodity Taxes Recoverable and Other Receivables (Tables)	12 Months Ended
	Jul. 31, 2020
Commodity Taxes Recoverable And Other Receivables [Abstract]
Schedule of commodity taxes recoverable and other receivables	July 31, 2020 July 31, 2019 Commodity taxes recoverable $ 12,821 $ 14,415 Accrued interest income — 570 Lease receivable - current ( 1) 630 — Other receivables 3,282 262 Total $ 16,733 $ 15,247 (1)

Convertible Debentures Receiv_2

Convertible Debentures Receivable (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure Of Convertible Note Receivable [Abstract]
Schedule of convertible debentures receivable	July 31, 2020 July 31, 2019 12% Convertible debentures $ — $ 12,024 Zero interest convertible debentures — 1,330 Total $ — $ 13,354

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Jul. 31, 2020
Classes of current inventories [abstract]
Schedule of inventories	As at July 31, 2020 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 29,702 $ 16,981 $ 46,683 Purchased dried cannabis 1,956 — 1,956 Oils 10,805 385 11,190 Hemp derived distillate 566 — 566 Packaging and supplies 4,538 — 4,538 $ 47,567 $ 17,366 $ 64,933 As at July 31, 2019 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 28,996 $ 19,349 $ 48,345 Purchased dried cannabis 8,087 — 8,087 Oils 17,377 5,366 22,743 Hemp derived distillate 1,523 — 1,523 Packaging and supplies 3,156 — 3,156 $ 59,139 $ 24,715 $ 83,854

Biological Assets (Tables)

Biological Assets (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure of detailed information about biological assets [abstract]
Schedule of changes in the carrying value of biological assets	For the years ended July 31, 2020 July 31, 2019 Balance, beginning of year $ 7,371 $ 2,332 Acquired through acquisition 1 — 3,291 Production costs capitalized 38,638 19,215 Net increase in fair value due to biological transformation 29,356 38,856 Transferred to inventory upon harvest (67,131 ) (56,323 ) Disposal of biological assets (663 ) — Balance, end of year $ 7,571 $ 7,371 1 Acquired through the Newstrike acquisition on May 24, 2019
Schedule of significant unobservable inputs, their range of values and sensitivity analysis	Unobservable inputs Input values An increase or decrease of 5% applied to the July 31, 2020 July 31, 2019 July 31, 2020 July 31, 2019 Weighted average selling price Derived from actual retail prices on a per product basis using the expected Flower and Trim yields per plant. $3.23 per dried gram $4.23 per dried gram $550 $480 Yield per plant Derived from historical harvest cycle results on a per strain basis. 46 - 135 grams per plant - grams per plant $376 $344 Stage of growth Derived from the estimates of stage of completion within the harvest cycle. Average of 43% completion Average of 29% completion $376 $1,148 Waste Derived from the estimates of planned removal and naturally occurring waste within the cultivation and production cycle. 0%-21% dependent upon the stage within the harvest cycle 0%-30% dependent upon the stage within the harvest cycle No material variance $302

Investments In Associates & J_2

Investments In Associates & Joint Ventures (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure Of Associate And Joint Ventures [Abstract]
Schedule of ownership interest in other entities	For the year ended July 31, 2020 July 31, 2019 Truss LP Other Total Truss LP Other Total $ $ $ $ $ $ Opening Balance 51,786 1,063 52,849 — — — Cash contributed to investment 29,155 1,231 30,386 11,476 1,106 12,582 Fair value of warrant consideration — — — 42,386 — 42,386 Capitalized transaction costs — 109 109 720 125 845 Share of net loss for the year (5,975 ) (356 ) (6,331 ) (2,796) (168 ) (2,964 ) Impairment — (707 ) (707 ) — — — Ending Balance 74,966 1,340 76,306 51,786 1,063 52,849
Schedule of investment in associate	Truss LP As at July 31, 2020 July 31, 2019 Statement of Financial Position $ $ Cash and cash equivalents 19,561 14,318 Current assets (excluded cash and cash equivalents) 7,867 5,701 Non- current assets 66,863 7,880 Current liabilities 11,112 7,477 Non-current liabilities 8,903 —
Schedule of investment in joint venture	Period year ended July 31, 2020 11 months ended July 31, 2019 Statement of Comprehensive Loss Revenue 705 (1) — Operating expenses excluding depreciation and amortization (12,243 ) (6,579 ) Depreciation and amortization (617 ) — Other expenses (7 ) — Loss from operations (13,423 ) (6,579 ) Interest income 1 — Interest expenses (233 ) — Income tax expenses — — Total comprehensive loss (13,655 ) (6,579 ) 1
Schedule for reconciliation of investment in associate	For the year ended July 31, 2020 July 31, 2019 $ $ Opening net assets 20,423 — Acquisition of associate/capital calls 68,600 27,002 Total comprehensive loss (14,059 ) (6,579 ) Closing net assets 74,964 20,423 Interest in associate 42.5% 42.5% Interest in associate value 31,860 8,680 Fair value of warrant consideration 42,386 42,386 Capitalized transaction costs 720 720 Total interest in associate value 74,966 51,786

Long-term Investments (Tables)

Long-term Investments (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure Of Long Term Investment Abstract
Schedule of long-term investments	Fair value July 31, 2019 Investment/ Divestiture Change in fair value Fair value July 31, 2020 $ $ $ $ $ Level 1 Investments Fire and Flower common shares — 1,232 — 60 1,292 Inner Spirit common shares 3,000 — (643 ) (1,097 ) 1,260 Other long-term investments — 517 — — 517 Level 2 Investments Inner Spirit common share purchase warrants 403 — — (403 ) — Level 3 Investments Greentank Technologies 6,574 — — (6,574 ) — Neal Brothers Inc. 4,000 — — (4,000 ) — Segra International Corp. 300 — — (160 ) 140 Total 14,277 1,749 (643 ) (12,174 ) 3,209 Fair value July 31, 2018 Investment Divesture Change in fair value Fair value July 31, 2019 $ $ $ $ $ Level 1 Investments Fire & Flower Inc. common shares — 2,970 (2,493 ) (477 ) — Fire & Flower Inc. common share purchase warrants 1 — 505 (262 ) (243 ) — Inner Spirit common shares 1 — 2,850 — 150 3,000 Level 2 Investments Inner Spirit common share purchase warrants 1 — 414 — (11 ) 403 Level 3 Investments Greentank Technologies 1 — 6,723 — (149 ) 6,574 Neal Brothers Inc. 1 — 4,000 — — 4,000 Segra International Corp. 100 — — 200 300 Total 100 17,462 (2,755 ) (530 ) 14,277 1

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jul. 31, 2020
Property, plant and equipment [abstract]
Schedule of property, plant and equipment	Cost Land Buildings Leasehold Cultivation Furniture, Construction Right-of-Use Total $ $ $ $ $ $ $ $ At July 31, 2018 1,038 32,536 206 4,031 2,471 15,433 — 55,715 Business acquisitions 4,301 18,855 — 9,913 648 12,286 — 46,003 Additions — 11,365 421 28,085 7,249 117,909 — 165,029 Transfers — 88,078 — — — (88,078 ) — — At July 31, 2019 5,339 150,834 627 42,029 10,368 57,550 — 266,747 Additions — 24,432 1,395 14,969 9,404 66,246 24,405 140,851 Disposals (3,683 ) (18,260 ) — (13,402 ) (909 ) (5,428 ) — (41,682 ) Transfers — 7,943 22,417 (10,135 ) 8 (20,233 ) — — At July 31, 2020 1,656 164,949 24,439 33,461 18,871 98,135 24,405 365,916 Accumulated depreciation and impairments At July 31, 2018 — 533 9 69 771 — — 1,382 Depreciation — 3,859 121 1,497 1,095 — — 6,572 Transfers — — — 650 (650 ) — — — At July 31, 2019 — 4,392 130 2,216 1,216 — — 7,954 Depreciation — 7,395 879 3,702 3,562 — 2,522 18,060 Transfers — — — 271 (271 ) — — — Disposals — (17,081 ) — (7,435 ) (366 ) — — (24,882 ) Impairments 307 19,006 — 9,937 — 48,990 1,178 79,418 At July 31, 2020 307 13,712 1,009 8,691 4,141 48,890 3,700 80,550 Net book value At July 31, 2018 1,038 32,003 197 3,962 1,700 15,433 — 54,333 At July 31, 2019 5,339 146,442 497 39,813 9,152 57,550 — 258,793 At July 31, 2020 1,349 151,237 23,430 24,770 14,730 49,145 20,705 285,366

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Jul. 31, 2020
Changes in intangible assets other than goodwill [abstract]
Schedule of intangible assets	Cost Cultivating and Brand Software Domain Patents Other Total $ $ $ $ $ $ $ At July 31, 2018 2,545 — 1,800 585 — 312 5,242 Business acquisitions 113,888 8,440 12 — — — 122,340 Additions — — 1,746 — 1,231 — 2,977 Transfers — — — — (312 ) (312 ) At July 31, 2019 116,433 8,440 3,558 585 1,231 — 130,247 Additions — — 702 — 875 — 1,577 Disposals — — (550 ) — (173 ) — (723 ) At July 31, 2020 116,433 8,440 3,710 585 1,933 — 131,101 Accumulated amortization At July 31, 2018 403 — 786 9 — — 1,198 Amortization 1,198 — 483 57 29 — 1,767 At July 31, 2019 1,601 — 1,269 66 29 — 2,965 Amortization 3,167 — 697 59 16 — 3,939 Impairment 106,189 2,000 — — — — 108,189 At July 31, 2020 110,957 2,000 1,966 125 45 — 115,093 Net book value At July 31, 2018 2,142 — 1,014 576 — 312 4,044 At July 31, 2019 114,832 8,440 2,289 519 1,202 — 127,282 At July 31, 2020 5,476 6,440 1,744 460 1,888 — 16,008

Business Acquisition (Tables)

Business Acquisition (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure of detailed information about business combination [abstract]
Schedule of fair value of net assets assumed as at the acquisition date	Note Number of Shares, Warrants and Options Share Price Amount Consideration Shares issued (i) 35,394,041 9.11 322,439 Warrants outstanding (ii) 7,196,164 12,229 Replacement options issued (iii) 2,002,365 7,134 Total fair value of consideration 341,802 Net assets acquired Current assets Cash and cash equivalents 49,366 Accounts receivable 1,204 Other receivables 4,585 Inventory 22,359 Biological assets 3,291 Long-term assets Property, Plant and Equipment 46,003 Investments (iv) 14,492 Convertible debenture receivable 1,220 Prepaid expenses 1,631 Prepaid expense and license 1,526 Software 10 Cultivation and processing license 113,888 Brand 8,440 Goodwill 111,877 Total assets 379,892 Current liabilities Accounts payable and accrued liabilities 12,849 Payment received in advance 5 Long-term liabilities Deferred tax liabilities 24,236 Total liabilities 37,090 Non-controlling 1,000 Total net assets acquired 341,802 Net accounts receivables acquired Total accounts receivable 5,789 Expected uncollectible receivables — Net accounts receivables acquired 5,789 (i) Share price based upon the TSX market price of common shares as at May 24, 2019. (ii) Warrants were valued using the Black-Scholes option pricing model as at the acquisition date May 24, 2019, using the following assumptions and inputs; • Risk free rate of 1.48% – 1.57% • Expected life of 0.73 – 4.07 years • Volatility rate of 75%; determined using historical volatility data • Exercise prices of $11.84 – $27.64 • Stock price of $9.11 (iii) All replacement options were valued using the Black-Scholes option pricing model as at the acquisition date of May 24, 2019, using the following assumptions and inputs; • Risk free rate of 1.48% – 1.57% • Expected life of 1.2 – 4.7 years • Volatility rate of 75%; determined using historical volatility data • Exercise prices of $6.00 – $17.37 • Stock price of $9.11 The fair value of the vested options as at the acquisition date was deemed consideration paid in the transaction. The fair value of those options not yet vested at the acquisition date was added to the Company's share-based payment reserve to be expensed over the remaining vesting period of the options as permitted under IFRS 3 - Business Combinations (iv) Included in total investments were two level 3 private company investments (see ' Greentank Technologies Neal Brothers Inc

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Jul. 31, 2020
Goodwill [Abstract]
Schedule of reconciliation of changes in goodwill	Balance as at July 31, 2018 $ — Additions 111,877 Balance as at July 31, 2019 $ 111,877 Impairment (111,877 ) Balance as at July 31, 2020 $ —

Warrant Liabilities (Tables)

Warrant Liabilities (Tables)	12 Months Ended
	Jul. 31, 2020
Warrant Liabilities [Abstract]
Schedule of warrant liabilities	2017 Unsecured Convertible Debentures Warrants USD$25,000 USD$20,000 Total Opening balance as at August 1, 2018 $ 3,130 $ — $ — $ 3,130 Exercised (6,367 ) — — (6,367 ) Loss in revaluation of financial instruments 3,730 — — 3,730 Balance as at July 31, 2019 $ 493 $ — $ — $ 493 Issued — 5,629 3,967 9,596 Exercised (106 ) — — (106 ) (Gain) in revaluation of financial instruments (387 ) (3,712 ) (2,434 ) (6,533 ) Balance as at July 31, 2020 $ — $ 1,917 $ 1,533 $ 3,450

Convertible Debentures (Tables)

Convertible Debentures (Tables)	12 Months Ended
	Jul. 31, 2020
Debt instruments held [abstract]
Schedule of convertible debentures	Balance as at July 31, 2019 $ — Issued at amortized, net issuance costs 45,922 Conversion (20,603 ) Interest expense 6,854 Interest paid (3,205 ) Balance as at July 31, 2020 $ 28,969

Lease Liabilities (Tables)

Lease Liabilities (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure of quantitative information about leases for lessee [abstract]
Schedule of lease liabilities	$ Balance as at July 31, 2019 — Adjustment on adoption of IFRS 16 (Note 3) 21,360 Balance as at August 1, 2019 21,360 Lease additions 9,030 Lease payments (4,341 ) Interest expense on lease liabilities 3,067 Balance as at July 31, 2020 29,116 Current portion 4,772 Long-term portion 24,344
Schedule of lease obligations over next five fiscal years and thereafter	Fiscal year 2021 2022 - 2023 2024 - 2025 Thereafter Total $ $ $ $ $ Lease obligations 4,737 9,787 8,764 31,082 54,370

Term Loan (Revised) (Tables)

Term Loan (Revised) (Tables)	12 Months Ended
	Jul. 31, 2020
Borrowings [abstract]
Schedule of term loan	July 31, 2020 July 31, 2019 (Revised – Note 37) Term loan $ $ Opening balance 34,125 — Additions — 35,000 Repayments (3,500 ) (875 ) Ending balance 30,625 34,125 Deferred financing costs $ $ Opening balance (751 ) — Additions (445 ) (1,643 ) Adjustments — 296 Amortization of deferred finance costs 501 596 Ending balance (695 ) (751 ) Total term loan 29,930 33,374 Current portion 3,069 3,117 Long-term portion 26,861 30,257

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Jul. 31, 2020
Share Capital [Abstract]
Schedule of stock option issued and outstanding	Number of shares Share Capital Balance at July 31, 2019 256,981,753 $ 799,706 June 2020 at the market offering (i) 32,942,479 33,263 May 2020 underwritten public offering (ii) 63,940,000 43,495 April 2020 underwritten public offering (iii) 59,800,000 22,928 January 2020 registered offering (iv) 11,976,048 21,073 December 2019 registered offering (v) 14,970,062 25,229 December 2019 private placement Note 17 37,325,000 72,005 Options exercised Note 22 116,532 223 Warrants exercised Note 21 4,413,874 5,866 Balance at July 31, 2020 482,465,748 $ 1,023,788

Common Share Purchase Warrants

Common Share Purchase Warrants (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure Of Common Share Purchase Warrants [Abstract]
Schedule of warrant activity	July 31, 2020 July 31, 2019 Number of Weighted average Number of Weighted average warrants exercise price 2 warrants exercise price Outstanding, beginning of year 29,585,408 $ 9.95 26,425,504 $ 4.35 Expired (15,559,483 ) 12.25 (531 ) — Assumed and reissued through acquisition 1 — — 7,196,164 23.10 Issued 123,905,556 1.24 11,500,000 6.00 Exercised (4,413,874 ) 0.97 (15,535,729 ) 3.61 Outstanding, end of year 133,517,607 $ 1.90 29,585,408 $ 9.95 1 2
Schedule of warrant issued	Issuance date Exercise price Warrants Expiry period October 4, 2018 $6.00 11,500,000 3 years May 24, 2019 (1) $11.84-$27.64 7,196,164 0.73—4.07 years Total assumed and issued during the year ended July 31, 2019 18,696,164 December 31, 2019 USD$2.45 7,485,032 5 years January 22, 2020 USD$2.45 5,988,024 5 years April 13, 2020 $0.96 59,800,000 5 years May 21, 2020 $1.05 31,970,000 5 years June 10, 2020 $1.00 14,746,875 3 years June 30, 2020 $1.00 3,915,625 3 years Total issued during the year ended July 31, 2020 123,905,556 1
Schedule of warrants outstanding	July 31, 2020 July 31, 2019 Number Book value Number Book value Classified as Equity $ $ 2018 Equity financing Exercise price of $5.60 expired January 30, 2020 — — 10,512,208 5,674 February 2018 financing warrants Exercise price of $27.64 expired February 16, 2020 — — 4,413,498 1,331 June 2019 financing warrants Exercise price of $15.79 expiring June 19, 2023 2,184,540 10,022 2,184,540 9,998 April 2020 underwritten public offering warrants Exercise price of $0.96 expiring April 13, 2025 56,017,500 18,906 — — May 2020 underwritten public offering warrants Exercise price of $1.05 expiring May 21, 2025 31,410,050 10,805 — — Conversion Unit warrants Exercise price of $1.00 expiring June 10, 2023 14,746,875 11,426 — — Exercise price of $1.00 expiring June 30, 2023 3,915,625 1,928 — — Broker / Consultant warrants Exercise price of $20.85 expired February 16, 2020 — — 264,809 160 Exercise price of $11.84 expired June 19, 2020 — — 262,021 610 Exercise price of $0.75 expiring November 3, 2021 175,618 78 175,618 78 Exercise price of $0.75 expiring March 14, 2022 94,282 66 94,282 66 Exercise price of $15.79 expiring June 19, 2023 61 — 61 — Inner Spirit warrants Exercise price of $15.63 expired July 21, 2020 — — 71,235 129 Molson warrants Exercise price of $6.00 expiring October 4, 2021 11,500,000 42,386 11,500,000 42,386 120,044,551 95,617 29,478,272 60,432 Classified as Liability 2017 secured convertible debenture warrants Exercise price of USD$0.76 expired November 14, 2019 — — 107,136 493 USD$25m Registered Direct Offering Warrants Exercise price of USD$2.45 expiring December 31, 2024 7,485,032 1,917 — — USD$20m Registered Direct Offering Warrants Exercise price of USD$2.45 expiring January 22, 2025 5,988,024 1,533 — — 13,473,056 3,450 107,136 493 133,517,607 99,067 29,585,408 60,925

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Jul. 31, 2020
Stock Options And Restricted Share Units [Abstract]
Schedule of stock option activity	July 31, 2020 July 31, 2019 Number of Weighted average Number of Weighted average options exercise price options exercise price Opening balance 24,288,919 $ 5.87 14,388,066 $ 3.02 Granted 11,946,027 1.62 12,693,118 7.27 Acquired and reissued through acquisition 1 — — 2,002,365 9.49 Forfeited (4,582,440 ) 5.55 (1,226,763 ) 6.33 Expired (1,521,271 ) 9.16 — — Exercised (116,532 ) 1.15 (3,567,867 ) 1.20 Closing balance 30,014,703 $ 4.07 24,288,919 $ 5.87 1
Schedule of stock option granted	Options granted Grant date Exercise price Executive and Non-executive Total Vesting terms Expiry period September 17, 2018 7.93 650,000 523,500 1,173,500 Terms A 10 years November 22, 2018 5.92 — 440,000 440,000 Terms A 10 years December 17, 2018 5.09 74,000 227,500 301,500 Terms A, C 10 years February 19, 2019 7.13 615,000 626,000 1,241,000 Terms A 10 years February 21, 2019 7.46 3,333,333 — 3,333,333 Terms D 10 years March 20, 2019 8.50 325,000 1,077,500 1,402,500 Terms A 10 years April 17, 2019 8.24 — 1,132,500 1,132,500 Terms A 10 years July 18, 2019 6.54 650,000 2,768,785 3,418,785 Terms A 10 years July 26, 2019 5.88 250,000 — 250,000 Terms A 10 years Total 5,897,333 6,795,785 12,693,118 October 29, 2019 3.30 829,034 2,732,277 3,561,311 Terms B 10 years January 29, 2020 1.80 — 293,021 293,021 Terms B 10 years April 28, 2020 0.69 900,000 2,565,322 3,465,322 Terms B 10 years June 26, 2020 1.02 3,055,025 732,410 3,787,435 Terms B 10 years July 28, 2020 0.96 — 838,938 838,938 Terms B 10 years Total 4,784,059 7,161,968 11,946,027
Schedule of stock options outstanding	Exercise price Number outstanding Weighted average Number exercisable Weighted average $0.58-$2.69 11,371,022 8.87 2,769,874 6.08 $3.30-$6.54 12,100,157 6.21 6,002,653 7.85 $7.13-$8.50 6,302,656 8.53 1,547,062 8.44 $8.84-$17.37 240,868 1.67 220,285 1.74 30,014,703 10,539,874
Schedule of Restricted Share Units activity	July 31, 2020 July 31, 2019 Units Value of units Units Value of units Opening balance — $ — — $ — Granted 2,438,548 2.13 — — Forfeited (90,114 ) 2.94 — — Closing balance 2,348,434 $ 2.10 — $ —
Schedule of Restricted Share Units Granted	RSUs granted Grant date Unit value Executive and Non-executive Vesting terms Expiry period October 29, 2019 $0.53 - $1.16 1,428,449 — Terms A, B 10 years June 26, 2020 $0.71 1,010,101 — Terms A 10 years
Schedule of fair value of stock options and restricted stock units granted	July 31, 2020 July 31, 2019 Exercise price (weighted average) $ 6.51 $ 5.99 Stock price (weighted average) $ 6.61 $ 6.11 Risk-free interest rate (weighted average) 1.79% 2.11% Expected life (years) of options (weighted average) 5 5 Expected annualized volatility (weighted average) 75% 69%
Schedule of equity-settled and cash-settled share-based payments	For the year ended July 31, 2020 July 31, 2019 Stock option share-based compensation $ 31,503 $ 29,793 RSU share-based compensation — — Total equity-settled share-based compensation 31,503 29,793 RSU share-based compensation 393 — Total cash-settled share-based compensation $ 393 $ —

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Jul. 31, 2019
Earnings per share [abstract]
Schedule of anti-dilutive securities excluded from computation of diluted earnings per share	Instrument July 31, 2020 July 31, 2019 Stock Options 29,996,748 24,288,919 RSUs 2,348,434 — 2017 Secured convertible debenture warrants — 107,136 2018 Equity warrants — 10,512,208 2018 February 2018 financing warrants — 4,413,498 2019 June financing warrants 2,184,540 2,184,540 USD$25m registered direct offering warrants 7,485,032 — USD$20m registered direct offering warrants 5,988,024 — 2020 April underwritten public offering warrants 56,017,500 — 2020 May underwritten public offering warrants 31,410,050 — Warrants issued under conversion of debentures 18,662,500 — Joint venture and Inner Spirit issued warrants 11,500,000 11,571,235 Convertible debenture broker/finder warrants 269,961 796,791 165,862,789 53,874,327

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure of detailed information about financial instruments [abstract]
Schedule of price risk	July 31, 2020 July 31, 2019 $ $ Financial assets 2,692 16,756 Financial liabilities (3,450 ) (493 ) Total exposure (758 ) 16,263
Schedule of aging of trade receivables	July 31, July 31, 2020 2019 $ $ 0-30 days 15,253 14,102 31-60 days 2,972 1,826 61-90 days 412 166 Over 90 days 789 3,599 Total 19,426 19,693

Operating Expenses by Nature (T

Operating Expenses by Nature (Tables)	12 Months Ended
	Jul. 31, 2020
Expenses by nature [abstract]
Schedule of expenses by nature	For the year ended July 31, 2020 July 31, 2019 Salaries and benefits $ 12,202 $ 25,349 Consulting 7,425 11,176 Professional fees 9,811 8,258 Facilities 6,895 5,697 Selling, general and administrative 14,409 4,462 Travel 2,051 2,710 Share-based compensation 25,790 28,008 Marketing and promotion 12,474 22,308 Amortization of intangible assets 3,939 1,767 Depreciation of property, plant and equipment 6,072 1,747 Total $ 101,068 $ 111,482
Schedule of share-based compensation	For the year ended July 31, 2020 July 31, 2019 General and administrative related share-based compensation $ 24,650 $ 26,322 Marketing and promotion related share-based compensation 1,140 1,686 Total operating expense related share-based compensation 25,790 28,008 Share based compensation capitalized to inventory 6,105 1,724 Total share-based compensation $ 31,895 $ 29,732
Schedule of payroll related wages and benefits	For the year ended July 31, 2020 July 31, 2019 General and administrative related wages and benefits $ 12,202 $ 17,975 Marketing and promotion related wages and benefits 5,625 6,162 Research and development related wages and benefits 2,717 1,212 Total operating expense related wages and benefits 20,544 25,349 Wages and benefits capitalized to inventory 21,128 10,905 Total wages and benefits $ 41,672 $ 36,254

Related Party Disclosure (Table

Related Party Disclosure (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure of transactions between related parties [abstract]
Schedule of compensation provided to key management	For the year ended July 31, 2020 July 31, 2019 Salary and/or consulting fees $ 3,069 $ 3,550 Termination benefits 1,043 470 Bonus compensation 42 481 Stock-based compensation 15,702 16,235 Total $ 19,856 $ 20,736

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure Of Commitments And Contingencies [Abstract]
Schedule of future minimum payments under contractual financial obligations	July 31, 2021 $ 14,741 July 31, 2022 3,666 July 31, 2023 3,444 July 31, 2024 3,444 July 31, 2025 2,450 Thereafter 19,274 $ 47,019

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Jul. 31, 2020
Disclosure Of Fair Value Of Financial Instruments Explanatory [Abstract]
Schedule of carrying values of financial instruments	The carrying values of the financial instruments as at July 31, 2020 are summarized in the following table: Financial liabilities Amortized designated as cost FVTPL as FVTPL Total Assets $ $ $ $ Cash and cash equivalents 184,173 — — 184,173 Restricted funds 8,261 — — 8,261 Trade receivables 19,426 — — 19,426 Commodity taxes recoverable and other receivables 16,773 — — 16,773 Lease receivable - long term 3,865 — — 3,865 Long - term investments — 3,209 — 3,209 Liabilities $ $ $ $ Accounts payable and accrued liabilities 32,451 — — 32,451 Warrant liability — 3,450 — 3,450 Lease liability - current 4,772 — — 4,772 Lease liability - long term 24,344 — — 24,344 Convertible debentures 28,969 — — 28,969 Term loan 29,930 — — 29,930 Other long-term liabilities — — 393 393 The carrying values of the financial instruments as at July 31, 2019 are summarized in the following table: Financial liabilities Amortized designated cost FVTPL as FVTPL Total Assets $ $ $ $ Cash and cash equivalents 113,568 — — 113,568 Restricted funds 22,350 — — 22,350 Short-term investments 25,937 — — 25,937 Trade receivables 19,693 — — 19,693 Commodity taxes recoverable and other receivables 15,247 — — 15,247 Convertible debenture receivable — 13,354 — 13,354 Long term investments — 14,277 — 14,277 Liabilities $ $ $ $ Accounts payable and accrued liabilities 45,581 — — 45,581 Warrant liability — 493 — 493 Deferred rent liability 946 — — 946 Term loan 33,374 — — 33,374

Non-Controlling Interest (Table

Non-Controlling Interest (Tables)	12 Months Ended
	Jul. 31, 2020
Non Controlling Interest [Abstract]
Schedule of information relating to subsidiary	July 31, 2020 July 31, 2019 KIT Neal Up Brands Inc. Current assets $ — $ 2,500 Non-current assets 7,455 — Current liabilities — — Non-current liabilities — — Non-controlling interest (%) 40% 40% Non-controlling interest $ 3,379 $ 1,000

Revenue from Sale of Goods (Tab

Revenue from Sale of Goods (Tables)	12 Months Ended
	Jul. 31, 2020
Revenue [abstract]
Schedule of gross revenue	For the year ended July 31, 2020 July 31, 2019 Revenue stream Cannabis sales Cannabis Total Cannabis sales Cannabis Total $ $ $ $ $ $ Retail 101,712 2,851 104,563 53,968 — 53,968 Medical 3,299 — 3,299 5,288 — 5,288 Wholesale 996 — 996 — — — International 1,291 — 1,291 — — — Total revenue from sale of goods 107,298 2,851 110,149 59,256 — 59,256

Restructuring Provision (Tables

Restructuring Provision (Tables)	12 Months Ended
	Jul. 31, 2020
Restructuring Provision Abstract
Schedule of restructuring provision	$ Balance payable as at July 31, 2019 — Total restructuring costs 4,767 Less: payments made (4,737 ) Balance payable as at July 31, 2020 30

Operating Cash Flow (Tables)

Operating Cash Flow (Tables)	12 Months Ended
	Jul. 31, 2020
Operating Cash Flow [Abstract]
Schedule of operating cash flow activity	For the year ended Note July 31, 2020 July 31, 2019 $ $ Items not affecting cash Income tax recovery (6,023 ) (18,213 ) Depreciation of property, plant and equipment 6,072 1,747 Depreciation of property, plant and equipment in cost of sales 3,567 — Amortization of intangible assets 3,939 1,767 Loss/(gain) on convertible debentures 4,806 (1,737 ) Unrealized gain on changes in fair value of biological assets (29,356 ) (38,856 ) Unrealized fair value adjustment on investments 12,880 315 Amortization of deferred financing costs 56 596 Accrued interest income 9,921 (397 ) Gain on investment (24 ) — Loss on induced conversion of debenture 54,283 — License depreciation and prepaid royalty expenses 389 117 Write-off of inventory and biological assets 5,055 — Write down of inventory to net realizable value 68,319 19,335 Realized fair value amounts on inventory sold 40,910 16,357 Loss from investment in associate and joint ventures 6,331 2,964 Share-based compensation 25 25,790 28,944 Revaluation of financial instruments (gain)/loss (6,533 ) 3,730 Impairment losses 299,484 — Loss on onerous contract 4,763 — Loss on disposal of property, plant and equipment 3,855 — Total items not affecting cash 508,484 16,669 Changes in non-cash operating working capital items Trade receivables 267 (17,845 ) Commodity taxes recoverable and other receivables (784 ) (6,425 ) Prepaid expenses 5,717 (4,927 ) Inventory (100,492 ) (90,748 ) Biological assets 28,493 37,108 Accounts payable and accrued liabilities 6,623 6,630 Excise taxes payable 3,627 3,494 Deferred rent liability — 946 Total non-cash operating working capital (56,549 ) (71,767 )
Schedule of additional supplementary cash flow information	For the year ended July 31, 2020 July 31, 2019 $ $ Property, plant and equipment in accounts payable 19,751 21,265 Right-of-use asset additions 24,405 — Capitalized borrowing costs 2,385 511 Interest paid 2,527 252

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2020
Income taxes paid (refund) [abstract]
Schedule of components of income tax expense	July 31, 2020 July 31, 2019 Current tax for the year $ — $ — Adjustments of previous years — — Total $ — $ —
Schedule of deferred income tax expense (recovery)	July 31, 2020 July 31, 2019 Origination and reversal of temporary differences $ (98,141 ) $ (13,007 ) Difference between statutory tax rate and deferred tax rate 2,555 172 Change in temporary difference for which no deferred tax assets are recorded 89,563 (5,378 ) Deferred income tax recovery $ (6,023 ) $ (18,213 )
Schedule of income tax rate reconciliation	July 31, 2020 July 31, 2019 Expected tax rate 26.54% 26.64% Earnings before income taxes $ (552,512 ) $ (87,281 ) Expected tax benefit resulting from loss (146,637 ) (23,252 ) Adjustments for the following items: Tax rate differences 2,555 172 Permanent differences 48,965 9,973 Change in temporary differences for which no tax assets are recorded 89,563 (5,770 ) True up and other (469 ) 664 $ (6,023 ) $ (18,213 )
Schedule of reconciliation of deferred tax assets and liabilities	Opening Recognized in Recognized in Ending August 1, 2019 income equity July 31, 2020 $ $ $ $ Taxable temporary differences 6,858 3,557 — 10,415 Biological assets (1,514 ) 184 — (1,330 ) Inventory (2,920 ) (2,168 ) — (5,088 ) Loss carryforward 23,369 (23,369 ) — — Share issue costs 721 (721 ) — — Intangible assets (32,537 ) 28,540 — (3,997 ) Net deferred tax asset (liability) (6,023 ) 6,023 — — Opening Recognized in Recognized in Ending August 1, 2018 income goodwill July 31, 2019 $ $ $ $ Taxable temporary differences (117 ) 7,195 (200 ) 6,858 Biological assets (458 ) (764 ) (292 ) (1,514 ) Inventory (1,432 ) (930 ) (559 ) (2,920 ) Loss carryforward 2,007 14,058 7,304 23,369 Share issue costs — (1,003 ) 1,724 721 Intangible assets — (344 ) ( 32,193 ) (32,537 ) Net deferred tax asset (liability) — 18,212 (24,236 ) ( 6,023 )
Schedule of deductible temporary differences and unused tax losses	July 31, 2020 July 31, 2019 $ $ Losses carried forward 255,635 5,898 Research and development expenditures 669 266 Fixed Assets, intangibles and other assets 84,482 — Share issue costs 22,599 8,612 363,385 14,776
Schedule of non-capital losses	$ 2025 187 2026 199 2027 279 2028 236 2029 257 2030 205 2031 291 2032 781 2033 473 2034 1,547 2035 3,601 2036 6,389 2037 14,100 2038 37,111 2039 51,142 2040 132,646 249,444

Basis of Presentation - Schedul

Basis of Presentation - Schedule of major joint ventures (Details)	12 Months Ended
	Jul. 31, 2020
HEXO MED A.E.
Disclosure of joint ventures [line items]
Proportion of ownership interest in joint venture	51.00%
Belleville Complex Inc.
Disclosure of joint ventures [line items]
Proportion of ownership interest in joint venture	25.00%

Basis of Presentation - Sched_2

Basis of Presentation - Schedule of major subsidiaries (Details)	12 Months Ended
	Jul. 31, 2020
HEXO Operations Inc.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
HEXO USA Inc.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
Keystone Isolation Technologies Inc. ("KIT")
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	60.00%
Neal Up Brands Inc.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	60.00%

Basis of Presentation - Sched_3

Basis of Presentation - Schedule of major associates (Details)	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Truss Limited Partnership ("Truss LP")
Disclosure of associates [line items]
Proportion of ownership interest in associate	42.50%	42.50%
Truss CBD USA LLC ("Truss CBD US")
Disclosure of associates [line items]
Proportion of ownership interest in associate	42.50%

Significant Accounting Polici_4

Significant Accounting Policies (Narrative) (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)	Aug. 01, 2019CAD ($)	Aug. 01, 2019USD ($)	Jul. 31, 2019CAD ($)
Disclosure of detailed information about property, plant and equipment [line items]
Lease liabilities	$ 29,116	$ 21,360		$ 0
As reported under IFRS 16 August 1, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Short term leases with lease terms of less than twelve months			$ 5,000
Lease liabilities		21,360
Right-of-use assets		$ 21,360
Total lease commitments				192,230
Total operating leases commitments				$ 101,741
Percentage of incremental borrowing rate of administrative real estate	8.00%
Percentage of incremental borrowing rate of production real estate	12.00%
Minimum
Disclosure of detailed information about property, plant and equipment [line items]
Maturity term for short-term investments	3 months
Maximum
Disclosure of detailed information about property, plant and equipment [line items]
Maturity term for short-term investments	12 months

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of terms and method use to calculate amortization of tangible assets (Details)	12 Months Ended
	Jul. 31, 2020
Land
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Not depreciated
Amortization term	No term
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 to 20 years
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	lease term
Furniture and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 years
Cultivation and production equipment
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 to 20 years
Vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 years
Computers
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	3 years
Construction in progress
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Not depreciated
Amortization term	No term

Significant Accounting Polici_6

Significant Accounting Policies - Schedule of terms and method use to calculate amortization of intangible assets (Details)	12 Months Ended
	Jul. 31, 2020
Domain names
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	10 years
Health Canada licenses
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	20 years
Software
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	3 to 5 years
Patents
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	20 years

Significant Accounting Polici_7

Significant Accounting Policies - Schedule of effect of the adjustment to the amounts recognized in consolidated statement of financial position (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Aug. 01, 2019	Jul. 31, 2019	Jul. 31, 2018
Non-current assets
Property, plant and equipment	$ 285,366		$ 258,793	$ 54,333
Total assets	692,869		878,623
Current liabilities
Lease liabilities	4,772
Non-current liabilities
Lease liabilities	24,344		0
Total lease liabilities	$ 29,116	$ 21,360	$ 0
August 1, 2019 as previously reported
Non-current assets
Property, plant and equipment		258,793
Total assets		258,793
Current liabilities
Lease liabilities		0
Non-current liabilities
Lease liabilities		0
Total lease liabilities		0
IFRS 16 remeasurement adjustments on August 1, 2019
Non-current assets
Property, plant and equipment		21,360
Total assets		21,360
Current liabilities
Lease liabilities		3,556
Non-current liabilities
Lease liabilities		17,804
Total lease liabilities		21,360
As reported under IFRS 16 August 1, 2019
Non-current assets
Property, plant and equipment		280,153
Total assets		280,153
Current liabilities
Lease liabilities		3,556
Non-current liabilities
Lease liabilities		17,804
Total lease liabilities		$ 21,360

Significant Accounting Polici_8

Significant Accounting Policies - Schedule of Reconciliation of total operating lease commitments to lease liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Aug. 01, 2019
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Less: Variable components of operating leases	$ (3,769)
Total lease liabilities	$ 29,116	$ 0	$ 21,360
IFRS 16 Leases
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Total operating leases commitments		101,741
Less: Variable components of operating leases		(49,330)
Less: Low value and/or short-term lease		(88)
Operating lease liability before discounting		52,323
Adjustment to reflect discounting of operating lease commitments at August 1, 2019, using the incremental borrowing rate		$ (30,963)
Total lease liabilities			$ 21,360

Cash, Cash Equivalents and Sh_3

Cash, Cash Equivalents and Short-Term Investments - Schedule of cash, cash equivalents and short-term investments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2018
Disclosure Of Short Term Investments [Line Items]
Cash and cash equivalents	$ 184,173	$ 113,568	$ 99,042
Short-term investments	$ 0	25,937
Operating cash
Disclosure Of Short Term Investments [Line Items]
Interest rate	0.00%
Cash and cash equivalents	$ 70,318	5,993
High interest savings accounts
Disclosure Of Short Term Investments [Line Items]
Interest rate	0.70%
Cash and cash equivalents	$ 113,855	107,575
Term deposits & GIC
Disclosure Of Short Term Investments [Line Items]
Maturity date	maturity of 3 to 12 months
Short-term investments	$ 0	$ 25,937
Term deposits & GIC | Minimum
Disclosure Of Short Term Investments [Line Items]
Interest rate	2.85%
Term deposits & GIC | Maximum
Disclosure Of Short Term Investments [Line Items]
Interest rate	4.25%

Restricted Funds - Schedule of

Restricted Funds - Schedule of restricted funds (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019
Restricted Cash [Line Items]
Restricted funds	$ 8,261	$ 22,350
Capital contribution held in trust
Restricted Cash [Line Items]
Restricted funds	0	4,076
Debt service reserve account - term loan
Restricted Cash [Line Items]
Restricted funds	8,191	9,200
Letters of credit, collateral and guarantees for purchases
Restricted Cash [Line Items]
Restricted funds	70	6,574
Neal Up Brands Inc.
Restricted Cash [Line Items]
Restricted funds	$ 0	$ 2,500

Commodity Taxes Recoverable a_3

Commodity Taxes Recoverable and Other Receivables - Schedule of commodity taxes recoverable and other receivables (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019
Commodity Taxes Recoverable And Other Receivables [Abstract]
Commodity taxes recoverable	$ 12,821	$ 14,415
Accrued interest income	0	570
Lease receivable - current	630	0
Other receivables	3,282	262
Total	$ 16,733	$ 15,247

Convertible Debentures Receiv_3

Convertible Debentures Receivable (Narrative) (Details) - CAD ($) $ / shares in Units, $ in Thousands	Feb. 11, 2020	Jan. 27, 2020	Feb. 18, 2020	Jan. 23, 2020	Nov. 30, 2019	May 24, 2019	Jul. 26, 2018	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Convertible Note Receivable [Line Items]
Current Convertible Note Receivable								$ 0	$ 13,354
12% Convertible debentures
Disclosure Of Convertible Note Receivable [Line Items]
Current Convertible Note Receivable								0	12,024
Zero interest convertible debentures
Disclosure Of Convertible Note Receivable [Line Items]
Current Convertible Note Receivable								$ 0	$ 1,330
Fire and Flower ("FF")
Disclosure Of Convertible Note Receivable [Line Items]
Payments for convertible note receivable							$ 10,000
Convertible debenture interest rate							8.00%
Description of convertible debenture maturity							July 31, 2020
Description of conversion of debt to equity							The convertible debentures included a conversion feature which allowed for the conversion of the debenture into common shares of FAF at the lower of $1.15 and the share price as defined within the agreement. The Company obtained the debenture as a part of a strategic investment into the private retail cannabis market. The convertible debentures are measured using a level 2 valuation methodology under the fair value hierarchy.
Fire and Flower ("FF") | 12% Convertible debentures
Disclosure Of Convertible Note Receivable [Line Items]
Convertible debenture interest rate								12.00%
Conversion of debt, converted amount	$ 7,000			$ 3,000
Conversion rate of convertible debentures	$ 1.15			$ 1.15
Conversion of debt, shares issued	6,086,956			2,608,695
Average market price		$ 1.0541	$ 0.75
Proceeds from sale of converted shares		$ 2,724	$ 4,504
Commission expenses		$ 26	$ 61
Accrued unpaid interest	$ 367
Shares received for accrued and unpaid interest	319,377
Realized loss on convertible debentures								$ 4,396
Fire and Flower ("FF") | Zero interest convertible debentures
Disclosure Of Convertible Note Receivable [Line Items]
Convertible debenture receivable						$ 1,220
Payments for convertible note receivable						$ 800
Convertible debenture interest rate						0.00%
Description of convertible debenture maturity						November 30, 2019
Conversion rate of convertible debentures					$ 0.80
Conversion of debt, shares issued					1,000,000
Realized loss on convertible debentures								$ 410

Convertible Debentures Receiv_4

Convertible Debentures Receivable - Schedule of convertible debentures receivable (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Convertible Note Receivable [Line Items]
Convertible debenture receivable	$ 0	$ 13,354
12% Convertible debentures
Disclosure Of Convertible Note Receivable [Line Items]
Convertible debenture receivable	$ 0	$ 12,024
Convertible debentures receivable interest rate	12.00%	12.00%
Zero interest convertible debentures
Disclosure Of Convertible Note Receivable [Line Items]
Convertible debenture receivable	$ 0	$ 1,330

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Classes Of Inventories [Line Items]
Inventory expensed to cost of goods sold	$ 127,424	$ 45,532
Fair value gain on biological fair value adjustments	29,356	38,856
Fair value adjustment on inventory sold	40,910	16,357
Inventories net realizable value	12,962	2,417
Stock based compensation expensed to costs of sales	6,105	1,724
Inventory capitalized depreciation costs	11,988	4,825
Inventory disposed	4,392
Impairment loss on inventory	$ (68,319)	$ (19,335)

Inventory - Schedule of invento

Inventory - Schedule of inventories (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019
Classes Of Inventories [Line Items]
Dried cannabis	$ 46,683	$ 48,345
Purchased dried cannabis	1,956	8,087
Oils	11,190	22,743
Hemp derived distillate	566	1,523
Packaging and supplies	4,538	3,156
Total inventory	64,933	83,854
Capitalized cost
Classes Of Inventories [Line Items]
Dried cannabis	29,702	28,996
Purchased dried cannabis	1,956	8,087
Oils	10,805	17,377
Hemp derived distillate	566	1,523
Packaging and supplies	4,538	3,156
Total inventory	47,567	59,139
Biological asset fair value adjustment
Classes Of Inventories [Line Items]
Dried cannabis	16,981	19,349
Purchased dried cannabis	0	0
Oils	385	5,366
Hemp derived distillate	0	0
Packaging and supplies	0	0
Total inventory	$ 17,366	$ 24,715

Biological Assets (Narrative) (

Biological Assets (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure of detailed information about biological assets [line items]
Disposal of biological assets	$ 663	$ 0
Plants | Level 3 Investments
Disclosure of detailed information about biological assets [line items]
Disposal of biological assets	$ 663

Biological Assets - Schedule of

Biological Assets - Schedule of changes in the carrying value of biological assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure of detailed information about biological assets [abstract]
Balance, beginning of year	$ 7,371	$ 2,332
Acquired through acquisition	0	3,291
Production costs capitalized	38,638	19,215
Net increase in fair value due to biological transformation and estimates	29,356	38,856
Transferred to inventory upon harvest	(67,131)	(56,323)
Disposal of biological assets	(663)	0
Balance, end of year	$ 7,571	$ 7,371

Biological Assets - Schedule _2

Biological Assets - Schedule of detailed information about biological assets (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)CAD_per_DriedgramGram	Jul. 31, 2019CAD ($)CAD_per_DriedgramGram
Derived from actual retail prices on a per product
Weighted average selling price input values per dried gram | CAD_per_Driedgram	3.23	4.23
Sensitivity analysis, impact of variance on selling price to valuation	$ 550	$ 480
Obtained through historical harvest cycle results on a per strain basis
Sensitivity analysis, impact of variance on average yield per plant to valuation	$ 376	$ 344
Obtained through the estimates of stage of completion within the harvest cycle
Average stage of completion within harvest cycle	43.00%	29.00%
Sensitivity analysis, impact of variance on average stage of growth per plant to valuation	$ 376	$ 1,148
Obtained through the estimates of wastage within the cultivation and production cycle
Sensitivity analysis impact of variance on wastage expectation result in change in valuation		$ 302
Minimum
Obtained through historical harvest cycle results on a per strain basis
Average yield per plant | Gram	46	15
Obtained through the estimates of wastage within the cultivation and production cycle
Wastage dependent upon the stage within the harvest cycle	0.00%	0.00%
Maximum
Obtained through historical harvest cycle results on a per strain basis
Average yield per plant | Gram	135	123
Obtained through the estimates of wastage within the cultivation and production cycle
Wastage dependent upon the stage within the harvest cycle	21.00%	30.00%

Investments In Associates & J_3

Investments In Associates & Joint Ventures (Narrative) (Details) - $ / shares	Oct. 04, 2018	Jul. 31, 2020	[1]	Jul. 31, 2019
Disclosure of joint ventures [line items]
Weighted average exercise price, Warrants issued during period		$ 1.24		$ 6
Truss LP
Disclosure of joint ventures [line items]
Number of shares held	42,500
Proportion of ownership interest in joint venture	42.50%
Truss LP | Molson Coors Canada (the "Partner")
Disclosure of joint ventures [line items]
Number of shares held	57,500
Proportion of ownership interest in joint venture	57.50%
Number of warrants granted	11,500,000
Period of warrants granted	3 years
Weighted average exercise price, Warrants issued during period	$ 6
[1]	USD denominated warrant's exercise price have been converted to the CAD equivalent as at the period end for presentation purposes.

Investments In Associates & J_4

Investments In Associates & Joint Ventures - Schedule of investment in associate and joint ventures (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Associate And Joint Ventures [Line Items]
Opening Balance	$ 52,849	$ 0
Cash consideration of investment	30,386	12,582
Fair value of warrant consideration	0	42,386
Capitalized transaction costs	109	845
Share of net loss for the year	(6,331)	(2,964)
Impairment	(707)	0
Ending Balance	76,306	52,849
Truss LP
Disclosure Of Associate And Joint Ventures [Line Items]
Opening Balance	51,786	0
Cash consideration of investment	29,155	11,476
Fair value of warrant consideration	0	42,386
Capitalized transaction costs	0	720
Share of net loss for the year	(5,975)	(2,796)
Impairment	0	0
Ending Balance	74,966	51,786
Other
Disclosure Of Associate And Joint Ventures [Line Items]
Opening Balance	1,063	0
Cash consideration of investment	1,231	1,106
Fair value of warrant consideration	0	0
Capitalized transaction costs	109	125
Share of net loss for the year	(356)	(168)
Impairment	(707)	0
Ending Balance	$ 1,340	$ 1,063

Investments In Associates & J_5

Investments In Associates & Joint Ventures - Schedule of investment in associate and joint ventures - Statement of financial position (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2018
Disclosure Of Associate And Joint Ventures [Line Items]
Cash and cash equivalents	$ 184,173	$ 113,568	$ 99,042
Current assets	305,703	312,136
Current liabilities	82,487	82,942
Truss LP
Disclosure Of Associate And Joint Ventures [Line Items]
Cash and cash equivalents	19,561	14,318
Current assets	7,867	5,701
Non-current assets	66,863	7,880
Current liabilities	11,112	7,477
Non-current liabilities	$ 8,903	$ 0

Investments In Associates & J_6

Investments In Associates & Joint Ventures - Schedule of investment in associate and joint ventures - Statement of comprehensive loss (Details) - CAD ($) $ in Thousands	11 Months Ended	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Associate And Joint Ventures [Line Items]
Revenue		$ 80,784	$ 47,541
Operating expenses excluding depreciation and amortization		(418,576)	(111,482)
Loss from operations		(476,551)	(86,974)
Interest income		1,902	5,187
Interest expenses		(10,043)	(469)
Income tax expenses		(6,023)	(18,213)
Total comprehensive loss		(546,489)	$ (69,608)
Truss LP
Disclosure Of Associate And Joint Ventures [Line Items]
Revenue	$ 0	705
Operating expenses excluding depreciation and amortization	(6,579)	(12,243)
Depreciation and amortization	0	(617)
Other expenses	0	(7)
Loss from operations	(6,579)	(13,423)
Interest income	0	1
Interest expenses	0	(233)
Income tax expenses	0	0
Total comprehensive loss	$ (6,579)	$ (13,655)

Investments In Associates & J_7

Investments In Associates & Joint Ventures - Schedule for reconciliation of investment in associate (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2018
Disclosure Of Associate And Joint Ventures [Line Items]
Total comprehensive loss	$ (546,489)	$ (69,608)
Total interest in associate value	76,306	52,849	$ 0
Truss LP
Disclosure Of Associate And Joint Ventures [Line Items]
Opening net assets	20,423	0
Acquisition of associate/capital calls	68,600	27,002
Total comprehensive loss	(14,059)	(6,579)
Closing net assets	$ 74,964	$ 20,423
Interest in associate	42.50%	42.50%
Interest in associate value	$ 31,860	$ 8,680
Fair value of warrant consideration	42,386	42,386
Capitalized transaction costs	720	720
Total interest in associate value	$ 74,966	$ 51,786	$ 0

Long-term Investments (Narrativ

Long-term Investments (Narrative) (Details) $ / shares in Units, $ in Thousands	Feb. 11, 2020shares	Nov. 30, 2019CAD ($)$ / sharesshares	Jul. 25, 2019CAD ($)	May 24, 2019CAD ($)$ / sharesshares	Feb. 19, 2019CAD ($)	Nov. 01, 2018CAD ($)Receipt	Jul. 31, 2020CAD ($)$ / sharesshares	Jul. 31, 2019CAD ($)$ / shares
Disclosure Of Long Term Investment [Line Items]
Proceeds from sale of investments							$ 7,871
Zero interest bearing convertible debentures							23,902
Conversion of convertible debenture amount							20,603
Fire & Flower Inc. common shares
Disclosure Of Long Term Investment [Line Items]
Conversion of debt, shares issued | shares	319,377	1,000,000
Conversion of debt, converted amount		$ 800
Conversion rate of convertible debentures | $ / shares		$ 0.80
Conversion of debt, fair value of shares issued		$ 920					$ 313
Conversion of debt, fair value of shares issued per share | $ / shares		$ 0.98					$ 0.98
Number of subscription | Receipt						1,980,000
Proceeds from subscription receipts						$ 2,970
Subscription receipts convert to common shares ratio					1
Fair value investment observable prices		$ 980			$ 2,970
Proceeds from sale of investments			$ 2,493
Fair value of investments
Losses on disposals of investments								477
Gains on disposals of investments		$ 60
Newstrike
Disclosure Of Long Term Investment [Line Items]
Market price of convertible debentures | $ / shares				$ 9.11
Percentage of voting equity interests acquired				100.00%
Newstrike | Fire & Flower Inc. common share purchase warrants
Disclosure Of Long Term Investment [Line Items]
Number of common share purchase warrants obtained | shares				1,000,000
Subscription receipts convert to common shares ratio				1
Fair value of investments				$ 243
Fair value of warrants				$ 505
Losses on disposals of investments								243
Market price of warrants | $ / shares				$ 1.33
Expected life of warrants				8 years 4 months 24 days
Dividends on warrants
Volatility rate of warrants				100.00%
Risk free rate of warrants				1.46%
Newstrike | Inner Spirit common shares
Disclosure Of Long Term Investment [Line Items]
Number of common shares obtained | shares				15,000,000
Fair value of investments				$ 2,850			$ 1,260
Number of common shares disposed | shares							6,005,500
Gains on disposals of investments							$ 24
Number of remaining common shares obtained | shares							8,994,500
Market price of shares held | $ / shares							$ 0.14	$ 0.20
Newstrike | Inner Spirit common shares | Minimum
Disclosure Of Long Term Investment [Line Items]
Market price of shares disposed | $ / shares							0.09
Newstrike | Inner Spirit common shares | Maximum
Disclosure Of Long Term Investment [Line Items]
Market price of shares disposed | $ / shares							$ 0.15
Newstrike | Inner Spirit common share purchase warrants
Disclosure Of Long Term Investment [Line Items]
Number of common share purchase warrants obtained | shares				7,500,000
Subscription receipts convert to common shares ratio				1
Fair value of warrants				$ 414
Losses on disposals of investments							$ 403	$ 11
Newstrike | Greentank Technologies
Disclosure Of Long Term Investment [Line Items]
Fair value of investments				$ 6,723
Number of preferred shares acquired | shares				1,953,125
Impairment Of Investment							6,574	(149)
Newstrike | Neal Brothers Inc.
Disclosure Of Long Term Investment [Line Items]
Fair value of investments				$ 4,000
Percentage of voting equity interests acquired				19.90%
Impairment Of Investment							$ 4,000

Long-term Investments - Schedul

Long-term Investments - Schedule of long-term investments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	$ 14,277
Long-term investments, ending balance	3,209	$ 14,277
Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	14,277	100
Investment/Transfer	1,749	17,462
Divestiture	(643)	(2,755)
Change in fair value	(12,174)	(530)
Long-term investments, ending balance	3,209	14,277
Fire & Flower Inc. common shares | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	0	0
Investment/Transfer	1,232	2,970
Divestiture	0	(2,493)
Change in fair value	60	(477)
Long-term investments, ending balance	1,292	0
Fire & Flower Inc. common share purchase warrants | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	0	0
Investment/Transfer		505
Divestiture		(262)
Change in fair value		(243)
Long-term investments, ending balance		0
Inner Spirit common shares | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	3,000	0
Investment/Transfer	0	2,850
Divestiture	(643)	0
Change in fair value	(1,097)	150
Long-term investments, ending balance	1,260	3,000
Inner Spirit common share purchase warrants | Level 2 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	403	0
Investment/Transfer	0	414
Divestiture	0	0
Change in fair value	(403)	11
Long-term investments, ending balance	0	403
Other long-term investments | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	0
Investment/Transfer	517
Divestiture	0
Change in fair value	0
Long-term investments, ending balance	517	0
Greentank Technologies | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	6,574	0
Investment/Transfer	0	6,723
Divestiture	0	0
Change in fair value	(6,574)	(149)
Long-term investments, ending balance	0	6,574
Neal Brothers Inc. | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	4,000	0
Investment/Transfer	0	4,000
Divestiture	0	0
Change in fair value	(4,000)	0
Long-term investments, ending balance	0	4,000
Segra International Corp | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance	300	100
Investment/Transfer	0	0
Divestiture	0	0
Change in fair value	(160)	200
Long-term investments, ending balance	$ 140	$ 300

Property, Plant and Equipment_2

Property, Plant and Equipment (Narrative) (Details) - CAD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jun. 17, 2020	Jan. 31, 2020	Jul. 31, 2020	Jul. 31, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Inventory capitalized depreciation costs			$ 11,988	$ 4,825
Average annual interest rate			7.22%	3.20%
Depreciation of property, plant and equipment			$ 6,072	$ 1,747
Impairments			79,418
Deferred rent liability				946
Loss on sale of assets			3,855
Sale of property and related assets			10,966
Impairment losses			43,585
Construction in progress
Disclosure of detailed information about property, plant and equipment [line items]
Transfers			21,100
Cultivation and production equipment
Disclosure of detailed information about property, plant and equipment [line items]
Transfers			12,941
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Capitalized borrowing costs			2,385	$ 511
Transfers			8,189
Abandonment of commercial administration building
Disclosure of detailed information about property, plant and equipment [line items]
Impairments			1,178
Deferred rent liability			$ 1,116
Sale Of Niagara Facility
Disclosure of detailed information about property, plant and equipment [line items]
Loss on sale of assets	$ 2,219
Sale of property and related assets	$ 12,250
Income based approach | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Increase in impairment loss		$ 24,283
Income based approach | DCF analysis, assumption one | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Short-term growth rate		10.00%
Terminal value growth rate		3.00%
Decrease in short-term growth rate		1.00%
Decrease in recoverable amount		$ 24,000
Income based approach | DCF analysis, assumption two | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Decrease in forecast revenues		3.00%
Decrease in recoverable amount		$ 34,000
Income based approach | DCF analysis, assumption three | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Terminal value growth rate		3.00%
Decrease in terminal value growth rate		1.00%
Decrease in recoverable amount		$ 38,000
Income based approach | DCF analysis, assumption four | Newstrike
Disclosure of detailed information about property, plant and equipment [line items]
Post tax discount rate		14.10%
Increase in post tax discount rate		1.00%
Decrease in recoverable amount		$ 59,000

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of property, plant and equipment (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	$ 258,793	$ 54,333
Impairments	79,418
Ending balance	285,366	258,793
Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	266,747	55,715
Business acquisitions		46,003
Additions	140,851	165,029
Transfers	0	0
Disposals	(41,682)
Ending balance	365,916	266,747
Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	7,954	1,382
Depreciation	18,060	6,572
Transfers	0	0
Disposals	(24,882)
Impairments	79,418
Ending balance	80,550	7,954
Land
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	5,339	1,038
Ending balance	1,349	5,339
Land | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	5,339	1,038
Business acquisitions		4,301
Additions	0	0
Transfers	0	0
Disposals	(3,683)
Ending balance	1,656	5,339
Land | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Depreciation	0	0
Transfers	0	0
Disposals	0
Impairments	307
Ending balance	307	0
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	146,442	32,003
Transfers	8,189
Ending balance	151,237	146,442
Buildings | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	150,834	32,536
Business acquisitions		18,855
Additions	24,432	11,365
Transfers	7,943	88,078
Disposals	(18,260)
Ending balance	164,949	150,834
Buildings | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	4,392	533
Depreciation	7,395	3,859
Transfers	0	0
Disposals	(17,081)
Impairments	19,006
Ending balance	13,712	4,392
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	497	197
Ending balance	23,430	497
Leasehold improvements | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	627	206
Business acquisitions		0
Additions	1,395	421
Transfers	22,417	0
Disposals	0
Ending balance	24,439	627
Leasehold improvements | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	130	9
Depreciation	879	121
Transfers	0	0
Disposals	0
Impairments	0
Ending balance	1,009	130
Cultivation and production equipment
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	39,813	3,962
Transfers	12,941
Ending balance	24,770	39,813
Cultivation and production equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	42,029	4,031
Business acquisitions		9,913
Additions	14,969	28,085
Transfers	(10,135)	0
Disposals	(13,402)
Ending balance	33,461	42,029
Cultivation and production equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	2,216	69
Depreciation	3,702	1,497
Transfers	271	650
Disposals	(7,435)
Impairments	9,937
Ending balance	8,691	2,216
Furniture, computers, vehicles and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	9,152	1,700
Ending balance	14,730	9,152
Furniture, computers, vehicles and equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	10,368	2,471
Business acquisitions		648
Additions	9,404	7,249
Transfers	8	0
Disposals	(909)
Ending balance	18,871	10,368
Furniture, computers, vehicles and equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,216	771
Depreciation	3,562	1,095
Transfers	(271)	(650)
Disposals	(366)
Impairments	0
Ending balance	4,141	1,216
Construction in progress
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	57,550	15,433
Transfers	21,100
Ending balance	49,145	57,550
Construction in progress | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	57,550	15,433
Business acquisitions		12,286
Additions	66,246	117,909
Transfers	(20,233)	(88,078)
Disposals	(5,428)
Ending balance	98,135	57,550
Construction in progress | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Depreciation	0	0
Transfers	0	0
Disposals	0
Impairments	48,990
Ending balance	48,890	0
Right-of-Use assets
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Ending balance	20,705	0
Right-of-Use assets | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Business acquisitions		0
Additions	24,405	0
Transfers	0	0
Disposals	0
Ending balance	24,405	0
Right-of-Use assets | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Depreciation	2,522	0
Transfers	0	0
Disposals	0
Impairments	1,178
Ending balance	$ 3,700	$ 0

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure of detailed information about intangible assets [line items]
Research and development expense	$ 4,639	$ 2,822
Impairment loss	108,189
Brand
Disclosure of detailed information about intangible assets [line items]
Impairment loss	2,000
Truss LP
Disclosure of detailed information about intangible assets [line items]
Transfer and other changes in Intangible assets	$ 212	$ 100

Intangible Assets - Schedule of

Intangible Assets - Schedule of intangible assets and other longer-term assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 127,282	$ 4,044
Impairment	108,189
Ending balance	16,008	127,282
Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	130,247	5,242
Business acquisitions		122,340
Additions	1,577	2,977
Transfers		(312)
Disposals	(723)
Ending balance	131,101	130,247
Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	2,965	1,198
Amortization	3,939	1,767
Impairment	108,189
Ending balance	115,093	2,965
Cultivating and processing license
Disclosure of detailed information about intangible assets [line items]
Beginning balance	114,832	2,142
Ending balance	5,476	114,832
Cultivating and processing license | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	116,433	2,545
Business acquisitions		113,888
Additions	0	0
Transfers		0
Disposals	0
Ending balance	116,433	116,433
Cultivating and processing license | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,601	403
Amortization	3,167	1,198
Impairment	106,189
Ending balance	110,957	1,601
Brand
Disclosure of detailed information about intangible assets [line items]
Beginning balance	8,440	0
Impairment	2,000
Ending balance	6,440	8,440
Brand | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	8,440	0
Business acquisitions		8,440
Additions	0	0
Transfers		0
Disposals	0
Ending balance	8,440	8,440
Brand | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	0
Amortization	0	0
Impairment	2,000
Ending balance	2,000	0
Software
Disclosure of detailed information about intangible assets [line items]
Beginning balance	2,289	1,014
Ending balance	1,744	2,289
Software | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	3,558	1,800
Business acquisitions		12
Additions	702	1,746
Transfers		0
Disposals	(550)
Ending balance	3,710	3,558
Software | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,269	786
Amortization	697	483
Impairment	0
Ending balance	1,966	1,269
Domain names
Disclosure of detailed information about intangible assets [line items]
Beginning balance	519	576
Ending balance	460	519
Domain names | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	585	585
Business acquisitions		0
Additions	0	0
Transfers		0
Disposals	0
Ending balance	585	585
Domain names | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	66	9
Amortization	59	57
Impairment	0
Ending balance	125	66
Patents
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,202	0
Ending balance	1,888	1,202
Patents | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,231	0
Business acquisitions		0
Additions	875	1,231
Disposals	(173)
Ending balance	1,933	1,231
Patents | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	29	0
Amortization	16	29
Impairment	0
Ending balance	45	29
Other
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	312
Ending balance	0	0
Other | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	312
Business acquisitions		0
Additions	0	0
Transfers		(312)
Disposals	0
Ending balance	0	0
Other | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	0
Amortization	0	0
Impairment	0
Ending balance	$ 0	$ 0

Business Acquisition (Narrative

Business Acquisition (Narrative) (Detail) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	May 24, 2019CAD ($)$ / shares	Jul. 31, 2020CAD ($)Year$ / shares	Jul. 31, 2019CAD ($)Year$ / shares
Disclosure of detailed information about business combination [line items]
Risk free interest rate of replacement options		1.79%	2.11%
Expected life of options (years) | Year		5	5
Expected volatility, share options granted		75.00%	69.00%
Exercise price of options granted | $ / shares		$ 6.61	$ 6.11
Net revenue | $		$ 80,784	$ 47,541
Net loss | $		(546,489)	(69,608)
Newstrike Brands Limited
Disclosure of detailed information about business combination [line items]
Percentage of voting equity interests acquired	100.00%
Exchange ratio	0.06332
Net revenue | $	$ 2,770
Net loss | $	$ (13,699)
Increase in net revenue based on management estimates If each acquisition had occurred | $			9,287
Increase in net loss based on management estimates If each acquisition had occurred | $			19,096
Non-capitalized transaction expenses | $			$ 3,958
Newstrike Brands Limited | Neal Brothers Inc.
Disclosure of detailed information about business combination [line items]
Percentage of voting equity interests acquired	60.00%
Newstrike Brands Limited | Warrants
Disclosure of detailed information about business combination [line items]
Volatility rate of warrants	75.00%
Stock price of warrants | $ / shares	$ 9.11
Newstrike Brands Limited | Warrants | Minimum
Disclosure of detailed information about business combination [line items]
Risk free rate of warrants	1.48%
Expected life of warrants	8 months 23 days
Exercise price of warrants | $ / shares	$ 11.84
Newstrike Brands Limited | Warrants | Maximum
Disclosure of detailed information about business combination [line items]
Risk free rate of warrants	1.57%
Expected life of warrants	4 years 25 days
Exercise price of warrants | $ / shares	$ 27.64
Newstrike Brands Limited | Replacement Options
Disclosure of detailed information about business combination [line items]
Expected volatility, share options granted	75.00%
Stock price of options | $ / shares	$ 9.11
Newstrike Brands Limited | Replacement Options | Minimum
Disclosure of detailed information about business combination [line items]
Expected life of warrants	1 year 2 months 12 days
Risk free interest rate of replacement options	1.48%
Exercise price of options granted | $ / shares	$ 6
Newstrike Brands Limited | Replacement Options | Maximum
Disclosure of detailed information about business combination [line items]
Expected life of warrants	4 years 8 months 12 days
Risk free interest rate of replacement options	1.57%
Exercise price of options granted | $ / shares	$ 17.37

Business Acquisition - Schedule

Business Acquisition - Schedule of business acquisition (Details) $ / shares in Units, $ in Thousands	Jul. 31, 2020CAD ($)	Jul. 31, 2019CAD ($)	May 24, 2019CAD ($)Share$ / sharesshares	Jul. 31, 2018CAD ($)
Long-term assets
Goodwill	$ 0	$ 111,877		$ 0
Newstrike Brands Limited
Disclosure of detailed information about business combination [line items]
Number of shares issued | Share			35,394,041
Par value of shares issued | $ / shares			$ 9.11
Amount of shares issued			$ 322,439
Number of Warrants outstanding | shares			7,196,164
Amount of Warrants outstanding			$ 12,229
Number of Replacement options issued | shares			2,002,365
Amount of Replacement options issued			$ 7,134
Total fair value of consideration			341,802
Current assets
Cash and cash equivalents			49,366
Accounts receivable			1,204
Other receivables			4,585
Inventory			22,359
Biological assets			3,291
Long-term assets
Property, plant and equipment			46,003
Investments			14,492
Convertible debenture receivable			1,220
Prepaid expenses			1,631
Prepaid expense and license			1,526
Software			10
Cultivation and processing license			113,888
Brand			8,440
Goodwill			111,877
Total assets			379,892
Current liabilities
Accounts payable and accrued liabilities			12,849
Payment received in advance			5
Long-term liabilities
Deferred tax liabilities			24,236
Total liabilities			37,090
Non-controlling interest			1,000
Total net assets acquired			341,802
Net accounts receivables acquired
Total accounts receivable			5,789
Expected uncollectible receivables			0
Net accounts receivables acquired			$ 5,789

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - CAD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2020	Jul. 31, 2020	Jul. 31, 2019
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill impairment loss		$ (111,877)	$ (111,877)
Newstrike | Market-based approach
Disclosure of reconciliation of changes in goodwill [line items]
Adjusted control premium	10.00%
Share price declined	5.00%
Increase in impairment loss	$ 26,647
Newstrike | Income based approach
Disclosure of reconciliation of changes in goodwill [line items]
Adjusted control premium	5.00%
Increase in impairment loss	$ 24,283
Newstrike | Income based approach | DCF analysis, assumption five
Disclosure of reconciliation of changes in goodwill [line items]
Short-term growth rate	10.00%
Terminal value growth rate	3.00%
Decrease in short-term growth rate	1.00%
Increase in impairment loss	$ 12,598
Newstrike | Income based approach | DCF analysis, assumption six
Disclosure of reconciliation of changes in goodwill [line items]
Terminal value growth rate	3.00%
Decrease in terminal value growth rate	1.00%
Increase in impairment loss	$ 27,000
Newstrike | Income based approach | DCF analysis, assumption seven
Disclosure of reconciliation of changes in goodwill [line items]
Post tax discount rate	15.90%
Increase in post tax discount rate	1.00%
Increase in impairment loss	$ 53,933

Goodwill - Schedule of reconcil

Goodwill - Schedule of reconciliation of changes in goodwill (Details) - CAD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jan. 31, 2020	Jul. 31, 2020	Jul. 31, 2019
Goodwill [Abstract]
Balance		$ 111,877	$ 0
Additions			111,877
Impairment	$ (111,877)	(111,877)
Balance		$ 0	$ 111,877

Warrant Liabilities (Narrative)

Warrant Liabilities (Narrative) (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 21, 2020CAD ($)USD_CADshares	Jan. 21, 2020USD ($)USD_CAD$ / sharesshares	Jul. 31, 2020CAD ($)USD_CADshares	Jul. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019CAD ($)USD_CADshares	Dec. 31, 2019USD ($)USD_CAD$ / sharesshares	Jul. 31, 2019CAD ($)USD_CAD$ / sharesshares	Jul. 31, 2019USD ($)$ / sharesshares	Jul. 31, 2020USD ($)USD_CADshares	Jul. 31, 2019USD ($)USD_CADshares	Jul. 31, 2018CAD ($)shares
Warrant Liabilities [Line Items]
Number of warrants exercised | shares			4,413,874	4,413,874			15,535,729	15,535,729
Number of outstanding warrants | shares			133,517,607				29,585,408		133,517,607	29,585,408	26,425,504
Number of warrants issued | shares			123,905,556	123,905,556			11,500,000	11,500,000
Value of warrants exercised			$ 106				$ 6,367
Value of warrants issued			9,596
Value of warrant outstanding			3,450				$ 493				$ 3,130
Stock price per share | $ / shares								$ 4.24
Expected life of warrants issued							12 months	12 months
Expected dividends, warrants issued
Expected volatility, warrants issued							74.00%	74.00%
Expected risk-free interest rate, warrants issued							1.61%	1.61%
Closing foreign exchange rate | USD_CAD							1.3148			1.3148
(Gain) Loss in revaluation of financial instruments			(6,533)				$ 3,730
Warrant liabilities			3,450				493			$ 375
USD$20,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Proceeds from direct offering		$ 20,000
Number of warrants issued | shares	5,988,024	5,988,024
Exercise price of warrants issued | $ / shares		$ 2.45
Term of warrant	5 years	5 years
Value of warrants exercised			0				0
Value of warrants issued			3,967
Value of warrant outstanding			$ 1,533				0		$ 1,144		0
Stock price per share | $ / shares		$ 1.45		$ 0.68
Expected life of warrants issued	2 years 6 months	2 years 6 months	2 years 6 months	2 years 6 months
Expected dividends, warrants issued
Expected volatility, warrants issued	80.00%	80.00%	97.00%	97.00%
Expected risk-free interest rate, warrants issued	1.57%	1.57%	0.22%	0.22%
Closing foreign exchange rate | USD_CAD	1.3116	1.3116	1.3404						1.3404
(Gain) Loss in revaluation of financial instruments			$ (2,434)				0
Finance costs	$ 223
USD$25,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Proceeds from direct offering						$ 25,000
Number of warrants issued | shares					7,485,032	7,485,032
Exercise price of warrants issued | $ / shares						$ 2.45
Term of warrant					5 years	5 years
Value of warrants exercised			0				0
Value of warrants issued			5,629		$ 5,629
Value of warrant outstanding			$ 1,917				0		$ 1,430		0
Stock price per share | $ / shares				$ 0.68		$ 1.59
Expected life of warrants issued			2 years 6 months	2 years 6 months	2 years 6 months	2 years 6 months
Expected dividends, warrants issued
Expected volatility, warrants issued			97.00%	97.00%	79.00%	79.00%
Expected risk-free interest rate, warrants issued			0.22%	0.22%	1.71%	1.71%
Closing foreign exchange rate | USD_CAD			1.3404		1.2988	1.2988			1.3404
(Gain) Loss in revaluation of financial instruments			$ (3,712)				$ 0
Finance costs					$ 350
2017 Unsecured Convertible Debentures Warrants
Warrant Liabilities [Line Items]
Number of warrants exercised | shares			71,424	71,424			863,693	863,693
Proceeds from warrants exercised			$ 72	$ 54			$ 863	$ 656
Exercise price of warrants exercised | $ / shares				$ 0.76				$ 0.76
Value of warrants exercised			106				6,367	$ 4,819
Value of warrants issued			0
Value of warrant outstanding			0				$ 493				$ 3,130
Expected life of warrants issued							12 months	12 months
Expected dividends, warrants issued
Expected volatility, warrants issued							75.00%	75.00%
(Gain) Loss in revaluation of financial instruments			$ (387)				$ 3,730
2017 Unsecured Convertible Debentures Warrants | Minimum
Warrant Liabilities [Line Items]
Stock price per share | $ / shares							$ 5.90
Expected risk-free interest rate, warrants issued							1.55%	1.55%
2017 Unsecured Convertible Debentures Warrants | Maximum
Warrant Liabilities [Line Items]
Stock price per share | $ / shares							$ 10.36
Expected risk-free interest rate, warrants issued							2.35%	2.35%

Warrant Liabilities - Schedule

Warrant Liabilities - Schedule of warrant liabilities (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)	Jul. 31, 2020USD ($)	Dec. 31, 2019CAD ($)	Jul. 31, 2019CAD ($)	Jul. 31, 2019USD ($)
Warrant Liabilities [Line Items]
Opening balance	$ 493			$ 3,130
Issued	9,596
Exercised	(106)			(6,367)
(Gain) Loss in revaluation of financial instruments	(6,533)			3,730
Ending balance	3,450			493
2017 Unsecured Convertible Debentures Warrants
Warrant Liabilities [Line Items]
Opening balance	493			3,130
Issued	0
Exercised	(106)			(6,367)	$ (4,819)
(Gain) Loss in revaluation of financial instruments	(387)			3,730
Ending balance	0			493
USD$25,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Opening balance	0			0
Issued	5,629		$ 5,629
Exercised	0			0
(Gain) Loss in revaluation of financial instruments	(3,712)			0
Ending balance	1,917	$ 1,430		0
USD$20,000 Registered Direct Offering
Warrant Liabilities [Line Items]
Opening balance	0			0
Issued	3,967
Exercised	0			0
(Gain) Loss in revaluation of financial instruments	(2,434)			0
Ending balance	$ 1,533	$ 1,144		$ 0

Convertible Debentures (Narrati

Convertible Debentures (Narrative) (Details) - CAD ($) $ / shares in Units, $ in Thousands	Jun. 10, 2020	Dec. 05, 2019	Jun. 30, 2020	May 31, 2020	Jul. 31, 2020
Disclosure of detailed information about borrowings [line items]
Principal amount of debentures					$ 40,140
Net present value of debt					26,600
Debentures allocated to conversion feature					13,540
Discounted early conversion price of conversion units				$ 0.80
Description of conversion units				Each Conversion Unit will provide the holder one common share and one half common share purchase warrant (with an exercise price of $1.00 and term of three years).
Exercise price of conversion units				$ 1
Conversion unit, term				three years
Conversion of convertible debenture amount					20,603
Loss from reduction of the conversion price to induce early conversion					54,283
Interest expense on debentures					6,854
Interest paid on unsecured convertible debentures					3,205
Accrued and unpaid interest					$ 202
Private Placement Unsecured Convertible Debentures
Disclosure of detailed information about borrowings [line items]
Principal amount of debentures		$ 70,000
Interest rate		8.00%
Conversion price		$ 3.16
Minimum daily volume weighted average trading price of common shares specified for conversion of debentures		$ 7.50
Number of consecutive trading days		15 days
Discounted gross proceeds of debentures		$ 46,098
Debentures allocated to conversion feature		23,902
Costs and fees incurred		204
Costs and fees allocated on pro rata basis to convertible debentures		176
Costs and fees allocated on pro rata basis to conversion feature		$ 28
First phase
Disclosure of detailed information about borrowings [line items]
Conversion of convertible debenture amount	$ 23,595
Percentage of principal amount of debentures converted	34.00%
Stock issued for conversion of convertible securities	29,493,750
Warrants issued for conversion of convertible securities	14,746,875
Second phase
Disclosure of detailed information about borrowings [line items]
Conversion of convertible debenture amount			$ 6,265
Percentage of principal amount of debentures converted			9.00%
Stock issued for conversion of convertible securities			7,831,250
Warrants issued for conversion of convertible securities			3,915,625

Convertible Debentures - Schedu

Convertible Debentures - Schedule of convertible debentures (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)
Debt instruments held [abstract]
Beginning balance	$ 0
Issued at amortized, net issuance costs	45,922
Conversion	(20,603)
Interest expense	6,854
Interest paid	(3,205)
Ending balance	$ 28,969

Lease Liabilities (Narrative) (

Lease Liabilities (Narrative) (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)
Disclosure of quantitative information about leases for lessee [abstract]
Expensed variable lease payments	$ 3,769

Lease Liabilities - Schedule of

Lease Liabilities - Schedule of lease liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Aug. 01, 2019	Jul. 31, 2019
Operating Lease [Line Items]
Total lease liabilities	$ 29,116	$ 21,360	$ 0
Lease additions	9,030
Lease payments	(4,341)
Interest expense on lease liabilities	3,067
Current portion	4,772
Long-term portion	$ 24,344		$ 0
Adjustment on adoption of IFRS 16
Operating Lease [Line Items]
Total lease liabilities		$ 21,360

Lease Liabilities - Schedule _2

Lease Liabilities - Schedule of lease obligations over next five fiscal years (Details) $ in Thousands	Jul. 31, 2020CAD ($)
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	$ 54,370
2021
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	4,737
2022 - 2023
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	9,787
2024 - 2025
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	8,764
Thereafter
Disclosure of maturity analysis of operating lease payments [line items]
Lease obligations	$ 31,082

Term Loan (Revised) (Narrative)

Term Loan (Revised) (Narrative) (Details) - CAD ($) $ in Thousands	1 Months Ended			3 Months Ended	12 Months Ended
	Jan. 31, 2020	Feb. 14, 2019	Feb. 14, 2019	Jul. 31, 2020	Jul. 31, 2020	Jul. 31, 2019	Dec. 31, 2019
Term loan
Disclosure of detailed information about borrowings [line items]
Proceeds from term loan		$ 35,000
Financing costs incurred		1,347
Minimum cash balance maintained	$ 15,000
Remaining undrawn facility							$ 15,000
Requirement of modification of financial covenants	i. Maintain a Tangible Net Worth Ratio of not more than 1:00 to 1:00 at all times; ii. Maintain a Cash Balance of more than $15,000 at all times; and iii. Maintain certain EBITDA requirements (as defined in the Credit Facility Agreement) with respect to each Fiscal Quarter.
Net revenue threshold to draw additional capacity				$ 28,400
Total interest expense					$ 723	$ 252
Interest costs capitalised					896	511
Non-cash interest expense relating to amortization of deferred financing costs					$ 501	$ 387
Canadian Imperial Bank of Commerce and Bank of Montreal
Disclosure of detailed information about borrowings [line items]
Amount of secured debt financing		65,000	$ 65,000
Expected averate rate of interest			mid-to-high 5% per annum range
Minimum repayment of outstanding balance in percentage			minimum 2.5% of the initial amount drawn each quarter
Canadian Imperial Bank of Commerce and Bank of Montreal | Term loan
Disclosure of detailed information about borrowings [line items]
Amount of secured debt financing		50,000	$ 50,000
Canadian Imperial Bank of Commerce and Bank of Montreal | Revolving loan
Disclosure of detailed information about borrowings [line items]
Amount of secured debt financing		$ 15,000	$ 15,000

Term Loan (Revised) - Schedule

Term Loan (Revised) - Schedule of term loan (Details) - Term loan - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Term Loan
Opening balance	$ 34,125	$ 0
Additions	0	35,000
Repayments	(3,500)	(875)
Ending balance	30,625	34,125
Deferred financing costs
Opening balance	(751)	0
Additions	(445)	(1,643)
Adjustments	0	296
Amortization of deferred finance costs	501	596
Ending balance	(695)	(751)
Total term loan	29,930	33,374
Current portion	3,069	3,117
Long-term portion	$ 26,861	$ 30,257

Share Capital (Narrative) (Deta

Share Capital (Narrative) (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands	Apr. 13, 2020CAD ($)$ / shares	Jun. 16, 2020CAD ($)	May 21, 2020CAD ($)$ / shares	Jan. 22, 2020CAD ($)	Jan. 22, 2020USD ($)$ / shares	Jul. 31, 2020CAD ($)shares	Jul. 31, 2019CAD ($)shares
Disclosure of classes of share capital [line items]
Number of shares | shares						482,465,748	256,981,753
Share issue related cost						$ (27)	$ (3,827)
June 2020 At-the-market ("ATM") Offering
Disclosure of classes of share capital [line items]
Proceeds from issuing shares						$ 34,551
Number of shares | shares						32,942,479
Receivable remained for irrevocable sales						$ 883
Number of remaining shares issued | shares						979,500
Share issue related cost						$ 1,288
June 2020 At-the-market ("ATM") Offering | Maximum
Disclosure of classes of share capital [line items]
Proceeds from issuing shares		$ 34,500
May 2020 Underwritten Public Offering
Disclosure of classes of share capital [line items]
Proceeds from issuing shares			$ 57,545
Number of shares | shares						63,940,000
Units issued in period, price per unit | $ / shares			$ 0.90
Warrants, grants in period, exercise price | $ / shares			$ 1.05
Net contribution to share capital, after warrant reserve adjustment			$ 46,547
Share issue related cost			$ 3,052
April 2020 Underwritten Public Offering
Disclosure of classes of share capital [line items]
Proceeds from issuing shares	$ 46,046
Number of shares | shares						59,800,000
Units issued in period, price per unit | $ / shares	$ 0.77
Warrants, grants in period, exercise price | $ / shares	$ 0.96
Net contribution to share capital, after warrant reserve adjustment	$ 25,863
Share issue related cost	$ 2,936
January 2020 Registered Direct Offering
Disclosure of classes of share capital [line items]
Proceeds from issuing shares				$ 26,290	$ 20,000
Number of shares | shares						11,976,048
Units issued in period, price per unit | $ / shares					$ 1.67
Warrants, grants in period, exercise price | $ / shares					$ 2.45
Net contribution to share capital, after warrant reserve adjustment				22,323
Share issue related cost				1,250
December 2019 Registered Direct Offering
Disclosure of classes of share capital [line items]
Proceeds from issuing shares				$ 32,411	$ 25,000
Number of shares | shares						14,970,062
Units issued in period, price per unit | $ / shares					$ 1.67
Warrants, grants in period, exercise price | $ / shares					$ 2.45

Share Capital (Schedule of issu

Share Capital (Schedule of issued and outstanding common shares) (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019
Disclosure of classes of share capital [line items]
Number of shares	482,465,748	256,981,753
Share capital	$ 1,023,788	$ 799,706
June 2020 at the market offering
Disclosure of classes of share capital [line items]
Number of shares	32,942,479
Share capital	$ 33,263
May 2020 underwritten public offering
Disclosure of classes of share capital [line items]
Number of shares	63,940,000
Share capital	$ 43,495
April 2020 underwritten public offering
Disclosure of classes of share capital [line items]
Number of shares	59,800,000
Share capital	$ 22,928
January 2020 registered offering
Disclosure of classes of share capital [line items]
Number of shares	11,976,048
Share capital	$ 21,073
December 2019 registered offering
Disclosure of classes of share capital [line items]
Number of shares	14,970,062
Share capital	$ 25,229
December 2019 private placement
Disclosure of classes of share capital [line items]
Number of shares	37,325,000
Share capital	$ 72,005
Options exercised
Disclosure of classes of share capital [line items]
Number of shares	116,532
Share capital	$ 223
Warrants exercised
Disclosure of classes of share capital [line items]
Number of shares	4,413,874
Share capital	$ 5,866

Common Share Purchase Warrant_2

Common Share Purchase Warrants (Narrative) (Details) - shares	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of warrants exercised	(4,413,874)	(15,535,729)
Broker compensation warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of warrants exercised		(1,916,527)

Common Share Purchase Warrant_3

Common Share Purchase Warrants - Schedule of warrant activity (Details) - $ / shares		12 Months Ended
		Jul. 31, 2020		Jul. 31, 2019
Disclosure Of Common Share Purchase Warrants [Abstract]
Number of warrants, Outstanding, beginning of year		29,585,408		26,425,504
Weighted average exercise price, Outstanding, beginning of year		$ 9.95	[1]	$ 4.35
Number of warrants, Expired during period		(15,559,483)		(531)
Weighted average exercise price, Expired during period		$ 12.25	[1]	$ 0
Number of warrants, Assumed and reissued through acquisition	[2]	0		7,196,164
Weighted average exercise price, Assumed and reissued through acquisition	[2]	$ 0	[1]	$ 23.10
Number of warrants, Issued		123,905,556		11,500,000
Weighted average exercise price, Warrants issued during period		$ 1.24	[1]	$ 6
Number of warrants, Exercised during period		(4,413,874)		(15,535,729)
Weighted average exercise price, Exercised during period		$ 0.97	[1]	$ 3.61
Number of warrants, Outstanding, end of year		133,517,607		29,585,408
Weighted average exercise price, Outstanding, end of year	[1]	$ 1.90		$ 9.95
[1]	USD denominated warrant's exercise price have been converted to the CAD equivalent as at the period end for presentation purposes.
[2]	Warrants cancelled and reissued on May 24, 2019, via the acquisition of Newstrike.

Common Share Purchase Warrant_4

Common Share Purchase Warrants - Schedule of warrants issued (Details)		12 Months Ended
		Jul. 31, 2020$ / sharesshares	Jul. 31, 2019$ / sharesshares	Jul. 31, 2020$ / shares
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants assumed and issued through acquisition			18,696,164
Number of warrants issued		123,905,556	11,500,000
Issuance on October 4, 2018
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares			$ 6
Number of warrants issued			11,500,000
Expiry period			3 years
Issuance on May 24, 2019
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants assumed and issued through acquisition	[1]		7,196,164
Issuance on May 24, 2019 | Minimum
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares	[1]		$ 11.84
Expiry period	[1]		8 months 23 days
Issuance on May 24, 2019 | Maximum
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares	[1]		$ 27.64
Expiry period	[1]		4 years 25 days
Issuance on December 31, 2019
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares				$ 2.45
Number of warrants issued		7,485,032
Expiry period		5 years
Issuance on January 22, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares				$ 2.45
Number of warrants issued		5,988,024
Expiry period		5 years
Issuance on April 13, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares		$ 0.96
Number of warrants issued		59,800,000
Expiry period		5 years
Issuance on May 21, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares		$ 1.05
Number of warrants issued		31,970,000
Expiry period		5 years
Issuance on June 10, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares		$ 1
Number of warrants issued		14,746,875
Expiry period		3 years
Issuance on June 30, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants exercise price | $ / shares		$ 1
Number of warrants issued		3,915,625
Expiry period		3 years
[1]	Warrants acquired and reissued on May 24, 2019, via the acquisition of Newstrike.

Common Share Purchase Warrant_5

Common Share Purchase Warrants - Schedule of warrants outstanding (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)$ / sharesshares	Jul. 31, 2020$ / shares	Jul. 31, 2019CAD ($)shares	Jul. 31, 2018shares
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	133,517,607		29,585,408	26,425,504
Net book value | $	$ 99,067		$ 60,925
Classified as Equity
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	120,044,551		29,478,272
Net book value | $	$ 95,617		$ 60,432
Classified as Equity | 2018 Equity financing exercise price of $5.60 expired January 30, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	0		10,512,208
Net book value | $	$ 0		$ 5,674
Warrants exercise price | $ / shares	$ 5.60
Warrants expiration date	Jan. 30, 2020
Classified as Equity | February 2018 financing warrants exercise price of $27.64 expired February 16, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	0		4,413,498
Net book value | $	$ 0		$ 1,331
Warrants exercise price | $ / shares	$ 27.64
Warrants expiration date	Feb. 16, 2020
Classified as Equity | June 2019 financing warrants exercise price of $15.79 expiring June 19, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	2,184,540		2,184,540
Net book value | $	$ 10,022		$ 9,998
Warrants exercise price | $ / shares	$ 15.79
Warrants expiration date	Jun. 19, 2023
Classified as Equity | April 2020 underwritten public offering warrants Exercise price of $0.96 expiring April 13, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	56,017,500		0
Net book value | $	$ 18,906		$ 0
Warrants exercise price | $ / shares	$ 0.96
Warrants expiration date	Apr. 13, 2025
Classified as Equity | May 2020 underwritten public offering warrants Exercise price of $1.05 expiring May 21, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	31,410,050		0
Net book value | $	$ 10,805		$ 0
Warrants exercise price | $ / shares	$ 1.05
Warrants expiration date	May 21, 2025
Classified as Equity | Conversion Unit warrants Exercise price of $1.00 expiring June 10, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	14,746,875		0
Net book value | $	$ 11,426		$ 0
Warrants exercise price | $ / shares	$ 1
Warrants expiration date	Jun. 10, 2023
Classified as Equity | Conversion Unit warrants Exercise price of $1.00 expiring June 30, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	3,915,625		0
Net book value | $	$ 1,928		$ 0
Warrants exercise price | $ / shares	$ 1
Warrants expiration date	Jun. 30, 2023
Classified as Equity | Broker/Consultant warrants exercise price of $20.85 expired February 16, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	0		264,809
Net book value | $	$ 0		$ 160
Warrants exercise price | $ / shares	$ 20.85
Warrants expiration date	Feb. 16, 2020
Classified as Equity | Broker/consultant warrants exercise price of $11.84 expired June 19, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	0		262,021
Net book value | $	$ 0		$ 610
Warrants exercise price | $ / shares	$ 11.84
Warrants expiration date	Jun. 19, 2020
Classified as Equity | Broker/consultant warrants Exercise price of $0.75 expiring November 3, 2021
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	175,618		175,618
Net book value | $	$ 78		$ 78
Warrants exercise price | $ / shares	$ 0.75
Warrants expiration date	Nov. 3, 2021
Classified as Equity | Broker/consultant warrants Exercise price of $0.75 expiring March 14, 2022
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	94,282		94,282
Net book value | $	$ 66		$ 66
Warrants exercise price | $ / shares	$ 0.75
Warrants expiration date	Mar. 14, 2022
Classified as Equity | Broker/consultant warrants Exercise price of $15.79 expiring June 19, 2023
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	61		61
Net book value | $	$ 0		$ 0
Warrants exercise price | $ / shares	$ 15.79
Warrants expiration date	Jun. 19, 2023
Classified as Equity | Inner Spirit warrants Exercise price of $15.63 expired July 21, 2020
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	0		71,235
Net book value | $	$ 0		$ 129
Warrants exercise price | $ / shares	$ 15.63
Warrants expiration date	Jul. 21, 2020
Classified as Equity | Joint Venture Molson warrants Exercise price of $6.00 expiring October 4, 2021
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	11,500,000		11,500,000
Net book value | $	$ 42,386		$ 42,386
Warrants exercise price | $ / shares	$ 6
Warrants expiration date	Oct. 4, 2021
Classified as Liability
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	13,473,056		107,136
Net book value | $	$ 3,450		$ 493
Classified as Liability | 2017 secured convertible debenture warrants exercise price of USD$0.76 expired November 14, 2019
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	0		107,136
Net book value | $	$ 0		$ 493
Warrants exercise price | $ / shares		$ 0.76
Warrants expiration date	Nov. 14, 2019
Classified as Liability | USD$25m Registered Direct Offering Warrants exercise price of USD$2.45 expiring December 31, 2024
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	7,485,032		0
Net book value | $	$ 1,917		$ 0
Warrants exercise price | $ / shares		2.45
Warrants expiration date	Dec. 31, 2024
Classified as Liability | USD$20m Registered Direct Offering Warrants exercise price of USD$2.45 expiring January 22, 2025
Disclosure Of Common Share Purchase Warrants [Line Items]
Number of outstanding warrants | shares	5,988,024		0
Net book value | $	$ 1,533		$ 0
Warrants exercise price | $ / shares		$ 2.45
Warrants expiration date	Jan. 22, 2025

Share-based Compensation (Narra

Share-based Compensation (Narrative) (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)Shareshares	Jul. 31, 2019CAD ($)Shareshares	Jul. 31, 2018Share
Stock Options And Restricted Share Units [Line Items]
Number of share options issued and outstanding	30,014,703	24,288,919	14,388,066
Share-based compensation | $	$ 31,895	$ 29,732
Amount of stock based compensation allocated to inventory | $	$ 6,105	$ 1,724
Omnibus Plan
Stock Options And Restricted Share Units [Line Items]
Description of maximum term of options granted for share-based payment arrangement	Expiry dates are up to 10 years from issuance, as determined by the Board of Directors at the time of issuance.
Expiry period of RSUs	10 years
Maximum percentage of common shares reserved for issuance for options	10.00%
Maximum number of common shares reserved for issuance for options | shares	48,246,574	25,698,175
Number of share options issued and outstanding	25,288,328
Maximum percentage of RSU authorized to issue for common shares inclusive of outstanding stock options	10.00%
Former Plan
Stock Options And Restricted Share Units [Line Items]
Number of share options issued and outstanding	4,305,048
Newstrike plan
Stock Options And Restricted Share Units [Line Items]
Number of share options issued and outstanding	421,327
RSU
Stock Options And Restricted Share Units [Line Items]
Share-based compensation | $	$ 406

Share-based Compensation - Sche

Share-based Compensation - Schedule of stock option activity (Details)	12 Months Ended
	Jul. 31, 2020Share$ / shares	Jul. 31, 2019Share$ / shares
Share Capital [Abstract]
Number of options, Opening balance | Share	24,288,919	14,388,066
Weighted average exercise price, Opening balance | $ / shares	$ 5.87	$ 3.02
Options Granted | Share	11,946,027	12,693,118
Weighted average exercise price, Granted | $ / shares	$ 1.62	$ 7.27
Options Acquired and reissued through acquisition | Share	0	2,002,365
Weighted average exercise price, acquired and reissued through acquisition | $ / shares	$ 0	$ 9.49
Options Forfeited | Share	(4,582,440)	(1,226,763)
Weighted average exercise price, Forfeited | $ / shares	$ 5.55	$ 6.33
Options Expired | Share	(1,521,271)	0
Weighted average exercise price, Expired | $ / shares	$ 9.16	$ 0
Options Exercised | Share	(116,532)	(3,567,867)
Weighted average exercise price, Exercised | $ / shares	$ 1.15	$ 1.20
Number of options, Closing balance | Share	30,014,703	24,288,919
Weighted average exercise price, Closing balance | $ / shares	$ 4.07	$ 5.87

Share-based Compensation - Sc_2

Share-based Compensation - Schedule of stock options granted (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2020Share$ / shares	Jul. 31, 2019CAD ($)Share$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price, share options granted | $ / shares	$ 6.61	$ 6.11
Options granted	11,946,027	12,693,118
Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	4,784,059	5,897,333
Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	7,161,968	6,795,785
Stock option grant date September 17, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		September 17, 2018
Exercise price, share options granted | $ / shares		$ 7.93
Options granted		1,173,500
Expiry period		10 years
Stock option grant date September 17, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		650,000
Stock option grant date September 17, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		523,500
Stock option grant date November 22, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		November 22, 2018
Exercise price, share options granted | $ / shares		$ 5.92
Options granted		440,000
Expiry period		10 years
Stock option grant date November 22, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date November 22, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		440,000
Stock option grant date December 17, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		December 17, 2018
Exercise price, share options granted | $ / shares		$ 5.09
Options granted		301,500
Expiry period		10 years
Stock option grant date December 17, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		74,000
Stock option grant date December 17, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		227,500
Stock option grant date December 17, 2018 | Director
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted | $		54,000
Stock option grant date February 19, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		February 19, 2019
Exercise price, share options granted | $ / shares		$ 7.13
Options granted		1,241,000
Expiry period		10 years
Stock option grant date February 19, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		615,000
Stock option grant date February 19, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		626,000
Stock option grant date February 21, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		February 21, 2019
Exercise price, share options granted | $ / shares		$ 7.46
Options granted		3,333,333
Expiry period		10 years
Stock option grant date February 21, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		3,333,333
Stock option grant date February 21, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date March 20, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		March 20, 2019
Exercise price, share options granted | $ / shares		$ 8.50
Options granted		1,402,500
Expiry period		10 years
Stock option grant date March 20, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		325,000
Stock option grant date March 20, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		1,077,500
Stock option grant date April 17, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		April 17, 2019
Exercise price, share options granted | $ / shares		$ 8.24
Options granted		1,132,500
Expiry period		10 years
Stock option grant date April 17, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date April 17, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		1,132,500
Stock option grant date July 18, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		July 18, 2019
Exercise price, share options granted | $ / shares		$ 6.54
Options granted		3,418,785
Expiry period		10 years
Stock option grant date July 18, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		650,000
Stock option grant date July 18, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		2,768,785
Stock option grant date July 26, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		July 26, 2019
Exercise price, share options granted | $ / shares		$ 5.88
Options granted		250,000
Expiry period		10 years
Stock option grant date July 26, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		250,000
Stock option grant date July 26, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date October 29, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	October 29, 2019
Exercise price, share options granted | $ / shares	$ 3.30
Options granted	3,561,311
Expiry period	10 years
Stock option grant date October 29, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	829,034
Stock option grant date October 29, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	2,732,277
Stock option grant date January 29, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	January 29, 2020
Exercise price, share options granted | $ / shares	$ 1.80
Options granted	293,021
Expiry period	10 years
Stock option grant date January 29, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	0
Stock option grant date January 29, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	293,021
Stock Option Grant Date April 28, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	April 28, 2020
Exercise price, share options granted | $ / shares	$ 0.69
Options granted	3,465,322
Expiry period	10 years
Stock Option Grant Date April 28, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	900,000
Stock Option Grant Date April 28, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	2,565,322
Stock option grant date June 26, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	June 26, 2020
Exercise price, share options granted | $ / shares	$ 1.02
Options granted	3,787,435
Expiry period	10 years
Stock option grant date June 26, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	3,055,025
Stock option grant date June 26, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	732,410
Stock option grant date July 28, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	July 28, 2020
Exercise price, share options granted | $ / shares	$ 0.96
Options granted	838,938
Expiry period	10 years
Stock option grant date July 28, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	0
Stock option grant date July 28, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	838,938

Share-based Compensation - Sc_3

Share-based Compensation - Schedule of stock options outstanding (Details) - Share	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2018
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	30,014,703	24,288,919	14,388,066
Number exercisable	10,539,874
Exercise Price $0.58-$2.69
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	11,371,022
Weighted average remaining contractual life (years)	8 years 10 months 13 days
Number exercisable	2,769,874
Weighted average remaining contractual life (years)	6 years 29 days
Exercise Price $3.30-$6.54
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	12,100,157
Weighted average remaining contractual life (years)	6 years 2 months 15 days
Number exercisable	6,002,653
Weighted average remaining contractual life (years)	7 years 10 months 6 days
Exercise Price $7.13-$8.50
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	6,302,656
Weighted average remaining contractual life (years)	8 years 6 months 10 days
Number exercisable	1,547,062
Weighted average remaining contractual life (years)	8 years 5 months 8 days
Exercise Price $8.84-$17.37
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	240,868
Weighted average remaining contractual life (years)	1 year 8 months 1 day
Number exercisable	220,285
Weighted average remaining contractual life (years)	1 year 8 months 26 days

Share-based Compensation - Sc_4

Share-based Compensation - Schedule of Restricted Share Units activity (Details)	12 Months Ended
	Jul. 31, 2020Share$ / shares	Jul. 31, 2019Share$ / shares
Stock Options And Restricted Share Units [Abstract]
Opening balance | Share	0	0
Opening balance, value of units | $ / shares	$ 0	$ 0
Granted | Share	2,438,548	0
Granted, value of units | $ / shares	$ 2.13	$ 0
Forfeited | Share	(90,114)	0
Forfeited, value of units | $ / shares	$ 2.94	$ 0
Closing balance | Share	2,348,434	0
Closing balance, Value of units | $ / shares	$ 2.10	$ 0

Share-based Compensation - Sc_5

Share-based Compensation - Schedule of Restricted Share Units Granted (Details)	12 Months Ended
	Jul. 31, 2020Share$ / shares	Jul. 31, 2019Share
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	2,438,548	0
October 29, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expiry period of RSUs	10 years
October 29, 2019 | Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unit value | $ / shares	$ 0.53
October 29, 2019 | Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unit value | $ / shares	$ 1.16
October 29, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	1,428,449
October 29, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	0
June 26, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unit value | $ / shares	$ 0.71
Expiry period of RSUs	10 years
June 26, 2020 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	1,010,101
June 26, 2020 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	0

Share-based Compensation - Sc_6

Share-based Compensation - Schedule of fair value of stock options and Restricted stock units granted (Details)	12 Months Ended
	Jul. 31, 2020Year$ / shares	Jul. 31, 2019Year$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price (weighted average)	$ 6.51	$ 5.99
Stock price (weighted average)	$ 6.61	$ 6.11
Risk-free interest rate (weighted average)	1.79%	2.11%
Expected life (years) of options (weighted average) | Year	5	5
Expected annualized volatility (weighted average)	75.00%	69.00%

Share-based Compensation - Sc_7

Share-based Compensation - Schedule of equity-settled and cash-settled share-based payments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total equity-settled share-based compensation	$ 31,503	$ 29,793
Total cash-settled share-based compensation	393	0
Stock option share-based compensation
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total equity-settled share-based compensation	31,503	29,793
RSU share-based compensation
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total equity-settled share-based compensation	0	0
Total cash-settled share-based compensation	$ 393	$ 0

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of anti-dilutive securities excluded from computation of diluted earnings per share (Details) - shares	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	165,862,789	53,874,327
Stock Options
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	29,996,748	24,288,919
RSUs
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	2,348,434	0
2017 Secured convertible debenture warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	0	107,136
2018 equity warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	0	10,512,208
2018 February 2018 financing warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	0	4,413,498
2019 June financing warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	2,184,540	2,184,540
USD$25m registered direct offering warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	7,485,032	0
USD$20m registered direct offering warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	5,988,024	0
2020 April underwritten public offering warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	56,017,500	0
2020 May underwritten public offering warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	31,410,050	0
Warrants issued under conversion of debentures
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	18,662,500	0
Joint venture and Inner Spirit issued warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	11,500,000	11,571,235
Convertible debenture broker/finder warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	269,961	796,791

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)	Jul. 31, 2019CAD ($)	Jul. 31, 2020USD ($)	Jul. 31, 2018CAD ($)
Disclosure of risk management strategy related to hedge accounting [line items]
Short-term investments	$ 0	$ 25,937
Current liabilities	82,487	82,942
Contractual commitments	47,019
Cash and cash equivalents	184,173	113,568		$ 99,042
Interest Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Short-term investments		517
Financial liabilities	$ 29,930	33,374
Immaterial increase or decrease in interest rate	1.00%
Price Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Financial liabilities	$ 3,450	493
Conversion of debt, converted amount	$ 29,860
Percentage of unsecured convertible debentures	8.00%
Percentage of increase or decrease in the fair value of financial assets	10.00%
Amount of increase or decrease in comprehensive loss due to 10% of increase or decrease in the fair value of these financial assets		340
Credit Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Cash and cash equivalents and short-term investments held in credit union without publicly available credit rating	$ 176
Expected credit loss	35	37
Maximum exposure to credit risk	$ 211,860	$ 194,902
Economic Dependence Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Percentage of sales recorded from crown corporations	70.00%	81.00%
Percentage of trade receivable from crown corporations Societe quebecoise du cannabis	47.00%	56.00%
Percentage of trade receivable from Ontario Cannabis Store	25.00%	23.00%
Liquidity Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Cash and cash equivalents and short-term investments	$ 184,173	$ 139,505
Trade receivables	19,426	$ 19,693
Current liabilities	82,487
Contractual commitments	14,741
Foreign Currency Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Cash and cash equivalents	$ 57,652		$ 42,981
Immaterial change in foreign exchange rates	1.00%

Financial Instruments - Schedul

Financial Instruments - Schedule of price risk exposure (Details) - Price Risk - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019
Disclosure of risk management strategy related to hedge accounting [line items]
Financial assets	$ 2,692	$ 16,756
Financial liabilities	(3,450)	(493)
Total exposure	$ (758)	$ 16,263

Financial Instruments - Sched_2

Financial Instruments - Schedule of aging of trade receivables (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	$ 19,426	$ 19,693
Credit Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	19,426	19,693
Credit Risk | 0-30 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	15,253	14,102
Credit Risk | 31-60 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	2,972	1,826
Credit Risk | 61-90 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	412	166
Credit Risk | Over 90 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	$ 789	$ 3,599

Operating Expenses by Nature -

Operating Expenses by Nature - Schedule of operating expenses by nature (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Expenses by nature [abstract]
Salaries and benefits	$ 12,202	$ 25,349
Consulting	7,425	11,176
Professional fees	9,811	8,258
Facilities	6,895	5,697
Selling, general and administrative	14,409	4,462
Travel	2,051	2,710
Share-based compensation	25,790	28,008
Marketing and promotion	12,474	31,191
Amortization of intangible assets	3,939	1,767
Depreciation of property, plant and equipment	6,072	1,747
Total expenses, by nature	$ 418,576	$ 111,482

Operating Expenses by Nature _2

Operating Expenses by Nature - Schedule of operating expenses by nature - stock based compensation (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Expenses by nature [abstract]
General and administrative related share-based compensation	$ 24,650	$ 26,322
Marketing and promotion related share-based compensation	1,140	1,686
Total operating expense related share-based compensation	25,790	28,008
Share based compensation capitalized to inventory	6,105	1,724
Total share-based compensation	$ 31,895	$ 29,732

Operating Expenses by Nature _3

Operating Expenses by Nature - Schedule of operating expenses by nature - payroll related wages and benefits (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Expenses by nature [abstract]
General and administrative related wages and benefits	$ 12,202	$ 17,975
Marketing and promotion related share-based compensation	5,625	6,162
Research and development related wages and benefits	2,717	1,212
Total operating expense related wages and benefits	20,544	25,349
Wages and benefits capitalized to inventory	21,128	10,905
Total wages and benefits	$ 41,672	$ 36,254

Related Party Disclosure (Narra

Related Party Disclosure (Narrative) (Details)

1 Months Ended

6 Months Ended

12 Months Ended

Jun. 26, 2020Share$ / sharesshares

Apr. 28, 2020CAD ($)$ / shares

Oct. 29, 2019CAD ($)$ / sharesshares

Jul. 26, 2019shares$ / shares

Jul. 18, 2019shares$ / shares

Mar. 20, 2019shares$ / shares

Feb. 21, 2019shares$ / shares

Feb. 19, 2019shares$ / shares

Dec. 17, 2018shares$ / shares

Oct. 31, 2018

Sep. 17, 2018CAD ($)shares$ / shares

Jun. 17, 2019shares

Jul. 31, 2020CAD ($)Share$ / shares

Jul. 31, 2019CAD ($)Share$ / shares

Disclosure of transactions between related parties [line items]

Number of stock options granted | Share

11,946,027

12,693,118

Exercise price | $ / shares

$ 1.62

$ 7.27

Description of granted stock options vesting period

Unless otherwise stated, the below granted stock options will vest on the one-year anniversary of the date of grant and the balance will vest quarterly over two years thereafter.

Exercise price of options granted | $ / shares

$ 6.61

$ 6.11

Truss Limited Partnership ("Truss LP")

Disclosure of transactions between related parties [line items]

Proportion of ownership interest in associate

42.50%

42.50%

Receivables due from associates | $

$ 3,405,000

Raw materials purchased | $

2,159,000

Revenue from rendering of services, related party transactions | $

2,531,000

Director

Disclosure of transactions between related parties [line items]

Number of stock options granted | Share

1,800,000

Executives

Disclosure of transactions between related parties [line items]

Number of stock options granted

1,255,025

900,000

829,034

250,000

650,000

325,000

615,000

74,000

650,000

Exercise price | $ / shares

$ 0.69

$ 5.88

$ 6.54

$ 8.50

$ 7.13

$ 5.09

$ 7.93

Description of granted stock options vesting period

One-third of the stock options will vest on each of the one-year anniversaries of the date of grant over a three-year period.

One-third of the stock options will vest on each of the one-year anniversaries of the date of grant over a three-year period.

54,000 stock options will fully vest at the 6-month anniversary of the grant date.

Number of stock option vested | shares

54,000

Number of RSU granted | shares

1,428,449

Value of RSUs granted | $ / shares

$ 3.30

Directors and executives

Disclosure of transactions between related parties [line items]

Exercise price | $ / shares

$ 1.02

Description of granted stock options vesting period

One-third of the stock options will vest on each of the one-year anniversaries of the date of grant over a three-year period.

Number of RSU granted | shares

1,010,101

Exercise price of RSU granted | $ / shares

$ 0.99

CEO

Disclosure of transactions between related parties [line items]

Number of stock options granted | shares

3,333,333

Exercise price | $ / shares

$ 7.46

Description of granted stock options vesting period

Additional to the standard vesting terms as defined in Note 11, is an achievement condition in which vesting may only occur once a volume weighted average trading price of $10 or greater is achieved for a 20-day period prior to a vesting date.

Belleville Complex Inc.

Disclosure of transactions between related parties [line items]

Percentage Of Interest Acquired In Related Party

25.00%

Percentage of ownership interest owned by directors

75.00%

Cash advances and loans made to related parties | $

$ 20,279,000

Consideration for interest on joint venture | $

Carrying value for interest on joint venture | $

Description of lease transaction

As part of the initial agreement, the Company will be the anchor tenant for a period of 20 years, with an option to renew for 10 years. On October 22, 2019, the lease agreement was amended to a 15-year anchor tenant period, with an option to renew for 15 years and additional space to rent. The Company has also subleased a portion of the space to Truss Limited Partnership (Note 10). As a result, the lease was reassessed resulting in an addition to the right-of-use asset and lease liability as well as a lease receivable on the sublease component (Note 6).

Lease and operating expenses | $

$ 7,511,000

$ 3,937,000

Related Party Disclosure - Sche

Related Party Disclosure - Schedule of compensation provided to key management (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure of transactions between related parties [abstract]
Salary and/or consulting fees	$ 3,069	$ 3,550
Termination benefits	1,043	470
Bonus compensation	42	481
Stock-based compensation	15,702	16,235
Total	$ 19,856	$ 20,736

Capital Management (Narrative)

Capital Management (Narrative) (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2018
Disclosure Of Capital Management [Abstract]
Shareholders' equity	$ 556,676	$ 788,712	$ 322,873

Commitments and Contingencies_2

Commitments and Contingencies (Narrative) (Details) - CAD ($) $ in Thousands	Jul. 03, 2019	Nov. 26, 2019	Aug. 21, 2019	Jul. 31, 2020	Apr. 04, 2020	Aug. 01, 2019
Commitments And Contingencies [Line Items]
Onerous contract provision				$ 4,763
Letter of Credit
Commitments And Contingencies [Line Items]
Maximum limit under agreement		$ 6,391	$ 250			$ 2,581
Period of letter of credit		6 months	5 years
Letter of credit annual amortization expense			$ 50
Letter of credit monthly amortization expense		$ 1,000
Surety Bond
Commitments And Contingencies [Line Items]
Maximum limit under agreement	$ 4,500
Percentage of premium of bond	0.30%
Surety amount of CRA deposit					$ 1,657

Commitments and Contingencies -

Commitments and Contingencies - Schedule of future minimum payments under contractual financial obligations (Details) $ in Thousands	Jul. 31, 2020CAD ($)
Commitments And Contingencies [Line Items]
Annual minimum payments payable	$ 47,019
July 31, 2021
Commitments And Contingencies [Line Items]
Annual minimum payments payable	14,741
July 31, 2022
Commitments And Contingencies [Line Items]
Annual minimum payments payable	3,666
July 31, 2023
Commitments And Contingencies [Line Items]
Annual minimum payments payable	3,444
July 31, 2024
Commitments And Contingencies [Line Items]
Annual minimum payments payable	3,444
July 31, 2025
Commitments And Contingencies [Line Items]
Annual minimum payments payable	2,450
Thereafter
Commitments And Contingencies [Line Items]
Annual minimum payments payable	$ 19,274

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of carrying value of financial instruments (Details) $ in Thousands, $ in Thousands	Jul. 31, 2020CAD ($)	Jul. 31, 2019CAD ($)	Jul. 31, 2019USD ($)	Jul. 31, 2018CAD ($)
Assets
Cash and cash equivalents	$ 184,173	$ 113,568		$ 99,042
Restricted cash	8,261	22,350
Short-term investments	0	25,937
Trade receivables	19,426	19,693
Commodity taxes recoverable and other receivables	16,773	15,247
Lease receivable - long term	3,865
Convertible debenture receivable	0	13,354
Long term investments	3,209	14,277
Liabilities
Accounts payable and accrued liabilities	32,451	45,581
Warrant liabilities	3,450	493	$ 375
Lease liability - current	4,772
Lease liability - long term	24,344	0
Convertible Debentures	28,969	0
Deferred rent liability		946
Term loan	29,930	33,374
Other long-term liabilities	393
Amortized cost of financial assets
Assets
Cash and cash equivalents	184,173	113,568
Restricted cash	8,261	22,350
Short-term investments		25,937
Trade receivables	19,426	19,693
Commodity taxes recoverable and other receivables	16,773	15,247
Lease receivable - long term	3,865
Convertible debenture receivable		0
Long term investments	0	0
Amortized cost of financial assets as FVTPL
Assets
Cash and cash equivalents	0	0
Restricted cash	0	0
Short-term investments		0
Trade receivables	0	0
Commodity taxes recoverable and other receivables	0	0
Lease receivable - long term	0
Convertible debenture receivable		13,354
Long term investments	3,209	14,277
Financial assets designated as FVTPL
Assets
Cash and cash equivalents	0	0
Restricted cash	0	0
Short-term investments		0
Trade receivables	0	0
Commodity taxes recoverable and other receivables	0	0
Lease receivable - long term	0
Convertible debenture receivable		0
Long term investments	0	0
Amortized cost of financial liabilities
Liabilities
Accounts payable and accrued liabilities	32,451	45,581
Warrant liabilities	0	0
Lease liability - current	4,772
Lease liability - long term	24,344
Convertible Debentures	28,969
Deferred rent liability		946
Term loan	29,930	33,374
Other long-term liabilities	0
Amortized cost of financial liability as FVTPL
Liabilities
Accounts payable and accrued liabilities	0	0
Warrant liabilities	3,450	493
Lease liability - current	0
Lease liability - long term	0
Convertible Debentures	0
Deferred rent liability		0
Term loan	0	0
Other long-term liabilities	0
Financial liabilities designated as FVTPL
Liabilities
Accounts payable and accrued liabilities	0	0
Warrant liabilities	0	0
Lease liability - current	0
Lease liability - long term	0
Deferred rent liability		0
Term loan	0	$ 0
Other long-term liabilities	$ 393

Non-Controlling Interest (Narra

Non-Controlling Interest (Narrative) (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)	Jul. 31, 2020USD ($)	Jul. 31, 2019CAD ($)
Disclosure of subsidiaries [line items]
Non-controlling interest	$ 3,379		$ 1,000
Keystone Isolation Technologies Inc. ("KIT")
Disclosure of subsidiaries [line items]
Percentage of ownership interest	60.00%
Proportion of ownership interests held by non-controlling interests	40.00%
Contributed cash	$ 4,075	$ 3,100
Non-controlling interest	$ 3,379

Non-Controlling Interest - Sche

Non-Controlling Interest - Schedule of non-controlling interest (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Disclosure of subsidiaries [line items]
Current assets	$ 305,703	$ 312,136
Current liabilities	82,487	82,942
Non-controlling interests	3,379	$ 1,000
KIT
Disclosure of subsidiaries [line items]
Current assets	0
Non-current assets	7,455
Current liabilities	0
Non-current liabilities	$ 0
Non-controlling interest (%)	40.00%
Non-controlling interests	$ 3,379
Neal Up Brands Inc.
Disclosure of subsidiaries [line items]
Current assets	2,500
Non-current assets	0
Current liabilities	0
Non-current liabilities	$ 0
Non-controlling interest (%)	40.00%
Non-controlling interests	$ 1,000

Revenue from Sale of Goods (Nar

Revenue from Sale of Goods (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Revenue [abstract]
Sales returns and recoveries	$ 6,942	$ 3,811

Revenue from Sale of Goods - Sc

Revenue from Sale of Goods - Schedule of gross revenue (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	$ 110,149	$ 59,256
Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	107,298	59,256
Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	2,851	0
Retail
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	104,563	53,968
Retail | Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	101,712	53,968
Retail | Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	2,851	0
Medical
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	3,299	5,288
Medical | Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	3,299	5,288
Medical | Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	0	0
Wholesale
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	996	0
Wholesale | Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	996	0
Wholesale | Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	0	0
International
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	1,291	0
International | Cannabis sales excluding beverages
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	1,291	0
International | Cannabis beverage sales
Schedule Of Gross Revenue [Line Items]
Revenue from sale of goods	$ 0	$ 0

Segmented Information (Narrativ

Segmented Information (Narrative) (Details)	12 Months Ended
	Jul. 31, 2020Segment
Disclosure of operating segments [abstract]
Number of operating segment	1

Restructuring Provision (Narrat

Restructuring Provision (Narrative) (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)
Restructuring Provision Abstract
Expense of restructuring activities	$ 4,767

Restructuring Provision - Sched

Restructuring Provision - Schedule of restructuring provision (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2020CAD ($)
Restructuring Provision Abstract
Balance payable as at July 31, 2019	$ 0
Total restructuring costs	4,767
Less: payments made	(4,737)
Balance payable as at July 31, 2020	$ 30

Operating Cash Flow - Schedule

Operating Cash Flow - Schedule of restructuring provision (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Items not affecting cash
Income tax recovery	$ (6,023)	$ (18,213)
Depreciation of property, plant and equipment	6,072	1,747
Depreciation of property, plant and equipment in cost of sales	3,567	0
Amortization of intangible assets	3,939	1,767
Loss/(gain) on convertible debentures	4,806	(1,737)
Unrealized gain on changes in fair value of biological assets	(29,356)	(38,856)
Unrealized fair value adjustment on investments	12,880	(315)
Amortization of deferred financing costs	56	596
Accrued interest income	9,921	(397)
Gain on investment	(24)	0
Loss on induced conversion of debenture	54,283	0
License depreciation and prepaid royalty expenses	389	117
Write-off of inventory and biological assets	5,055	0
Write down of inventory to net realizable value	68,319	19,335
Realized fair value amounts on inventory sold	40,910	16,357
Loss from investment in associate and joint ventures	6,331	2,964
Stock-based compensation	25,790	28,944
Revaluation of financial instruments (gain)/loss	(6,533)	3,730
Impairment losses	299,484	0
Loss on onerous contract	4,763	0
Loss on disposal of property, plant and equipment	3,855	0
Total items not affecting cash	508,484	16,669
Changes in non-cash operating working capital items
Trade receivables	267	(17,845)
Commodity taxes recoverable and other receivables	(784)	(6,425)
Prepaid expenses	5,717	(4,927)
Inventory	(100,492)	(90,748)
Biological assets	28,493	37,108
Accounts payable and accrued liabilities	6,623	6,630
Excise taxes payable	3,627	3,494
Deferred rent liability	0	946
Total non-cash operating working capital	$ (56,549)	$ (71,767)

Operating Cash Flow - Schedul_2

Operating Cash Flow - Schedule of additional supplementary cash flow information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Operating Cash Flow [Abstract]
Property, plant and equipment in accounts payable	$ 19,751	$ 21,265
Right-of-use asset additions	24,405	0
Capitalized borrowing costs	2,385	511
Interest paid	$ 2,527	$ 252

Income Taxes - Schedule of comp

Income Taxes - Schedule of components of income tax expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Income taxes paid (refund) [abstract]
Current tax for the year	$ 0	$ 0
Adjustments of previous years	0	0
Total	$ 0	$ 0

Income Taxes - Schedule of defe

Income Taxes - Schedule of deferred income tax expense (recovery) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Income taxes paid (refund) [abstract]
Origination and reversal of temporary differences	$ (98,141)	$ (13,007)
Difference between statutory tax rate and deferred tax rate	2,555	172
Change in temporary difference for which no deferred tax assets are recorded	89,563	(5,378)
Deferred income tax recovery	$ (6,023)	$ (18,213)

Income Taxes - Schedule of inco

Income Taxes - Schedule of income tax rate reconciliation (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Income taxes paid (refund) [abstract]
Expected tax rate	26.54%	26.64%
Earnings before income taxes	$ (552,512)	$ (87,281)
Expected tax benefit resulting from loss	(146,637)	(23,252)
Adjustments for the following items:
Tax rate differences	2,555	172
Permanent differences	48,965	9,973
Change in temporary differences for which no tax assets are recorded	89,563	(5,770)
True up and other	(469)	664
Income Tax Expense	$ (6,023)	$ (18,213)

Income Taxes - Schedule of reco

Income Taxes - Schedule of reconciliation of deferred tax assets and liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2020	Jul. 31, 2019
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	$ (6,023)	$ 0
Recognized in income	6,023	18,212
Recognized in goodwill		(24,236)
Recognized in Equity/OCI	0
Ending balance	0	(6,023)
Taxable temporary differences
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	6,858	(117)
Recognized in income	3,557	7,195
Recognized in goodwill		(200)
Recognized in Equity/OCI	0
Ending balance	10,415	6,858
Biological assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(1,514)	(458)
Recognized in income	184	(764)
Recognized in goodwill		(292)
Recognized in Equity/OCI	0
Ending balance	(1,330)	(1,514)
Inventory
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(2,920)	(1,432)
Recognized in income	(2,168)	(930)
Recognized in goodwill		(559)
Recognized in Equity/OCI	0
Ending balance	(5,088)	(2,920)
Loss carryforward
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	23,369	2,007
Recognized in income	(23,369)	14,058
Recognized in goodwill		7,304
Recognized in Equity/OCI	0
Ending balance	0	23,369
Share issue costs
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	721	0
Recognized in income	(721)	(1,003)
Recognized in goodwill		1,724
Recognized in Equity/OCI	0
Ending balance	0	721
Intangible assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(32,537)	0
Recognized in income	28,540	(344)
Recognized in goodwill		(32,193)
Recognized in Equity/OCI	0
Ending balance	$ (3,997)	$ (32,537)

Income Taxes - Schedule of dedu

Income Taxes - Schedule of deductible temporary differences and unused tax losses (Details) - CAD ($) $ in Thousands	Jul. 31, 2020	Jul. 31, 2019
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	$ 363,385	$ 14,776
Losses carried forward
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	255,635	5,898
Research and development expenditures
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	669	266
Fixed Assets, intangibles and other assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	84,482	0
Share issue costs
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	$ 22,599	$ 8,612

Income Taxes - Schedule of non-

Income Taxes - Schedule of non-capital losses (Details) $ in Thousands	Jul. 31, 2020CAD ($)
Income taxes paid (refund) [abstract]
2025	$ 187
2026	199
2027	279
2028	236
2029	257
2030	205
2031	291
2032	781
2033	473
2034	1,547
2035	3,601
2036	6,389
2037	14,100
2038	37,111
2039	51,142
2040	132,646
Total	$ 249,444